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1H NMR  Proton Nuclear Magnetic Resonance 
HAP  Histo-aspartic protease 
Hb   Haemoglobin 
Hex   Hexane 
His   Histidine 
H2O   Water 
HSQC  Heteronuclear single quantum coherence (in NMR) 
Hz   Hertz 
IC50   50% Inhibitory concentration 
IUPAC  International Union of Pure and Applied Chemistry 
J   Coupling constant 
K2CO3  Potassium carbonate 
KOH  Potassium hydroxide 
Leu   Leucine 
m   Multiplet (in 1H NMR) 
M   Molar 
mA   MilliAmpere(s) 
MCR   Multi-component reactions 
MDR  Multidrug resistance 
MeOH  Methanol 
min   Minute(s) 
ml   Millilitre 
mM   Millimolar 
m.p.   Melting point 
m/z   Mass to charge ratio 
NaBH4   Sodium borohydride 
NaCNBH3 Sodium cyanoborohydride 
NADH  Nicotinamide adenine dinucleotide (reduced form) 
NADPH  Nicotinamide adenine dinucleotide phosphate 














NaOMe  Sodium methoxide 
Na2SO4  Sodium sulfate 
nM   Nanomolar 
NMP  N-Methyl-2-pyrrolidine 
PBP   Penicillin-binding proteins 
PBS   Phosphate buffered saline 
PFA   Paraformaldehyde 
pfcrt   P. falciparum chloroquine resistance transporter gene 
PfCRT  P. falciparum chloroquine resistance transporter protein 
pfmdr1  P. falciparum multidrug resistance 1 
Pgh 1  P-glycoprotein homologue 1 
Pgp   P-glycoprotein 
Ph   Phenyl 
PHA  Phytohaemagglutinin 
Phe   Phenylalanine 
PM   Plasmepsin(s) 
ppm   Parts per million 
PPh3  Triphenyl phosphine 
q   Quartet (in 1H NMR) 
QSAR  Quantitative structure-activity relationship 
RBC  Red blood cell(s) 
Rf    Retention factor 
RI   Resistance Index 
s   Singlet (in 1H NMR) 
SAR  Structure-activity relationship 
SERCA  Sarco/endoplasmic reticulum Ca2+-ATPase 
SO3･Pyr   Sulfur trioxide/pyridine complex 
t    Triplet (in 1H NMR) 
td   Triple of doublets (in 1H NMR) 
THF   Tetrahydrofuran 
TI   Therapeutic index 
TLC   Thin layer chromatography 
TMSCl  Tetramethylsilyl chloride 
U-4CC  Ugi four-component condensation 
Ugi 3C-4CC Ugi 3-component 4-centre condensation 
V   Volt(s) 
















Malaria remains to be one of the leading causes of morbidity and mortality throughout 
recorded history. It is caused by protozoan parasites of the genus Plasmodium, where P. 
falciparum is the most lethal. Current estimates are that over 500 million people are afflicted, 
while 3 million people die annually. With the emergence of resistance to antimalarial drugs 
in the malaria parasite, it is critical to develop new chemotherapeutic agents that can combat 
the disease and/or overcome resistance. This may be achieved by identifying molecules that 
target or interfere with unique parasitic pathways such as haemoglobin degradation or 
parasitic endocytosis. 
 
This thesis describes the design and synthesis of novel antimalarial agents based on the 
‘Designed Multiple Ligand’ approach. Compounds were synthesized via conjugate addition 
or multi-component condensation reaction. 4-Aminoquinolines were hybridized with 
artemisinin or 1,4-naphthoquinone derivatives; selected hybrids were further investigated for 
their effect on the parasitic endocytosis pathway and compared to the effect of chloroquine 
and artemisinin on the same pathway. The effects of drug treatment on the morphology and 
haemoglobin levels in the parasites as well as localization of transport vesicles via 
immunofluorescence microscopy were determined. 
 
A series of β-lactam derivatives containing a terminal acetylene moiety were synthesized via 
the Staudinger and Ugi 3-component 4-centre condensation reactions. The compound with 
the best activity from the series was used to couple these reactions to post-condensation 














create a more diversified library. A small series of 4-aminoquinoline analogues, including 
amodiaquine-like compounds and bisquinoline derivatives, was also prepared in an attempt 
to elucidate their structure-activity relationships. 
 
The antiplasmodial and cytotoxic activities were determined for all compounds; where 
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INTRODUCTION TO MALARIA 
 
Malaria or a disease resembling malaria has infected humans for over 50 000 years,1 where 
references of the unique periodic fevers were found throughout recorded history, as far back 
as 2700 BC in China;2 early documentations were also found in Greece and ancient Egypt. 
Due to its association with swamps and wetlands, malaria was termed “mala aria” – which 
translates to ‘bad air’ in Medieval Italian. In 1880, Charles Louis Alphonse Laveran was the 
first to discover that the cause of malaria is a protozoan, and was awarded the Nobel Prize in 
1907.3 The discovery that mosquitoes transmit malaria was made in 1897 by Ronald Ross, a 
British officer in the Indian Medical Service, where he demonstrated that mosquitoes could 
transmit malaria parasites from bird to bird, and established the complete parasite life cycle. 
He was awarded the Nobel Prize in 1902 for his pioneering work.4  
 
1.1 World Distribution 
 
Of all the parasitic tropical diseases occurring in man, malaria is the most dangerous and 
widespread disease, and is the fifth deadliest infectious disease worldwide. About 350–500 
million cases arise annually, and contributing to approximately 1 million deaths,5 especially 
among children and pregnant women.6 Malaria is transmitted to humans by four species of 
parasitic protozoa, Plasmodium falciparum, vivax, malariae and ovale. 7  Of these, P. 
falciparum is the most important, as it causes almost all the deaths associated with malaria. P. 
falciparum exists in over 100 countries, but is mainly confined to poorer tropical areas of 















some temperate zones, P. ovale is mainly confined in tropical West Africa, and P. malariae is 
found worldwide but very locally distributed.8 More than 90% of malaria cases and the great 
majority of malaria deaths occur in tropical Africa.7 It also poses risk to travellers and 
immigrants, with imported cases increasing in non-endemic areas.6 The spreading of the 
disease to these areas may also be a result of changing land utilization, especially plantation 
agriculture, which led to increasing cases in highland areas of East Africa.7  
 
 
Figure 1.1. World distribution of malaria infections.9 
 
1.2 Life Cycle of the Malaria Parasite 
 
The human malaria parasite has a complex life cycle (Fig. 1.2) that requires both human host 















When in people, they reproduce asexually (by cell division) first in the liver cells 
(hepatocytes), then repeatedly in the red blood cells (erythrocytes). A person is infected with 
malaria when bitten by an infected female Anopheles mosquito. The mosquito sucks blood to 
nourish her eggs, and at the same time injects saliva that contains sporozoites, the infectious 
form of the parasite, into the person’s bloodstream. The sporozoite promptly invades liver 
cells, developing into tissue schizonts. The schizont is a structure that contains thousands of 
tiny rounded merozoites. Upon maturation of the schizonts, merozoites are released into the 
bloodstream of the human host. These merozoites rapidly invade red blood cells, where they 
develop into ring forms and trophozoites, enlarging in the process, and eventually become 
schizonts. During the trophozoite stage, the parasite is actively metabolizing the 
oxygen-carrying haemoglobin by ingestion from the host cytoplasm, and proteolysis of 
haemoglobin into amino acids. Within a few days in a non-immune host, the parasitaemia 
may rise up to 1011. They then go through further rounds of asexual reproduction, forming 
more schizonts and merozoites. Every 48-78 hours, the red blood cells rupture synchronously, 
dispersing more parasites in the merozoite stage along with waste products and toxins into 
the bloodstream. This produces the clinical signs of malaria: fever, chills and anemia. The 
newly released merozoites invade more erythrocytes, and the infection continues its cycle 
until it is brought under control by medicine or the body’s immune defenses, or the patient 
dies. The parasite is pathogenic only in the blood stage; erythrocytes that are infected by 
malaria at the blood stage adhere to endothelial cells and sequester in the microvasculature 
of vital organs, including the brain, heart and lungs. Sequestration in the brain often leads to 
cerebral malaria. 
 
Some of the merozoites that penetrate red blood cells do not change into schizonts, but into 















anopheles mosquito bites an infected person, she sucks up these gametocytes along with 
blood. These gametocytes then develop into sperm-like male gametes or large, egg-like 
female gametes. Upon fertilization of the male and female gametes, an oocyst filled with 
infectious sporozoites is produced. When the oocyst matures, it ruptures, and thousands of 
sporozoites migrate to the salivary gland of the mosquito, ready to recommence the cycle 
when the mosquito feeds again. 
 


















1.3 Treatment and prevention of malaria 
 
Chemotherapy of malaria can specifically target the parasites. As the liver stage is the 
longest single stage in the parasite’s life cycle, studies have shown that the liver is the ideal 
target for drugs and vaccines to treat and prevent malaria.11 When the parasites enter the 
liver, they remain there for at least five and a half days before being released into the blood 
stream. During this time, the patient displays no symptoms of the disease. This period is 
hence a tremendous window to attack the parasites, but it is, however, extremely difficult to 
study the liver stages of the parasites, and most of the curative drugs act against the blood 
stages of the parasites. 
 
1.4 Classes of Antimalarial Drugs 
 
1.4.1 Clinically Established Drugs 
 
Antimalarial drugs can be categorized by (a) the stage of the malaria parasite at which it 
affects and the corresponding clinical objective,12 and (b) the mode of action through which 
they act.13 
 
1.4.1.1 Based on the stage of the life cycle 
 
Antimalarial drugs can be classified as blood schizonticides, tissue schizonticides, 

















Blood schizonticides - active against the asexual intra-erythrocytic stages of the parasite. 
They act by suppressing the replication of Plasmodia species within 
the erythrocyte. 
Tissue schizonticides - prevent the development of hepatic schizonts. They are more of 
prophylactic drugs than curative. 
Gametocides - prevent transmission between hosts by destroying the 
intra-erythrocytic sexual forms of the parasite. 
Sporontocides -  block the development of oocysts and sporozoites in the mosquito. 
 
1.4.1.2 Based on the Mode of Action 
 
Antimalarial drugs can also be classified according to the mode action by which they act in 
the parasite. Subclasses to which most of the currently marketed drugs belong are 
summarized below. 
 
1.4.1.2.1 Compounds Acting on Haem Detoxification 
 
Drugs in this group act by interfering with the formation of haemozoin, a detoxification 
process specific to the malaria parasites. These drugs include chloroquine and amodiaquine, 
belonging to the class of 4-aminoquinolines. Other drugs in this group include quinine and 
quinidine, which are alkaloids isolated from the bark of Cinchona ledgenaria (‘fever tree’). 
The bark was used as an ancient remedy for the treatment of malaria, by mixing the ground 



























Figure 1.3. Chemical structures of chloroquine, amodiaquine, quinine and quinidine. 
 
Chloroquine has been the drug of choice in malaria treatment for many years, until the 
emergence of widespread chloroquine resistance where malaria is endemic. A more detailed 
discussion on the mode of action and resistance of chloroquine is presented in Chapter 2. 
Due to the widespread of resistance to chloroquine, WHO initiated efforts to synthesize new 




















































1.4.1.2.2 Inhibitors of Nucleic Acid Synthesis 
 
Inhibitors in this group include sulfonamides, antifolates and naphthoquinones. 
Sulfonamides act by mimicking para-aminobenzoic acid (PABA) to compete for the active 
site of dihydropteroate synthase, hence preventing the formation of dihydropteroate from 
hydroxymethyldihydropterin. This leads to reduced dihydropyrimidine synthesis, which 
affects DNA, serine and methionine formation. Resistance to sulfonamides arises from point 
mutations in the gene that encodes for dihydropteroate synthase.15 An example of a 
sulfonamide is Sulfadoxine, which is used in combination with pyrimethamine (see below) 






Figure 1.5. Chemical structure of sulfadoxine. 
 
Antifolates inhibit dihydrofolate reductase, causing a depletion of tetrahydrofolate and 
consequently DNA synthesis. Similar to sulfonamides, resistance to antifolates may be from 
point mutations in the gene encoding for dihydrofolate reductase.15 Examples of antifolate 
inhibitors include pyrimethamine and proguanil.  
 
Atovaquone is the most successful drug in the class of 1,4-naphthoquinones, and is 
administered in a fixed preparation with proguanil as Malarone®. Malarone has fewer side 

























malaria. This combination is more efficacious than either drug alone, has a favourable safety 
margin, and also effective against strains that are resistant to a variety of other antimalarials. 
The mode of action of atovaquone is generally agreed to be acting on the mitochondrial 





      
Figure 1.6. Chemical structures of pyrimethamine, proguanil and atovaquone. 
 





         
Figure 1.7. Chemical structures of tetracycline and doxycycline. 
 
In this group are antibiotics, which have a long history in the treatment of malaria. With the 
emergence of chloroquine-resistant and multidrug resistant strains of P. falciparum, there has 
been a renewed interest in the use of antibiotics to treat malaria. Antibiotics such as 
























































         
Figure 1.8. Chemical structures of artemisinin, artemether, arteether and artesunate. 
 
Peroxides such as artemisinin and its family of derivatives, which include artemether, 
arteether, artesunate and many others fall under this category. They are believed to generate 
oxidative stress within the parasite via the endoperoxide group, which is important for 
antimalarial activity.17 Other mechanisms of action include the inhibition of the plasmodial 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). 18  SERCA is responsible for the 
maintenance of calcium ion concentrations, which is important for the generation of 
calcium-medicated signaling and the correct folding and post-translational processing of 
proteins. To date, the mechanism(s) of action is widely debated, and is discussed in more 
detail in Chapter 2. 
 
1.4.1.2.5 Iron chelating agents 
 
Iron chelators such as desferrioxamine enhance the clearance of parasites in cases of mild 





































quinine and Fansidar® can hasten the recovery from deep coma.19 The mechanism(s) of 
action of these iron chelators has been widely debated, but several hypotheses have been 
proposed. These include formation of free radicals, iron binding and inhibition of iron- 
dependent enzymes, such as ribonucleotide reductase, phosphoenol pyruvate carboxykinase, 







Figure 1.9. Chemical structure of desferrioxamine. 
 
1.4.2 Novel Inhibitors of Parasitic Pathways and Enzymes 
 
In light of the rapid development of resistance to antimalarial drugs, there is a pressing need 
for new chemical entities with no cross-resistance to existing antimalarials. Identification of 
new biological targets will be useful to base new treatment strategies on. A number of 
biosynthetic processes are known to be occurring within the malaria parasite, some of which 
are unique to the organism. As some of these processes are essential for parasite survival, 
their inhibition could result in parasite death. This strategy is currently under exploitation, 
and several targets have been identified and validated. Some of these targets include host cell 
proteins, the mitochondrion, membrane biosynthesis, cell cycle control, the plastid organelle 































1.5 Endocytosis of the malaria parasite 
 
Endocytosis is a fundamental process occurring in all eukaryotic cells. Cells rely on 
endocytosis to uptake external macromolecules (such as proteins), particles and fluids as 
nutrient sources to sustain their survival.22 The malaria parasite has only a limited capacity 
to synthesize amino acids de novo or scavenge them exogenously, thus it must obtain them 
from the host23 by degrading host haemoglobin (Hb). The parasites can degrade up to 75% 
of the Hb once they enter the red blood cell.24 These Hb are ingested via the endocytosis 
pathway. They do so by invaginations of the parasitophorous vacuolar membrane and the 
parasite plasma membrane known as the cytostome, enclosing the red blood cell cytoplasm 
(rich in Hb) in double-membraned endocytotic vesicles called transport vesicles.25 Some 
proteolytic digestion of the enclosed Hb cytoplasm may have already occurred at this stage.26 
These transport vesicles deliver the ingested Hb to the food vacuole by fusing their outer 
membrane with the single membrane-delimited food vacuole. Fusion releases a single 
membraned-vesicle,27,28 which is then lysed to release the haemoglobin.29 The endocytosis 
pathway is illustrated in Fig. 1.10. The food (or digestive) vacuole, where Hb catabolism 
occurs, is a specialized acidic lysosomal organelle with pH 5.2 – 5.6.30 The Hb proteolysis 
yields not only the needed amino acids, but also releases toxic free haem into the food 
vacuole.23 Here, the iron of the haem moiety is oxidized from the predominantly ferrous (II) 




























         
Figure 1.10. Schematic drawing showing the parasite in RBC, and the endocytosed haemoglobin 
transported to the FV via transport vesicles. A, cytostome; B, double-membraned transport vesicle; C, 
single membraned-transport vesicle; D, lysed transport vesicle; E, haemozoin crystals. 
 
The oxidation of haem to haematin leads to the production of hydrogen peroxide from 
superoxide generated through the one electron oxidation of Fe (II). Furthermore, the 
concentration of haematin released into the food vacuole can reach as high as 0.4 M, which 
is potentially toxic.31,32 Thus the parasite requires a detoxification mechanism. This involves 
the conversion of haematin to a crystalline haem aggregate known as haemozoin (malaria 
pigment).33 The chemical nature and structure of haemozoin has been elucidated only in the 
past decade. It is now known to be a cyclic dimer of ferriprotoporphyrin IX (Fe[III]PPIX) 
(see Fig. 1.11). By converting haematin to hemozoin, the parasite removes it permanently 
from solution, and deposits the iron porphyrin in a relatively harmless solid form.34 
 
Ginsburg and co-workers have observed that the parasite generates more amino acids from 















haemoglobin-derived amino acids are diffused into the host cell. This has raised the 
possibility that there may be additional functions to haemoglobin catabolism. One 
hypothesis is that the parasite prevents premature red cell lysis by digesting host cell cytosol, 








Figure 1.11. Structure of the malaria pigment, haemozoin.34 Dimers are formed through the Fe1 – 
O41 bonds between stacking ferriprotoporphyrins, and are linked to other dimers by hydrogen bonds 
through O36 and O37. 
 
1.6 Haem degradation pathway 
 
The Hb is degraded in the food vacuole by the cooperative process involving a number of 
proteases, such as aspartic (plasmepsins), 37 , 38  cysteine (falcipains) 39 , 40  and 
metalloproteases,41 and at least one cytosolic metalloaminopeptidase.42 When the lysate of 
the food vacuole was added to denatured globin and incubated at acidic pH, activities of both 
the aspartic and cysteine proteases were detected. Aspartic proteases account for 60-80%, 
and cysteine proteases account for 20-40% of the haemoglobin-degrading activity in purified 

















The availability of the full P. falciparum genome sequence and biochemical studies have 
rendered the identification of additional members of the above-mentioned protease families. 
Four plasmepsins were proposed to be involved in the onset of haemoglobin degradation;44 
these include plasmepsins (PM’s) I, II, IV and histo-aspartic protease (HAP),45 the third 
gene encoding an aspartic protease that was identified.46 HAP and PM IV are homologous to 
PM I and PM II.47 Falcipain 1, -2 and -3 were identified in the cysteine protease family.39,40 
A fourth member has also been identified via the expanded analysis of the complete P. 
falciparum genome, and is 96% and 93.4% identical at the nucleotide and amino acid level, 
respectively, to falcipain-2.48 The original gene (PF11-0165) is referred to as falcipain 2A, 
and upstream homologue (PF11-0161) is referred to as falcipain 2B. Another gene 
homologous to falcipain-2 and falcipain-2’ has been reported recently by Singh et al;49 they 
have shown that falcipain-2 and falcipain-2’, differing by only 3 amino acids, share more 
similarity in comparison to falcipain-2 and falcipain-3.  
 
1.6.1 Order of Action 
 
Data has suggested that the Hb degradation process is ordered, and that it requires an aspartic 
protease-mediated initial cleavage, followed by secondary aspartic protease and cysteine 
protease cleavages.37,43 Hb degradation assays have implicated that two aspartic proteases, 
plasmepsins I and II, are involved in the early stages of the degradative process, and cleave 
the native globin at acidic pH.38 Both of these enzymes, with 75% homology, can cleave the 
Phe33-Leu34 bond in the hinge region of the haemoglobin, the domain responsible for 
holding the tetramer together when oxygen is bound.50 , 51  This region is also highly 
conserved among vertebrate species.52 This is thought to be the crucial first step in Hb 















plasmepsins and other proteases.44  
 
Studies have shown that HAP and PM IV act later in the haemoglobin degradation pathway, 
as they prefer to cleave denatured globin rather than native haemoglobin at a site known to 
be the essential primary cleavage site in the haemoglobin hydrolysis pathway.45 Studies have 
shown that haemoglobin-degrading plasmepsins may not be promising targets, as minimal 
effect on parasite growth was observed when plasmepsin was treated with pepstatin A, a 
potent protease inhibitor.53 Hanspal et al54 have proposed that falcipain-2 may have a 
second role, in that the enzyme assists in the cleavage of specific components of the 
erythrocyte skeleton at the inner surface of the parasite membrane.  
 
Once the tertiary structure of Hb has been lost, falcipains-2 and -3, belonging to the class of 
cysteine proteases, degrade the larger fragments into smaller peptides (Fig 1.12). This is 
consistent with the notion of ordered proteolysis, as falcipains did not cleave haemoglobin 
unless it has been first denatured by reducing conditions, acid-acetone treatment, or cleavage 
by plasmepsins.38,43 These two proteases both require a reducing environment and acidic pH 
for optimal activity.55 The two enzymes share sequence homology (68%) and substrate 
specificity, but have markedly different activities. 56  Falcipain-2’, which was recently 
discovered, has similar biochemical properties to those of falcipain-2. These include 
sequence homology (99%), pH optima (5.5 – 7.0), reducing requirements, substrate 
preference and both readily hydrolyze haemoglobin. When compared to falcipain-2, 
falcipain-2’ displayed similar inhibitory activity against cysteine protease inhibitors. This 




























Figure 1.12. Proposed pathway for haemoglobin degradation in P. falciparum. Adapted from 25. 
 
The zinc metalloprotease falcilysin57 cleaves relatively smaller peptides (up to 20 amino 
acids) at polar residues of the Hb fragment under an acidic pH (optimum of 5.2),41 and is 
unable to cleave either haemoglobin or denatured globin. These small peptide residues are 
then transported from the food vacuole into the parasite cytosol by aminopeptidases, where 
the ultimate steps in haemoglobin degradation takes place.58 Falcilysin cleaves sites along 
the α- and β-chains of haemoglobin and are polar in character.41 It was also demonstrated 
that the enzyme is robustly active at neutral pH, but with a substantially different substrate 
specificity. This hypothesis is supported by imaging studies, which suggest that falcilysin 
may have an extended role beyond globin catabolism and may function as two different 





























1.7 Erythrocyte Rupture and Invasion 
 
Plasmodial proteases are not only involved in haem degradation, but also play a role in 
erythrocyte invasion59,60 and rupture.61,62 Early observations have suggested that the transit 
through the erythrocyte cytoskeleton is made possible by plasmodial proteases, as protease 
inhibitors blocked both erythrocyte rupture and invasion by malaria parasites.63 Studies to 
characterize the specific proteases involved in these processes have found that some of the 
same proteases that degrade haemoglobin also degrade cytoskeletal proteins, and are 
discussed below. 
 
1.7.1 Erythrocyte Rupture 
 
At the completion of each asexual cycle, erythrocytes must be ruptured to release free 
merozoites. The cytoskeletal proteins of the erythrocyte must be hydrolyzed by plasmodial 
proteases to allow parasite egress.64 Cysteine and serine proteases seem to play a role in this 
process; when leupeptin and chymostatin (cysteine and serine protease inhibitors, 
respectively) were added to the parasite culture, an accumulation of mature schizonts was 
observed.61,62 Two studies have provided improved insight in this process. Salmon et al65 
have shown that the addition of E-64, a cysteine protease inhibitor, to mature schizonts could 
block the lysis of the parasitophorous vacuole membrane, which surrounds the 
intraerythrocytic parasite. This suggests that cysteine protease activity is required for the 
hydrolysis of parasitophorous vacuole membrane-associated proteins to mediate merozoite 
release. Studies by Wickham et al66 have demonstrated that the lysis of the erythrocyte 
membrane is blocked by leupeptin and antipain, an oligopeptide cysteine protease inhibitor 















firstly, the hydrolysis of proteins associated with the parasitophorous vacuole, and secondly, 
the hydrolysis of erythrocyte membranes. However, the sequence of these two steps is in 
dispute.67  
 
Although there has been no report on aspartic protease activities in erythrocyte rupture, a 
study by Le Bonniec et al68 that showed plasmepsin II may be involved. Plasmepsin II was 
also shown to be localized both inside and outside the erythrocytic schizont, which suggests 
it has activities against more than one target. Additionally, Le Bonniec et al have also 
demonstrated that plasmepsin II and the cysteine protease falcipain-2 cleave haemoglobin at 
acidic pH in the food vacuole, and cytoskeletal proteins at neutral pH.68 Hence, it is likely 
that the proteases are transported to the food vacuole for haemoglobin degradation (and not 
synthesized in the food vacuole), and also capable of exiting the parasite to act against host 
cytoskeletal proteins. 
 
1.7.2 Erythrocyte Invasion 
 
During the invasion of the erythrocyte by merozoites, the cytoskeletal proteins of the 
erythrocytes are once again hydrolyzed by parasite proteases released from merozoite 
secretory organelles.69 The proteolysis of the complex cytoskeletal network is necessary, as 
this allows movement of the parasite into the erythrocyte.  
 
The invasion of erythrocytes by merozoites takes place in a sequence of three discreet steps, 
involving (1) the reversible attachment of the merozoite to erythrocyte receptors,         
(2) realignment of the merozoite such that its apical end apposes the erythrocyte membrane 















parasitophorous vacuole.70 During this process, the contents of three different types of 
secretory organelles (rhoptries, micronemes and dense granules) are released from the apical 
end of merozoites, which are believed to include proteases that facilitate erythrocyte entry.69  
 
Protease activities involved in erythrocyte invasion by merozoites have been shown to 
involve chymotrypsin-like serine proteases.59,60 Two plasmodial serine proteases have been 
well-described, they are Pfsub-171 and Pfsub-272, and are both subtilisin-like proteases. 
Studies that evaluated invasion of isolated merozoites have showed that there has been no 
inhibition of invasion by the cysteine and trypsin-like protease inhibitor leupeptin,61 the 
cysteine protease inhibitor E-64,73 or the aspartic protease inhibitor pepstatin.61,73  
 
Proteases in P. falciparum are summarized in Table 1.1 below.   
 
Table 1.1. Proteases of Plasmodium falciparum 
Protease Class Substrate(s) Putative Role(s) 
Falcipain cysteine haemoglobin, ankyrin haemoglobin hydrolysis, 
erythrocyte rupture 
Plasmepsins aspartic haemoglobin, spectrin haemoglobin hydrolysis, 
erythrocyte rupture 
Falcilysin metalloprotease globin fragments haemoglobin hydrolysis 
Aminopeptidase metalloaminopeptidase globin fragments haemoglobin hydrolysis 
Pfsub-1 and Pfsub-2 serine ? parasite proteins erythrocyte invasion 


















1.8 Cysteine Proteases 
 
Cysteine proteases, one of the main catalytic proteases involved in the haemoglobin 
degradation pathway, have aroused interest to many scientists as they are very widespread in 
nature, and play a vital role in the metabolism of both eukaryotic and prokaryotic organisms. 
In humans, cysteine proteases have been implicated in cardiovascular, inflammatory, 
neurological, respiratory, viral, musculoskeletal, immunological, CNS disorders and 
cancer.75 Cysteine proteases are also essential for the life cycle and pathogenicity of several 
parasites, such as cruzain from Trypanosoma cruzi, the causing agent of Chagas’ disease,76,77 
falcipain from Plasmodium falciparum, the causing agent of malaria,78 and rhodesain from T. 
brucei, the causing agent of the African sleeping sickness.79  
 
1.8.1 Cysteine Protease Superfamilies 
 
In 1879, the first cysteine protease was purified and characterized from the papaya fruit 
Carica papaya, and was thus named papain.80 Two amino acid residues in the parasitic 
cysteine protease, namely Cys 25 and His 159, are actively involved in the hydrolysis of 
peptide bonds. The cysteine thiol functionality is responsible for the catalytic activity of 
cysteine proteases Proteases that possess sequences in common with papain have been 
referred to as ‘papain-like’. Cysteine proteases are categorized into three structurally distinct 
groups based on their sequence homology; these are papain-like (clan CA), ICE-like (clan 
CD) and picomain-like (clan PA(C)).81 Clan CA and clan CD contain the majority of 
cysteine proteases in which the catalytic residues (Cys 25 and His 159) are highly conserved 
among all the members. Clan CA are well-characterized for many eukaryotic organisms and 















comprises of cathepsins, calpains, and parasite cysteine proteases. Clan CD includes several 
important enzymes including caspases, clostripain, gingipains, legumain and separase. The 
human rhinoviruses (HRVs), which are the single most significant cause of the common cold, 
belong to Clan PA(C).81   
 
1.8.2 Protease Binding and Classification of Binding Pockets 
 
A protease must bind the protein or peptide substrate in its active site before hydrolysis can 
take place. The binding efficiency is determined by the respective chemical environments 
that the protease subsites create, and the chemical nature of the substrate that interacts with 
the active site groove. Other important factors that affect interactions between the active site 
and a substrate include size, charge, polarity, hydrophobicity and accessibility.80  
 
A nomenclature to designate substrate residues and the corresponding enzyme subsites have 
been established by Schechter and Berger,83 and are labeled based on their relative position 
to the scissile peptide bond (Fig. 1.13). ‘P’ denotes amino acid residues from the peptide 
backbone, and the subsites that interact with these residues are denoted ‘S’. Amino acid 
residues and subsites at the carboxyl side are conventionally referred to as P1’, P2’, S1’, S2’, 
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1.8.3 Mechanism of Proteolysis 
 
The proposed mechanism of peptide hydrolysis of cysteine proteases is illustrated in Scheme 
1.1, in which a cysteine thiol in the active site is involved in the hydrolysis. The close 
proximity of His-159 to Cys-25 polarizes the thiol group of the cysteine, allowing the 
generation of a highly nucleophilic thiolate/imidazolium ion pair by deprotonation of the 
thiol group to be possible at near neutral pH (Scheme 1.1A).84 The strongly nucleophilic 
thiolate ion attacks the carbonyl carbon of the scissile amide bond to form a tetrahedral 
intermediate (Scheme 1.1B). The oxyanion intermediate is stabilized via H-bonding to the 
NH backbone of Cys-25 and to the NH2 group of the Gln-19 side chain. This is followed by 
acylation of the enzyme and the concomitant release of the C-terminal portion of the 
substrate (Scheme 1.1C). A base-catalyzed hydrolysis of the acyl-enzyme takes place, 
forming another tetrahedral intermediate (Scheme 1.1D). The final step in the hydrolysis is 
where this intermediate collapses (Scheme 1.1E) to regenerate the free enzyme and releasing 
the N-terminal portion of the substrate (Scheme 1.1F). 
 
1.8.4 Inhibitors of Cysteine Proteases 
 
The development in cysteine protease inhibitors has rapidly increased owing to advances in 
knowledge, computer-aided design and the use of combinatorial syntheses. To date, a wide 
range of cysteine protease inhibitors exist, and are broadly categorized into three distinct 




































     
Scheme 1.1. Mechanism of substrate hydrolysis by the papain superfamily of cysteine proteases. 
 
1.8.4.1 Irreversible Inhibitors 
 
Inhibitors belonging to this class bind covalently to the active site of the enzyme with a high 
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These inhibitors stay in the active site for a longer time which disables the enzyme 
permanently. Examples include epoxide 1.1,87  α,β-unsaturated ester and vinyl sulfone 










Figure 1.14. Epoxide 1.1, α,β-unsaturated ester and vinyl sulfone Michael acceptors 1.2 and 1.3 
as irreversible cysteine protease inhibitors 
 
1.8.4.2 Reversible Inhibitors 
 
Inhibitors that interact reversibly via covalent or non-covalent bond formations with the 
active site of the protease are termed reversible inhibitors. The bonds that form are weak and 
do not permanently disable the enzyme. Examples of such inhibitors include 
methylisatin-5-carboxamide 1.4,89 cyclic ketones 1.5,90 ureas 1.6,91 nitriles 1.7,92 thio- 
























































   
Figure 1.15. Methylisatin-5-carboxamide 1.4, cyclic ketones 1.5, ureas 1.6, nitriles 1.7, 
thiosemicarbazones 1.8 and pyrazolines 1.9 as reversible cysteine protease inhibitors. 
 
1.8.4.3 Slow Turnover Inhibitors 
 
Slow turnover inhibitors are compounds that act by forming a stable thioacyl-enzyme 
complex that is slow to hydrolyze. Principal examples of inhibitors belonging to this class 
include aza-substituted peptides such as peptidyl carbazate ester 1.1094 and diacyl hydrazine 







Figure 1.16. Peptidyl carbazate ester 6.10 and diacyl hydrazine 6.11 as slow turnover inhibitors 
of cysteine proteases. 
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CHLOROQUINE AND ARTEMISININ AS ANTIMALARIALS 
 
There has been a long history for the use of chloroquine and artemisinin as antimalarials. 
This chapter presents their background, mode of action and resistance to the causative agents 




Chloroquine, belonging to the class of 4-aminoquinolines, 
was synthesized by Hans Andersag in Germany in 1934, 
and was first named as Resochin by its founder.  
 
2.1.1 Mode of Action 
 
Despite its many years of field use and study, the mode of action of chloroquine remains 
disputed. In 1964, Cohen et al1 showed that chloroquine associates with haematin, and in 
1980, Fitch and co-workers proposed that haematin is the target of chloroquine.2 It wasn’t 
until 1992 when it was proposed by Slater and Cerami that chloroquine inhibits an enzyme 
responsible for malaria pigment formation.3 It is widely believed that chloroquine is 
selectively taken up by the parasite into the food vacuole, where the parasite actively digests 
haemoglobin.4 Chloroquine, at neutral pH, diffuses across the membrane against a pH 
gradient using energy. Once it reaches the food vacuole, the basic nitrogen atoms present in 
























is often referred to as ‘pH trapping’. Here, only the free base diffuses across the food vacuole 
membrane, and the increased protonation of the drug at low pH in the vacuole results in 
inflow of more drug until free base concentrations are equal on both sides of the membrane. 
 
Inside the food vacuole, chloroquine may form a complex with haematin via π-π stacking 
with the porphyrin system (Fig. 2.1),6 which may further enhance drug accumulation.7 The 
incorporation of haematin into haemozoin is thus inhibited, resulting in a buildup of toxic 
haematin and chloroquine-haematin complexes. 8  The accumulation of haematin and 
chloroquine-haematin adduct may potentially inhibit key enzymes, leading to parasite death, 
as well as bind to membranes, compromising membrane integrity and resulting in 







Figure 2.1. Schematic representation of the proposed π-π stacking between chloroquine and haematin. 
 
However, another mode of action of chloroquine and related drugs has been proposed by 
Ginsburg and co-workers.10 Haematin in concert with reactive oxygen species is thought to 
catalyze oxidation reactions and protein damage. Haematin that is released from the food 
vacuole in the cytosol may be rapidly reduced back into haem by glutathione and other 
reducing agents, which then enter the Fenton reaction (Fig. 2.2, eq 1) to form hydroxyl 


















species remain bound to the haem iron, and can initiate attack on the porphyrin ring to cause 
protoporphyrin protein destruction.    











Figure 2.2. Formation of hydroxyl radical and higher oxidation state transition metal species 
initiated via the Fenton reaction. 
 
This reaction is well-known in cytochrome c chemistry, 11  and investigations of the 
autoxidation of haemoglobin in the presence of glutathione at the molecular level have been 
carried out by Beuzard and co-workers.12 It has been postulated that glutathione indirectly 
contributes to haem degradation, via the Fenton reaction, in the cytosol by redox-cycling the 
haematin (Fe III) to haem (Fe II).13 The inhibitory effect in Plasmodium parasites displayed 
by chloroquine and the related 4-aminoquinolines may also be the result of the inhibition of 
the glutathione-dependent haem degradation, by slowing the overall rate of the haem redox 
cycling.10  
 
Stucture-activity relationship studies by Egan et al14 have shown that the following are 
important for biological activity (see Fig. 2.3): 
(a) The aminoquinoline ring – involved in π-π stacking with the porphyrin system, 
important for haem binding; 
(b) An electron withdrawing group at C7 – plays an important role in inhibition of 
haemozoin formation; 
(c) Basic nitrogen atoms – assist in vacuolar accumulation via pH trapping. 
Fe2+ + H2O2 → Fe3+ + HO․ + OH¯      (1) 















(d) Aminoalkyl side chain – required for antiplasmodial activity. Additionally, 
Krogstad and co-workers have found that changes in length of the side chain alter 









Figure 2.3. Representation of important groups for activity in chloroquine. 
 
2.1.2 Mechanism of chloroquine resistance 
 
The development of resistance to chloroquine was gradual, suggesting that multiple 
mutations may be required to produce the resistant phenotype. Resistance to chloroquine was 
localized to South America and South East Asia in the early stage resistance development, 
but to date the resistance has spread to virtually all areas where malaria is endemic.16 
 
To understand the occurrence of resistance towards quinoline drugs in P. falciparum, three 
fundamental points needs to be considered: (a) the cellular mechanism(s) by which the 
parasites escape the toxic action of the drugs, (b) possible changes in gene expression or 
genetic mutations that may lead to development of resistance, and (c) reversal of resistance 
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It was found that when compared to non-resistant strains of P. falciparum, the resistant 
strains have exhibited a reduction in cellular accumulation of chloroquine. 17 , 18  This 
reduction may arise from either a reduced uptake of the drug, or an enhanced drug efflux 
from the infected cell.19 In cancer, multidrug resistance (MDR) arises from the presence of 
an ATP-dependent (ATP – adenosine triphosphate, an energy source in cells), 
membrane-bound protein called P-glycoprotein (Pgp),19, 20  belonging to the family of 
ATP-binding cassette (ABC) transporters. The simultaneous binding of the drug substrate 
and ATP to Pgp is followed by ATP hydrolysis, which shifts the substrate into a position 
ready to be excreted from the cell. The release of a phosphate from ATP (forming ADP – 
adenosine diphosphate) is accompanied by substrate excretion. ADP is released, and a new 
molecule of ATP binds to the secondary ATP-binding site. The hydrolysis of this ATP resets 
the protein, ready for another round of drug substrate binding. 
 
Chemosensitizers are compounds typically without any inherent cytotoxicity, but are able to 
completely reverse the resistance of cells to the cytotoxic action of drugs.20 Reversal of 
resistance to MDR in cancer was observed when chemosensitizers such as verapamil were 
combined with chloroquine. Verapamil was believed to compete with anticancer drugs for 
Pgp binding, thereby preventing efflux from the cell compartments. The similarities between 
MDR and chloroquine resistance in malaria parasites suggest that a similar 
energy-dependent efflux protein may be present in the malaria parasite.17,21 It was found that 
the P. falciparum multidrug resistance 1 (pfmdr1) gene codes for a trans-membrane protein 
















2.1.2.2 Plasmodium falciparum Chloroquine Resistance Transporter 
 
Recent studies have shown that chloroquine resistance may be associated with a second gene, 
called Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene,23,24 encoding 
the protein PfCRT. PfCRT, a member of the drug metabolite/transporter superfamily, is 
located on the membrane of the food vacuole in the parasite, and has been directly linked 
with chloroquine resistance. Studies have found that this protein functions as a transporter 
that directly mediates the efflux of chloroquine from the food vacuole.24 The cause of 
resistance seems to be a common mutation (K76T) across the different chloroquine resistant 
strains. 
 
2.1.2.3 Other Hypotheses of Chloroquine Resistance 
 
The inhibition of glutathione-dependent haem modification by chloroquine implicated the 
participation of glutathione in the developing resistance to chloroquine. Studies have shown 
that when the level of glutathione was elevated in the malaria parasite, increase in resistance 
to chloroquine was observed, while depletion of the glutathione content restored the 
chloroquine-sensitivity in the chloroquine-resistant strains.13,25  
 
Other hypotheses include reduced Na+/H+ exchanger (NHE),26 increased vacuolar pH27 and 



















2.1.3 Application in Cancer 
 
The anticancer activities of chloroquine against various cancer cell lines have also been 
widely studied. It has been found that at lower concentrations, chloroquine is able to inhibit 
A549 lung cancer cell growth by increasing the volume of lysosomes, while at higher 
concentrations, apoptosis (self-killing) and necrosis are induced, using a mechanism 
different to growth inhibition.28  
 
It was also observed that chloroquine may improve mid-term survival (the median survival 
was double in the chloroquine group compared with controls) for glioblastoma multiforme, 
the most common and most aggressive type of primary brain tumour, when it was given in 
addition to conventional therapies.29 Loehberg et al have demonstrated that chloroquine 
exhibits a breast-cancer protective effect in an animal model, indicating that a short prior 
exposure to chloroquine may have a preventative application for mammary carcinogenesis.30 
 
Transferrin-CRM107 (Tf-CRM107) is a conjugate of transferrin and a point mutant of 
diphtheria toxin that selectively kills cells expressing high levels of the transferring receptor, 
such as brain tumour cells. However, it is also toxic against central nervous system in the 
brain. A study by Hagihara et al has shown that chloroquine was able to reduce the toxicity 
of Tf-CRM107 and widen its therapeutic window for malignant brain tumour therapy.31 The 
mechanism by which chloroquine acts may be via blocking the lysosomal processing of the 
endocytosed toxin in the tumour cells.32 
 
Very recently, chloroquine has been shown to be able to inhibit autophagy (self-ingestion) in 















lymphoma in mice.33 Autophagy, like apoptosis, is also a mode of self-destruction in cells.34 
However, when cells experience nutrition deprivation, autophagy is activated, which 
degrades damaged organelles, and recycles them as an alternate energy source.35 Hence the 
inhibition of autophagy by chloroquine does not prevent the cell from eating itself to death, 




Artemisinin (Qinghaosu; Chinese 青蒿素) and its derivatives 
are endoperoxide-containing natural products, isolated from 
Qinghao (Artemisia annua L, or sweet wormwood; Chinese 青
蒿, Fig. 2.4). It belongs to the Compositae family, grows 
abundantly and is indigenous all over China. It has been used 
for about 2 000 years to treat hemorrhoids and fever in Chinese 
folk medicine. Chemically, artemisinin is a sesquiterpene lactone, the first and last naturally 
occurring 1,2,4-trioxane.36 This unusual compound has been of interest to many researchers 
due to the interesting chemical structure, and also the lack of a nitrogen-containing hetero- 
cyclic ring, which is found in most antimalarials.  
 
Artemisinins exhibit a quick onset of action and high efficacy against the blood stages of 
Plasmodium. They have been shown to act against even the early stages (ring forms) of the 
parasite,37 and have been shown to reduce the number of gametocytes in the blood,38 owing 
to their activity against both the precursors of the sexual stages and early (stage I – III) 
gametocytes. Additionally, artemisinins also decrease the infectivity of the surviving 








































This effect may not be evident in high transmission areas, as rapidly re-infected individuals 





Figure 2.4. Flower and leaves of Artemisia annua L, sweet wormwood. 
 
2.2.1 Discovery of Qinghaosu 
 
The earliest written reference for qinghao discovered so far was documented in the “Recipes 
for 52 kinds of diseases”, which was unearthed from the Mawangdui Tomb of the West Han 
Dynasty (168 BC) in Changsha, Hunan Province. In “The Handbook of Prescriptions for 
Emergency Treatments”, Ge Hong (AD 281 – 340, Eastern Jin Dynasty) recommended the 
taking of an aqueous infusion of the plant to alleviate the chills and fever of malaria.41 In 















famous work “Compendium of Medical Herbs”.42 In the now modern countryside of 
Southeast China, people believed that patients will recover soon after drinking the aqueous 
extraction of qinghao. This led to great interest in qinghao by many research groups, but the 
isolation of the active ingredient has suffered repeated setbacks, as water or alcohol extracts 
of qinghao never showed antimalarial activity. It was only until the early 1970’s when three 
research groups in Beijing, Yunnan Province and Shandong Province almost simultaneously 
obtained the active ingredient by extracting with ethyl ether, petroleum ether or acetone 
respectively.43 The neutral isolations possessed good antimalarial activity in mice infected 
with Plasmodium berghei and in monkeys infected with Plasmodium cynomolgi,41,42 and was 
soon found that the component was very effective in clinical trials. The colourless needle 
crystal was hence named quinghaosu (active essence of qinghao) in Chinese, and artemisinin 
(sometimes called arteannuin) in English. Its structure and relative configuration was proved 
by X-ray crystal structural analysis, and the absolute configuration was obtained by X-ray 




The effectiveness of artemisinin and its derivatives as antimalarials has received increasing 
attention in recent years for their treatment of chloroquine, mefloquine, or multidrug 
resistant malaria. However, the usefulness of artemisinin has been impaired by its (a) high 
rate of recrudescence,45 (b) poor solubility in oil and water,46 (c) short plasma half-life47,48 
and (d) poor oral activity (active only at very high dosage).45 Dihydroartemisinin, obtained 
by sodium borohydride reduction of artemisinin, was reported to be therapeutically more 
active than the parent compound.46 However, it is also associated with toxicity49 and short 















in oil (i.e. arteether and artemether46,51) and water (i.e. sodium artelinate52 and sodium 
artesunate53) were synthesized from dihydroartemisinin. These are the most well-known 
analogues of the so-called first-generation derivatives of artemisinin. Although showing 
higher potency than artemisinin in vitro, the oil-soluble artemether and arteether have poor 
bioavailability principally as a result of the metabolic instability of the acetal function. For 
example, one of the principal routes of metabolism of artemether involves oxidative 
dealkylation to the toxic DHA, which produced fatal central nervous system (CNS) toxicity 
in chronically dosed rats and dogs.54,55,56  
 
The desire for a water-soluble derivative of artemisinin for the treatment of advanced cases 
of P. falciparum malaria led to the design and synthesis of sodium artesunate. Water-soluble 
derivatives can be injected intravenously (iv), and thus drugs can be delivered more quickly 
than by intramuscular (im) injection.57  Due to its high water-solubility, treatment of 
comatose cerebral malaria patients with sodium artesunate had resulted in a rapid diminish in 
parasitaemia and restoration of consciousness.57 However, the usefulness of sodium 
artesunate was offset due to its lability to chemical hydrolysis in aqueous solution,52 high 
rate of recrudescence and the extremely short plasma half-life (20 – 30 min).58 Due to its 
high recrudescence rate, sodium artesunate is normally administered in combination therapy, 
most often with mefloquine.59 Out of all the first generation analogues of artemisinin, 
sodium artesunate is currently the drug of choice.60 
 
To overcome the hydrolytic instability of artesunate, sodium artelinate was synthesized. It 
turned out to be not only more stable than artemether and arteether in aqueous solution, but 
also has a much longer half-life (1.5 – 3 h). Literature has also suggested that sodium 


























Figure 2.5. Artemisinin and its derivatives. 
 
2.2.3 Activity against multidrug resistant parasites 
 
The phenomenon of drug resistance is most common in southeast Asia. On the borders of 
Thailand, this phenomenon has been studied intensively where mefloquine-resistant parasites 
emerged after only a few years of monotherapy.62 Efficacy can be restored in some areas 
when artemisinins are combined with drugs that no longer work well enough. The 
combination of artesunate and mefloquine was able to consistently cure more than 95% of 
patients, where mefloquine alone only worked for about 50-60% of cases.62,63 
 
These findings have given rise to the idea that antimalarial drugs should be combined for an 
effective treatment of patients, and that such a combination should always include an 
artemisinin derivative.64 The advantages of using artemisinin in combination is that (a) cure 
rates can be raised when combined with antimalarials that are taken from different classes, 
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The use of artemisinin in combination is also beneficial in terms of the metabolism of 
artemisinins, as treatment with artemisinin drugs causes reduction of parasitaemia below 
detectable levels without eliminating all parasites, resulting in a higher risk of 
recrudescence.65,66 Additionally, a fraction of the parasites exposed to the drug are thought 
to become dormant and unsusceptible to further dosing until reactivation.67 Therefore, in 
order to completely eliminate the parasites, combinations with other longer-acting drugs are 
necessary. 68 , 69  The World Health Organization (WHO) has currently recommended 
artemisinin combination therapies (ACT) as the first-line antimalarial treatment for P. 
falciparum malaria.70 Several ACTs have been developed, including Coartem® (artemether 
+ lumefantrine), and combination of artesunate with amodiaquine, mefloquine or 
sulfadoxine-pyrimethamine.68,70  
 
2.2.4 Theories on Mechanism of action 
 
2.2.4.1 Non-specific proposed mechanisms of action 
 
Artemisinin and its derivatives kill malaria parasites at nanomolar concentrations, but they 
are only toxic to mammalian cells at micromolar concentrations. Meshnick et al have found 
that this selectivity is due to the enhanced uptake of artemisinin by the malaria parasite.71 
They have shown that the concentration of [3H]-dihydroartemisinin and [14C]-artemisinin in 
P. falciparum infected erythrocytes is >100 times more concentrated than that of uninfected 
erythrocytes. Desoxo derivatives72 which lack the endoperoxide bridge, and the 1-carba 
analogue of artemisinin,73 in which one of the peroxide oxygen atoms is replaced by a 
carbon atom (Fig. 2.5), are inactive towards malaria. This indicates that the peroxide 































Scheme 2.1. Pathways of radical formation 
 
2.2.4.1.1 Generation of reactive oxygen species from the peroxide  
 
It has been proposed that the peroxide entity of artemisinin may generate reactive oxygen 
species, such as hydroxyl, alkoxyl, superoxide or peroxyl radicals, within the parasitized 
erythrocyte. The formation of these reactive oxygen species can be enhanced            
through the Fe2+-dependent Fenton reaction, as illustrated in pathway A in Scheme 2.1. 





























































































































































supporting the hypothesis that Fe2+ plays an important role. These reactive oxygen species 
may overwhelm the parasite anti-oxidant defense system, leading to parasite death.75 
 
2.2.4.1.2 Activation by “free” ferrous iron  
 
The reductive cleavage of a peroxide by Fe2+, via the Fenton reaction, to generate O-centred 
or alkoxyl radicals, which rearranges to C-centred radicals and finally neutral products has 
been well understood and thoroughly examined before the advent of the artemisinins.76 The 
peroxide entity is cleaved and generates two different alkoxyl radicals, labeled ‘O-1’ and 
‘O-2’ radicals, as illustrated in pathway B in Scheme 2.1. The ‘O-2’ radical is adjacent to an 
oxygen atom, and is predisposed to undergo ‘α-cleavage’, which is the cleavage of the 
C3–C4 bond, to generate the ‘seco’ C-4 radical. On the other hand, the ‘O-1’ radical 
abstracts the nearby α-disposed hydrogen atom on C-4 to generate the C-4 radical. The 
anticipated targets of the carbon-centered radicals include haem-binding proteins and 
proteases involved in haemoglobin degradation.77,78  
 
2.2.4.1.3 Inconsistencies in the iron-activation theory 
 
Eckstein-Ludwig et al have later shown that the Fe2+-dependent activation of artemisinin is 
independent of haem.79 The use of a protease inhibitor inhibited the activity of chloroquine, 
as was widely accepted that chloroquine acts by binding to haem. In contrast, no antagonism 
or synergism was observed between the protease inhibitor and artemisinin activity. 
Furthermore, the fluorescent labeling of artemisinin derivatives has shown that instead of 
being localized in the parasite FV, as would be expected in the case of haem-dependent 















Artemisinin derivatives that are chemically unable to react with haem, 
but are very potent antimalarials have been found by Haynes et al.80 
10-Deoxoartemisinin, possessing superior in vitro activity against P. 
falciparum and is approximately equipotent in vivo against P. berghei 
compared to artemisinin, is hydrolytically more stable than 
artemisinin and dihydroartemisinin, and was found to not interfere at all with haemozoin 
formation. This shows that binding of artemisinin to Fe(III)PPIX is unnecessary for 
antimalarial activity, as the inhibition of β-haematin does not relate to biological activity.81  
 
Several workers have proposed that the parasite death in the presence of artemisinin may 
involve high affinity binding of the intact artemisinin to an active site, prior to any 
“activation”, as opposed to non-specific or random cell damages caused by freely diffusing 
oxygen radical species. 
 
2.2.4.2 Parasite-specific proposed mechanisms of action 
 
Results by Avery et al82 and Golenser et al83 have shown that for various analogs of 
artemisinin, the IC50 for Plasmodium is less than that of L. major and other eukaryotic cells 
by several orders of magnitude (0.10 nM and 0.63 μM respectively for DHA), suggesting a 
specific mechanism of action of the artemisinin class of antimalarials.  
 
2.2.4.2.1 Inhibition of plasmodial sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) 
 
Research done by Krishna and Haynes65,78 have suggested that artemisinin undergoes 






















activity of artemisinin is sensitive to steric effects. For example, the replacement of the 
methyl group at C3 of artemisinin and 10-deoxodihydro-artemisinin by much larger groups 
(e.g. phenylethyl) results in a decrease in activity. As artemisinin is structurally similar to 
thapsigargin (extracted from the plant Thapsia gargania), also a sesquiterpene lactone, 
which is a highly specific inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), it 
was hypothesized by Eckstein-Ludwig et al that artemisinins specifically inhibit P. 







Figure 2.6. Chemical structure of thapsigargin. 
 
SERCA is responsible for the maintenance of calcium ion concentrations, which is important 
for the generation of calcium-mediated signaling and the correct folding and 
post-translational processing of proteins. Eckstein-Ludwig et al have found that artemisinin 
completely inhibited PfATP6, the only SERCA-type Ca2+-ATPase in P. falciparum, with 
high specificity. Addition of thapsigargin and artemisinin to P. falciparum cultures showed 
antagonism, indicating that both drugs have a common target. Further tests done by 
Eckstein-Ludwig et al have also suggested that artemisinin binds to the same region in the 
protein that binds thapsigargin.79  
 
Artemisinins may bind to PfATP6 by hydrophobic interactions while leaving the peroxide 
bonds exposed, as demonstrated by three-dimensional modeling of the PfATP6 amino acid 



























allow its cleavage by iron to generate carbon-centered radicals (as discussed earlier), leading 
to enzyme inactivation and parasite death. This theory is supported by the fact that a single 
amino acid mutation in the plasmodial SERCA modulates sensitivity to artemisinins in 
vitro,85 and is also the most widely accepted as the possible mechanism of action. 
 
2.2.4.2.2 Research contradicting protein-binding as a mode of action 
 
Research conducted by various groups has produced results that contradict the findings of 
Eckstein-Ludwig et al.86,87 del Pilar Crespo et al86 have found that thapsigargin caused a 
marked contraction and re-organization of the endoplasmic reticulum; however, this was not 
observed for artemisinin. Additionally, they have also found that there was no antagonism 
between thapsigargin and artemisinin based on their isobolograms. These results thus do not 
support the reported antagonism between artemisinin and thapsigargin by Eckstein-Ludwig 
et al.  
 
Hartwig et al87 have studied the distribution of fluorescent dansyl trioxane derivatives in 
living, intraerythrocytic-stage P. falcipaum parasites using microscopic imaging. The 
fluorescent trioxanes rapidly accumulate in parasitized erythrocytes, and localizes within 
food vacuole-associated neutral lipid bodies of trophozoites and schizonts, and surrounding 
the developing merozoite membranes. They have found that artemisinin pre-treatment 
significantly reduced fluorescent labeling of neutral lipid bodies. However, thapsigargin 
pre-treatment resulted in no such effect. Moreover, staining of thapsigargin-treated parasites 
with Nile Red has demonstrated that neutral lipid bodies formation was unaffected by 
thapsigargin pre-treatment, thus once-again suggesting that artemisinin and thapsigargin act 















The PfATPase-dependent model of activity and the differences in the antimalarial activity of 
enantiomeric forms of artemisinins suggest that the highly specific, noncovalent interaction 
between artemisinins and a protein target could result in stereoselectivity. However, results 
from O’Neill et al have shown otherwise.88 They have found that the enantiomers of 
trioxanes structurally related to artemisinin showed equivalent levels of activity against 
chloroquine-sensitive, chloroquine-resistant and multidrug-resistant strains of P. falciparum. 
This implies that the activation of artemisinin does not depend on stereospecific interaction 
with a protein. Additionally, introduction of bulky side groups to artemisinin may cause 
either an increase or decrease in activity, depending on the residues added.89 Both points 
described here weaken the theory that a protein-binding site is crucial for artemisinin 
activity. 
 
2.2.4.2.3 Interference with mitochondrial electron transport 
 
Li et al have shown that the addition of artemisinin causes depolarization of the 
mitochondrial membrane, using genetic manipulation in yeast models.90 They have found 
that two yeast genes that encode NADH dehydrogenases are vital for artemisinin sensitivity 
or resistance, and a gene homologous to one of the two are found in the P. falciparum 
database. This suggests that artemisinin and its derivatives are activated by the transition 
metals, including iron, in the mitochondria, and subsequently cause local production of 
reactive oxygen species and depolarization of the mitochondrial membrane. Artemisinin has 
also been shown to inhibit the respiratory chain of both sexual and asexual stages of P. 
falciparum. 91  The loss of membrane potential in the parasite affects pyrimidine 
















Artemisinin derivatives may be active via several mechanisms. At this point, there is no 
decisive evidence as to the absolute target(s) that they act against.  
 
2.2.5 Semisynthetic and synthetic endoperoxide antimalarial drugs 
 
Semisynthetic and synthetic endoperoxide derivatives have been synthesized by various 
research groups, and found to possess potent antimalarial activities. These include the 







Figure 2.7. Structures of representative semisynthetic and synthetic endoperoxide derivatives. 
 
2.2.6 Artemisinins as anti-cancer drugs 
 
Anti-cancer properties of artemisinins have been assayed in vitro since the late 1980’s. It has 
been found that apart from anti-malarial activities, artemisinins such as artesunate has also 
been found to be active against a variety of unrelated tumour cell lines, being the most 
effective against leukemia and colon cancer, while inhibitory effects on cancer cell growth 
such as lung, melanomas, breast, ovarian, renal, prostate, CNS cancer cells including many 
drug resistant cancer cells have been reported.96,97 Other studies have also shown that 
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2.2.6.1 Possible mechanisms of action 
 
The potential general mechanism against these tumour cells has been identified to be the 
inhibition of angiogenesis100 (formation of new blood vessels from existing host capillaries), 
and the normalization of the upregulated Wnt/b-catenin pathway in colorectal cancer.101 
Artemisinins also inhibit the proliferation, migration and tube formation of human umbilical 
vein endothelial cells (HUVEC), as well as vascular endothelial growth factor (VEGF) 
binding inhibition to surface receptors on HUVEC, and a reduction in the expression of 
VEGF receptors Flt-1 and KDR/flk-1 on HUVECs.100 f-h The reduction in the expression of 
the VEGF receptor KDR/flk-1 was also observed in tumour and endothelial cells.100 b-d 
 
Artemisinins may function in different ways to classical cancer chemotherapeutic drugs, as 
when genes that encode for transporters that mediate drug resistance, such as MDR gene 1, 
MDR associated protein 1 and breast cancer resistance protein, were over-expressed, a 
change in susceptibility was not observed. These studies have also shown that the delivery of 
iron by the use of holotransferrin enhances the anticancer properties of artemisinins in some 
cell lines.102,103 
 
2.2.6.2 Development of Artesunate as a drug candidate 
 
Artesunate acts at targets different to those of many current cancer chemotherapeutics, and 
hence unlikely to pose antagonistic effects to existing anticancer agents.104 A study in which 
an animal model carries a human colorectal cancer cell line have confirmed that artesunate 
has independent antitumour activity, and can decrease the size of primary tumours and 















cases of human studies105 and a recent Phase II study of lung cancer106 both support the idea 
that artesunate should be forthwith studied as a primary or adjunct antitumour agent, 
particularly for leukaemia and colorectal cancers. The relatively low toxicity on normal 
human cells,102 ease of administration and good oral bioavailability of artesunate also makes 
it an ideal drug candidate. 
 
2.3 Aims and objectives 
 
Overall aim: 
- To design and synthesize new antimalarial agents that target or interfere with unique 
parasitic pathways such as haemoglobin degradation or parasitic endocytosis. 
 
Objectives: 
- To synthesize antimalarials based on the “Designed Multiple Ligand” approach, in which 
quinoline inhibitors of β-haematin formation are hybridized with artemisinin, which is 
believed to act via the inhibition of the plasmodial sarco/endoplasmic reticulum Ca2+ 
ATPase (SERCA), or 1,4-naphthoquinones, which are inhibitors of glutathione redutase. 
- To synthesize β-lactams via the Staudinger reaction or the Ugi 3-component 4-centre 
condensation, and subsequent post-condensation modifications via the Mannich reaction. 
- To synthesize amodiaquine-like and bisquinoline compounds. 
- To pharmacologically evaluate the synthetic compounds in order to identify potential 
new antimalarials, and the exploration of their effects on plasmodial endocytosis, and/or 
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DESIGNED MULTIPLE LIGANDS VIA 




This chapter describes the synthesis, characterization and biological evaluations of novel 
artemisinin derivatives, some of which contain a 4-aminoquinoline group, the pharmaco- 
phore responsible for antiplasmodial activity in chloroquine. These compounds were 
designed and synthesized primarily to determine their antiplasmodial and anticancer 
activities. 
 
3.2 Definition of Pharmacophore 
 
The definition of a pharmacophore was first described by Paul Ehrlich as “a molecular 
framework that carries (phoros) the essential features responsible for a drug’s (pharmacon) 
biological activity”.1 This definition remained unperturbed for over 90 years, until the 
currently widely used definition was presented in 1977 by Peter Gund as “a set of structural 
features in a molecule that is recognized at a receptor site and is responsible for that 
molecule’s biological activity”.2 The IUPAC definition of a pharmacophore is “an ensemble 
of steric and electronic features that is necessary to ensure the optimal supramolecular 


























Figure 3.1 Pharmacophore of artemisinin. 
 
The pharmacophore of artemisinin has been identified as the 1,2,4-trioxane (6-membered 
ring containing 3 oxygen atoms) moiety.4,5 Studies have shown that, when compared to 
artemisinin, in vitro activities have vastly decreased for artemisinin analog without the 
endoperoxide bridge,4 or carba-analog where O-3 is replaced by a carbon atom.5  
 






Figure 3.2 Pharmacophore of chloroquine. 
 
As discussed in Chapter 2, the various components responsible for biological activity of 
chloroquine have been identified. In general, the pharmacophore of chloroquine has been 





























3.3 Rationale of Pharmacophore Hybridization 
 
The antimalarial activities of artemisinin and chloroquine have been long established. Here, 
these two pharmacophores are combined into a single agent, and their antiplasmodial 
activities assessed compared to their parent drugs (Fig. 3.3). This combination is based on 
the idea of designed multiple ligands (DML),7 and is analogous to combination therapy 
whereby two or more drugs are administered at the same time.8 These DMLs hold potential 





Figure 3.3. A DML containing chloroquine and artemisinin pharmacophores. 
 
The antimalarial properties of such hybrid molecules have previously been investigated. 
Examples include trioxane-aminoquinoline chimeras (‘trioxaquines’), 9  1,2,4,5-tetraoxa- 
cycloalkane-aminoquinoline chimeras (‘tetraoxaquines’), 10  artemisinin-quinine hybrids 11 
and acridine-endoperoxide derivatives.12 Structures of selected examples are shown in Fig. 
3.4. Studies have demonstrated that the trioxaquines and artemisinin-quinine hybrids 
possessed improved antimalarial activity in comparison to parent drugs;9,11 
acridine-endoperoxide derivatives have also displayed low nanomolar in vitro activities.12 In 
particular, a few trioxaquines were able to alkylate haem13 and inhibit β-haematin formation 
better than chloroquine,14 and a few tetraoxaquines cured mice in a modified Thompson test 



























Figure 3.4. Chemical structures of trioxaquine 3.1 (Du-1102), tetraoxaquine 3.2 and 
artemisinin-quinine hybrid 3.3. 
 
3.4 Designed Multiple Ligands in Drug Discovery 
 
The pharmaceutical industry today is dominated by the ‘one-target, one-disease’ approach, 
where many successful drugs have emerged from this strategy. However, this approach has 
been readily challenged, and strategies to develop agents that can modulate multiple targets 
simultaneously (polypharmacology) were designed. The aim of this strategy was to enhance 
the efficacy or improve the safety relative to drugs that only focus on a single target.15,16,17  
 
There are three approaches to polypharmacology (Figure 3.5): 
A. Drug cocktail, administered in the form of two or more individual tablets; 
B. Multicomponent drugs, whereby two or more agents are coformulated into a single 
tablet; 
C. Multiple ligands, whereby a single chemical compound is able to simultaneously 
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Figure 3.5. Three main approaches to polypharmacology. Adapted from reference7  
 
3.4.1 Advantages and disadvantages of these approaches 
 
Drug cocktail therapies are often accompanied by poor patient compliance.18 However, it 
offers greater dose flexibility when compared to multicomponent and multiple ligand drugs. 
The pharmacokinetic/pharmacodynamic relationships for multicomponent drugs may be 
highly complex, as the relative rates of metabolism may be very different between patients. 
This leads to unpredictable variability between patients, hence compelling extensive and 
expensive clinical studies. 
 
The multiple ligand approach has a different risk-benefit profile when compared to 
multicomponent drugs, as summarized in Table 3.1. The increased complexity in the design 
and optimization of such ligands is shifted toward the earlier stages of the drug discovery 
process. The clinical development of multiple ligand drugs is in principle no different from 
the development of any other single entity, in terms of the risks and costs involved. 
Drug-drug interactions are also lower when compared to the other two approaches.19 
However, a major disadvantage of multiple ligand drugs is that it is difficult to adjust the 






















Patient compliance Bad Good Good 
Dose flexibility Yes No No 
Ease of clinical 
development 
Yes No Yes 
Possible drug-drug 
interactions 
Yes Yes No 
 
Many of the drugs that are currently marketed are in essence multiple ligands, while very 
few were rationally designed to be so. Their mechanisms of action were conventionally 
elucidated retrospectively. An increase in the number relevant publications indicates the 
growing interest in the rational design of ligands acting specifically on multiple targets. 
However, DMLs should not be confused with ‘nonselective’ ligands that possess significant 
activity at irrelevant targets, with undesirable cross-reactivity that may lead to deleterious 
side effects. 
 
3.4.2 Pharmacophore Combination Approach 
 
The current predominant technique used for the generation of multiple ligands is the 
methodical combination of pharmacophores from selective ligands. A ‘conjugate’ is a 
multiple ligand where the underlying pharmacophore element for each target is separated by 
a distinct linker group that is not found in either of the selective ligands. A ‘cleavable 
conjugate’ is designed to release two ligands that interact independently with each target 
when metabolized. As the size of the linker decreases, a point is reached where the two 
















these are regarded as ‘fused’. The pharmacophores can also be ‘merged’ by integrating 
common structural motifs that are present in both ligands.7 
 
The degree of overlap of these pharmacophores forms a continuum, with high-molecular 
weight conjugates at the one end, and simple, low-molecular weight but highly integrated (or 









Figure 3.6. DML continuum. Adapted from references 7and 18. 
 
3.5 Rationale for Drug Design 
 
The rationale for the design of drug compounds in this chapter is based on the idea of DML 
as illustrated in section 3.3. In principle, biological activities are envisaged to be maximized 
by the incorporation of the artemisinin core and 4-amino-7-chloroquinoline moiety into a 
single molecule, through modification on C-10 of the artemisinin core (Fig. 3.7). This 
concept was first proposed by Vennerstrom.9c Additionally, the emergence of drug resistance 
could potentially be overcome or delayed when a drug acts against multiple targets.  
 
conjugate                     fused                   merged 
linker 
Increasing degree of overlap of two pharmacophores 


























Figure 3.7. Rationale for design of target molecules. 
 
In addition to what was discussed in section 2.1, it has also been found that the length of the 
alkyl group between the two nitrogen atoms on the 4-amino side chain may play a role in the 
degree of biological activity of chloroquine. Chloroquine analogs where this alkyl chain is 
shortened to 2 or 4 atoms between the nitrogen atoms, or lengthened to 10 or 12 atoms, 
retain their activities against chloroquine resistant strains; while those with chain lengths 
similar to chloroquine (5 – 8 atoms) have intermediate activities. 20  The level of 
accumulation of CQ depends upon the pKa of the quinoline side chain nitrogen.6,21 
 
It has been found that having a chloro-, bromo- or iodo- group at the C-7 position of the 
quinoline ring had enhanced activities, and that 7-iodo- and 7-bromoquinolines had activities 
superior to 7-chloroquinolines, although not to a significant degree. Studies by Egan and 
co-workers on β-haematin (synthetic haemozoin) inhibition of quinolines established that the 
association of β-haematin depends on the nature of the substituent at C-7 of the quinoline 
Inhibition of haemozoin formation.  
Cl, Br, I favoured,  
reverses CQ resistance; 
NH2, OH, OMe, CF3, F, NO2 not favoured. 
Vacuolar accumulation 
n = 1 – 4, 10 – 12, favoured,  
reverses CQ resistance; 




























moiety, although this does not translate directly to good antiplasmodial activity.22 They have 
found that strongly electron-donating groups at C-7 exerted the most effect in β-haematin 
inhibition, but moderately electron-withdrawing groups displayed better antiplasmodial 
activities. Inhibition of β-haematin formation was found to correlate with good 
antiplasmodial activity, as the in vitro IC50 values had a linear dependence on the inhibition 
of β-haematin formation. 
 
Before discussing the synthesis of the target compounds, the general reactivity and behavior 
of quinoline towards nucleo- and electrophiles are described in the next section. 
 




      
Figure 3.8. Structure of Quinoline 
 
A quinoline is a fused benzo[b]pyridine heterocycle, derived from the fusion of a benzene 
and pyridine ring. Its activity can also be viewed as similar to its parent rings, i.e. 
electrophilic reactions occur on the benzene ring, and nucleophilic reactions occur on the 
pyridine ring. The nitrogen atom in the ring causes quinoline to be more π-deficient through 
mesomeric and inductive effects, as illustrated in Fig. 3.9. The effect is most pronounced in 
C-2 and C-4 positions, which are in close proximity to the nitrogen atom. Reactivity at these 
positions can be further enhanced by the presence of electron-withdrawing substituents, such 






























     
Figure 3.9. Canonical structures for the inductive and mesomeric effects of the nitrogen atom on 
quinoline ring. 
 
Quinoline is more reactive towards electrophiles when compared to pyridine, as the reaction 










Figure 3.10. Sites of electrophilic substitution on quinoline ring, as depicted by mesomeric effects. 
 
Electrophilic substitutions predominantly take place at C-5 and C-8, as these intermediates 
































Resonance stabilization at C-5 Resonance stabilization at C-8
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3.7 Synthesis of Target Compounds via the aza-Michael Addition 
 
Many nitrogen-containing biologically important compounds, such as β-amino alcohols, 
1,2-diamines and β-lactams, 23  can be synthesized from the β-aminocarbonyl building 
block.24 A number of efficient methods for the preparation of this unit have been developed, 
such as the Mannich reaction,25 which has been the reaction of choice for many years. 
However, it often requires harsh reaction conditions. The Aza-Michael reaction has recently 
attracted much attention as an alternative route, owing to its mildness and operational 
simplicity. Most aza-Michael reactions employ Lewis acid catalysts, such as transition 
metals, or Brønsted acid catalysts, such as PdCl2(MeCN)2,
26  InCl3,







33 etc. These methods, however, are 
often associated with drawbacks, e.g. high price and toxicity of catalysts, harsh reaction 
conditions and unexpected side reactions such as polymerization of Michael acceptors. 
 
Yeom et al34 have since developed a protocol for the aza-Michael addition, employing 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as a promoter, for the synthesis of 
β-aminocarbonyl compounds, and this mild alternative was chosen for the synthesis of our 






































3.7.1 Strategies for the synthesis of target compounds 
 
The combination of artemisinin and chloroquine pharmacophores via the aza-Michael 
addition can be realized by placing the two pharmacophores on either ends of the 








Figure 3.11. Rationale for the inputs of aza-Michael addition, where P1 and P2 represent various 
pharmacophores; ART and CQ represent the artemisinin and chloroquine pharmacophores, 
respectively. 
 
We have chosen to synthesize target compounds via path A, i.e. conjugate addition of 
7-chloro-4-aminoquinoline amines to artemisinin-acrylate. 
 
3.7.2 Synthesis of Artemisinin Acrylate 
 
To incorporate an α,β-unsaturated system to the artemisinin core, dihydroartemisinin (DHA) 







ART NH2 CQ acrylate





























Scheme 3.2. Reagents and conditions: (i) acryloyl chloride (1.2 eq), Et3N (1.2 eq), DCM, N2, 0 °C to 
r.t., 12 h.  
 
The requisitive acrylate was obtained as a diastereomeric (α and β) mixture. 
 
3.7.2.1 Spectroscopic Analyses 
 
1H NMR of the crude material shows that the products are present in 4.7:5.3 ratio of α- and 
β-isomers (Fig. 3.12a), starting from a 1:1 mixture of α- and β-anomers of 
dihydroartemisinin, evident from the integration of H-10 and H-12 for the two isomers. 
Purification by column chromatography yielded pure stereoisomers (Fig. 3.12b, only 4.5 to 

























α -isomer β -isomer















































































































The α- and β-isomers of A-acr can be differentiated from their coupling constants; 3JHH 
between C-9 and C-10 for α-isomer is expected to be much larger than that of the β-isomer, 
arising from axial-axial coupling of the two protons on α-isomer as opposed to the 
axial-equatorial coupling on the β-isomer. This is illustrated in Fig. 3.13. The typical 






      
Figure 3.13. Coupling between C-9 and C-10 for the two isomers. 
 
Protons on the alkene system can also be easily assigned by looking at the magnitude of the 
coupling constants. Protons that are trans across a double bond typically show larger vicinal 
coupling (13 – 18 Hz) than cis-protons (7 – 12 Hz), hence 3JHH between H-17 and H-19 is 
expected to be larger than that of H-17 and H-18. This was indeed observed in 1H NMR. 
Although geminal couplings are typically large for saturated carbons (12 – 15 Hz), they are 
generally quite small in alkenes (0 – 3 Hz). The observed coupling constants for the alkene 
system in A-acr were: H-17, 17.2 and 10.4 Hz; H-18, 10.4 and 1.6 Hz, and H-19, 17.2 and 




























α-isomer      β-isomer 






















13C NMR of A-acr can be assigned via 2D NMR techniques such as HSQC. For artemisinin 
derivatives, the most distinguishable peaks are the four signals between 80 and 105 ppm, 
which are carbons 12a, 12, 10 and 3. They are away from the high field region, where 













Figure 3.15. 13C NMR of A-acr. 
 
3.7.3 Synthesis of Quinoline Amines 
 
A series of 7-chloro-4-aminoquinolines were synthesized using standard protocols that have 
been widely used.35,36 Amines QN01 – QN04 were chosen such that the number of atoms 
between the two nitrogen atoms on the side chain span across the optimal and intermediate 
biological activities (except for long carbon chains, such as 10 or more carbon atoms), as 











































synthesized, as the corresponding starting diamine was not commercially available at the 
time of synthesis. QN05, incorporating a piperazine moiety at the 4’ position, was also 
synthesized.  
 
Using the protocol described by De et al37, QN01 – QN04 were synthesized in neat from 
4,7-dichloroquinoline and an excess (approximately 20 eq) of the corresponding alkyl 
diamines. The large excess (no less than 4 eq) was necessary to avoid the formation of 
terminally disubstituted amines. The synthesis of QN05 was achieved by, again, an excess of 
piperazine, using N-methylpyrrolidinone (NMP) as the solvent, with Et3N as the base and a 








Scheme 3.3. Reagents and conditions: (i) piperazine (5.0 eq), Et3N (1.2 eq), K2CO3 (0.5 eq), NMP, N2, 
150 °C, 4 h. (ii) H2N(CH2)nNH2 (20 eq), 110 – 150 °C, 4 h. 
 
As indicated earlier, quinoline is particularly susceptible to nucleophilic attack when 
electronegative groups are present at the C-2 and C-4 positions. The quinoline nitrogen acts 
as an “electron sink”, which aids in directing the incoming nucleophile to the C-4 position 
and displacing the chloride. Hence the regioselectivity is driven by resonance stability 














n = 1: QN01;
   = 2: QN02;
   = 3: QN03; 





















Scheme 3.4. Mechanism of formation of 1-(7’-chloro-4’-amino)-diamines. 
 
The isolated yields and melting points of the 7-chloro-4-aminoquinoline amines are 
tabulated in Table 3.2. 
 





Compound n Yield (%) 
Melting point (°C) 
observed literature 
QN01 1 64 136 – 139 137 – 13935 
QN02 2 88 123 – 126 124 – 14735 
QN03 3 87 43 – 46 43 – 4735 
QN04 5 95 135 – 138 136 – 13835 
QN05 - 89 113 – 116 113 – 11536 
 
3.7.3.1 Spectroscopic Analyses 
 
Quinolines exhibit a unique pattern in 1H and 13C NMR spectra, and can be easily recognized. 
The 1H NMR spectrum of QN05 is used as an example for the discussion on their coupling 






























































9.0 Hz between H-5 and H-6. H-6 is often seen as a doublet of doublet (dd), due to 
additional long-range coupling to H-8, with a typical J value of 2.1 Hz. The piperazine N-H 
(H-11) appeared as a pentet at 3.31 ppm, with a coupling constant of 1.8 Hz. Piperazine 













Figure 3.16. 1H NMR spectrum of QN05. 
 
3.7.4 Syntheses of Target Compounds 
 
3.7.4.1 Using 7-chloro-4-aminoquinoline amines 
 
The target compounds were synthesized via the DBU-promoted aza-Michael addition, as 
described earlier (Scheme 3.5). In order to prevent over-alkylation of the amine, 1.5 
















both starting materials (especially the quinoline amines in this case) is crucial, as a solvent 
that is unable to fully dissolve the quinoline amine, due to its extreme polarity, creates an 
environment where there is more artemisinin acrylate than quinoline amine in the solution 







Scheme 3.5. Reagents and conditions: (i) QN01-05 (1.5 eq), DBU (0.5 eq), DMF, N2, r.t., 12 h. 
 
For example, an attempt at the synthesis of MIC 13B using acetonitrile alone as the solvent 
yielded not only the desired product, but also the bis-Michael adduct, MIC 13A, as the  
quinoline amines are only partially soluble in acetonitrile (Scheme 3.6). Hence acetonitrile 
alone is not an ideal solvent for these starting materials, and a more polar solvent, such as 
N,N’-dimethylformamide (DMF), was chosen as the solvent for the syntheses of 

































































Mechanistically, it may be speculative that the aza-Michael addition commences via the 
nucleophilic attack of DBU at the β-carbon of the acrylate, forming a resonance-stabilized 
β-ammonium enolate. Although DBU is normally regarded as a hindered and 
non-nucleophilic base, relative to secondary amines, the nucleophilicity of the amine is 
apparently less important than the resonance stabilization of the β-ammonium enolate as is 
the case with DBU. This stabilization increases the equilibrium concentration of the 
β-ammonium enolate which results in a higher rate of formation. Enhanced reaction rates 




































































































After the Michael addition by DBU, the resulting β-enolate ungergoes attack by the 
secondary amine, regenerating DBU promoter at the same time. The enolate then picks up a 
proton to form an enol, yielding the desired product after tautomerization to the keto 
tautomer (Scheme 3.7). 
 
3.7.4.2 Using commercial amines 
 
Apart from the target compounds where 7-chloro-4-aminoquinoline amines were added to 
the artemisinin acrylate, commercially available amines were also used in the conjugate 
addition. Acetonitrile was used as the solvent, as there were no solubility problems. After the 
necessary reaction time, no work-up was required, as the solvent was simply removed under 










































3.7.4.3 Spectroscopic Analyses 
 
The 1H NMR spectra of MIC 13B and MIC 06 are presented in Fig. 3.17 and 3.18. In the 
case of MIC 13B, the five quinoline protons were, as discussed earlier, easily distinguished 
in the lower field region. H-10 appeared at 6.32 ppm with J = 3.2 Hz, confirming the stereo 
orientation at C-10 (β-isomer). The propylene protons from the quinoline amine appeared at 
3.43, 2.92 and 1.94 ppm, each with a coupling constant of 5.6 Hz. Protons H-17 and H-18, 
which were previously on an alkene system, have transformed from doublet of doublets to 
triplets, each with J of 6.4 Hz. The three methyl groups on C-14, 15 and 16 remain 
unchanged compared with the starting acrylate, with H-14 being a singlet, while H-15 and 





































Figure 3.17 1H NMR spectrum of MIC 13B. 
 
The 1H NMR spectrum of MIC 06 is similar to that of MIC 13B, but with no proton signals 
after 6.0 ppm. Proton signals from the morpholine appeared at 3.70 and 2.47 ppm, with J = 
































































































Figure 3.18 1H NMR spectrum of MIC 06. 
 
13C NMR spectra of MIC 05 and MIC 06 are used here as representatives (Fig. 3.19). The 
confirmation for the successful syntheses of the desired products is the shifting of the two 













































































































































2 x C-9’  
2 x C-10’  
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Structures of the target compounds and their yields are tabulated in Table 3.3 below. 
 















N Cl  
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MIC 08 α N
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3.8 Results and Discussion 
 
3.8.1 Antimalarial Activities 
 
The target compounds, along with their parent compounds, were tested for their in vitro 


























General structure of artemisinin conjugates 
Cmpd C-10 R n 










α - - 5.85 9.27 1.6 6.37 687 
A-acr- 
beta 
β - - 7.54 12.43 1.6 2.88 232 
QN01 - - - 231 1142 4.9 7.22 6 
QN02 - - - 240 1251 5.2 9.83 7 
QN03 - - - 482 2266 4.7 11.24 5 
QN04 - - - 2164 1861 0.9 15.69 8 
QN05 - - - 1463 1639 1.1 27.58 17 
MIC 01 β - 2 20.60 20.14 1.0 9.47 470 
MIC 02 β - 4 24.04 27.48 1.1 10.13 368 
MIC 03, MIC 04,      MIC 01, MIC 02,  



























































Cmpd C-10 R n 








MIC 03 β N
 
- 7.74 11.33 1.5 4.56 402 
MIC 04 α N
 
- 11.33 11.36 1.0 NDc - 
MIC 05 β - - 10.10 10.03 1.0 6.58 656 
MIC 06 α N
O
 
- 6.23 9.02 1.4 4.80 532 
MIC 07 α N
 
- 12.98 13.62 1.0 6.02 442 
MIC 08 α N
 
- 5.27 6.16 1.2 4.48 727 




- 16.88 18.68 1.1 13.04 698 
MIC 10 α N
NH
 
- 9.22 16.03 1.7 8.91 556 
MIC 11 α N
N
 
- 7.16 12.56 1.8 6.55 521 




- 5.59 7.27 1.3 5.76 792 
MIC 13A β - 3 6.98 4.24 0.6 9.13 2153 
MIC 13B β - 3 18.67 24.39 1.3 5.58 229 
MIC 14 β - 6 55.63 53.55 0.9 0.37 7 
ART - - - 25.50 25.36 1.0 ND - 
CQ - - - 30.61 145.3 4.7 9.67 66 
Cisplatin - - - NDc NDc - 0.142 - 
a RI, resistance index, calculated as [IC50 (Dd2)] / [IC50 (D10)]; 
b TI, therapeutic index, calculated 
as [IC50 (HeLa)] / [IC50 (Dd2)]; 

















Antiplasmodial activities are expressed as the 50% inhibitory concentration (IC50) of the 
compounds against a chloroquine sensitive (D10) and resistant (Dd2) strain of Plasmodium 
falciparum, using a standard parasite viability assay which measures parasite lactate 
dehydrogenase activity after 48 hours of drug exposure. Cytotoxicities were obtained by 
determining the IC50s of the compounds against a human ovarian cancer cell line (HeLa) 
using a standard MTT assay which measures the redox activity of live cells after 48 hours of 
drug exposure. Antiplasmodial results against chloroquine-sensitive (D10) and resistant 
(Dd2) strains of malaria have shown that almost all of the target compounds, including the 
artemisinin-acrylate precursor, displayed better activities than their parent compounds, 
artemisinin and chloroquine. It also seems that the orientation at C-10 does not have an 
impact on biological activity, as both α- and β-stereoisomers display activities to the same 
extent. This is not unexpected, as artesunate and artelinic acid have different orientations at 
C-10, but are both active antimalarials. 
 
The activities of the quinoline amine precursors in Dd2 are much lower than those in the 
chloroquine-sensitive D10 strain (as indicated by the high resistance index, RI), which is 
expected, as these are chloroquine-like compounds. Their activities are also at least 12 times 
lower than their corresponding conjugates. Additionally, the gradual decrease in in vitro 
activities for the quinoline amines with increasing length of side-chains, is also observed in 
the corresponding conjugates (MIC 01, 13B, 02 and 14, in the order of increasing side-chain 
length). Out of the five intended quinoline-containing conjugates, compound MIC 05 is the 
most active, with IC50 values of 10 nM in both D10 and Dd2. Interestingly, the bis-Michael 
adduct MIC 13A displayed activities far better than the other five quinoline-containing 
conjugates, and is almost 6 times more active than the intended conjugate adduct MIC 13B 















In general, conjugate adducts with commercial amines exhibited better activities than those 
containing quinoline moieties. The best compounds out of this series are MIC 08, 12 and 
13A, with the latter being the most active in the Dd2 strain. The side-chains of MIC 08 and 
12 are N-methylbenzylamine and phenylpiperazine respectively, which do not bear structural 
similarities, except maybe the phenyl ring that is present in both MIC 08 and 12. However, 
the phenylpiperazine unit has been identified as a ‘privileged’ structure, which, according to 
Evans, is a substructure that confers activities to multiple proteinaceous receptor surfaces.40 
Unsubstituted phenylpiperazines have been shown to exhibit antiplasmodial activities, 
displaying mefloquine-type antimalarial behavior in being more potent against 
chloroquine-resistant than chloroquine-sensitive strains in P. falciparum. 41  Thus the 
enhanced activity of MIC 12 may partly be due to the inherent activities of the 
phenylpiperazine unit. 
 
It is worth noting that although the improvements in activities of the quinoline-containing 
conjugates were not to a great extent, when compared to artemisinin and chloroquine, 
resistance in Dd2 strain was abolished (RI values typically around 1). This suggests that the 
incorporation of artemisinin can aid 4-aminoquinolines in circumventing 
chloroquine-resistance. 
 
Cytotoxic activities of these compounds were assessed in HeLa cells (human 
adenocarcinoma of the cervix), using cisplatin as the control. All compounds, with the 
exception of MIC 14, displayed cytotoxic activities in the low micromolar range. This 
renders large therapeutic windows, and the therapeutic indices (TI) with respect to the Dd2 
strain are about 500 for the target compounds. The specificity towards plasmodial cells 















3.8.2. Anticancer Activities 
 
The low micromolar activities of the target compounds against HeLa cells have prompted 
further tests against non-cancerous cells. Selected compounds (based on cytotoxicity 
activities in HeLa cells) were tested against primary resting and phytohaemagglutinin 
(PHA)-stimulated lymphocytes.  
 
Primary resting lymphocytes are cells that grow naturally in the body, undergoing normal 
cell cycles. When these cells are stimulated by PHA, the speed of cell cycles was increased, 
mimicking that of cancerous cells. It is important to note that PHA-stimulated cells will only 
replicate to a point, while cancerous cells will divide indefinitely. 
 
The activities of the selected compounds are tabulated in Table 3.5. The tumour specificity 
of these compounds were also shown, calculated by taking the average of the IC50 in resting 
and PHA-stimulated primary lymphocytes, and dividing it by the IC50 in HeLa cells. 
 
Here, we have found that all of the selected compounds displayed low toxicities towards 
non-cancerous mammalian cells, but also with low tumour specificity. Only one compound, 
MIC 14, displayed good potential, with tumour specificity of 31. This high tumour 
specificity renders MIC 14 to be a good potential anticancer lead, and should be further 




























        
General structure of artemisinin conjugates 
Cmpd C-10 R n HeLa IC50 (μM)
Primary lymphocytes 







α - - 6.37 39.58 11.47 4.0 
A-acr- 
beta 
β - - 2.88 30.53 9.22 6.9 
MIC 01 - - - 9.47 > 50 16.94 1.8 
MIC 02 - - - 10.13 32.40 8.99 2.0 
MIC 03 - N
 
- 4.56 > 50 38.16 8.4 
MIC 05 - - - 6.58 44.61 14.04 4.5 
MIC 06 - N
O
 
- 4.80 > 50 27.27 5.7 
MIC 07 β N
 
2 6.02 > 50 30.45 5.0 
MIC 08 β N
 
4 4.48 > 50 25.00 5.6 





























































3.9 Conclusion and Future Work 
 
Biological results of the artemisinin-based compounds against D10 and Dd2 strains of P. 
falciparum have shown that four compounds, MIC 06, 08, 12 and 13A displayed most 
potent activities. As artemisinins are well-known for their short plasma half-lives, as 
described in section 2.2.2, it would be useful to assess the half-lives and metabolites of these 
compounds in comparison to those of artemisinin or artesunate. Additionally, it would also 
be worthwhile to modify the phenyl ring on the piperazine unit in MIC 12 for quantitative 
structure-activity relationship (QSAR) studies, which may aid in generating further 
compounds with even more potent activities than the ones reported here. 
 
In terms of development as possible anticancer agents, only MIC 14 was found to be a good 
potential lead. Further in vivo studies have been planned, and will be under way in 2009. 









MIC 10 β N
NH
 
- 8.91 > 50 30.98 3.5 
MIC 11 α N
N
 
- 6.55 > 50 27.18 4.1 




- 5.76 > 50 27.56 4.8 
MIC 13A α - - 9.13 32.44 1.44 1.9 
MIC 13B α - - 5.58 21.52 4.71 2.4 
MIC 14 α - - 0.37 19.03 3.40 30.7 
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Continuing on the idea of designed multiple ligands, pharmacophores can also be integrated 
into a single molecule by employing multi-component reactions. This chapter describes the 
synthesis, characterization and biological evaluation of hybrid molecules of artemisinin and 
1,4-naphthoquinones with 4-aminoquinolines, and their effect on plasmodial endocytosis. 
 
4.2 Multi-Component Reactions 
 
Multi-component reactions (MCR) are chemical reactions that utilize three or more different 
starting materials as chemical structure inputs in a one-step-one-pot synthesis to yield one 
single product that contains features of all inputs. Such reactions are highly efficient, as they 
create molecular complexity by generating more than two chemical bonds per operation.1 
The Strecker synthesis of α-amino acids via α-amino cyanides, first published in 1850, is 
generally considered to be the first MCR2. Other well-known MCR’s include Hantzsch’s 
dihydropyridine synthesis (1882), 3  Biginelli’s dihydropyrimidine synthesis (1891), 4 
Mannich Reaction (1912),5 Passerini reaction (1921)6 and the Ugi Reaction (1958),7 just to 
name a few. NifedipinTM, a cardiovascular drug, is one of the early examples of a drug 




















Scheme 4.1. Hantzsch synthesis of Nifedipin. 
 
The MCR has been widely used to study structure-activity relationships and also to create 
libraries of organic molecules.8 The various inputs do not come together simultaneously, but 
rather a series of ordered steps, where two inputs condense first to form an intermediate, 
which then condenses with the third input, and so on. MCRs can be grouped into three basic 
types, as presented in Table 4.1 below.  
 
Table 4.1. The basic types of MCRs.8 
MCR Type General reaction scheme 
I A  +  B  C  D … O  P 
II A  +  B  C  D … O  P 
III A  +  B  C  D … O  P 
 
Type I: Starting materials, intermediates and products are all in a mobile equilibrium. Yield 
ranges between 0 and 100%, depending on the state of balance that prevails in the reaction. 
This is not the ideal type of MCR, as in most cases, the products occur as mixtures with the 
intermediates and/or starting materials, and are difficult to isolate. Further impurities may 

























Type II: All reactions are in reversible equilibra, while only the product forming step is 
irreversible. This is advantageous for preparative chemistry as the total equilibrium is shifted 
to the side of the products by the last irreversible step. Reactions belonging to this type 
therefore produce products with higher yield and purity when compared to conventional 
sequential reactions of forming the same product. 
 
Type III: They consist of a sequence of irreversible reactions that seldom occur in 
preparative chemistry, but mostly in biochemical reactions. Many of these reactions are 
actually irreversible partial reactions, either due to the thermodynamic circumstances or due 
to the combination of endothermal with exothermal reactions. 
 
4.2.1 Isocyanide Based Multi-Component Reactions 
 
Isocyanide based multi-component reactions (IMCR) have been around for almost 90 years. 
The first of these IMCR’s was described by the Italian Passerini in 1921 (Scheme 4.2), and 




Scheme 4.2.The Passerini Reaction. 
 
While most of the classical MCRs have been found by chance, new MCRs are being 
discovered by using novel methods such as rational and combinatorial approaches.9,10 Up 































4.2.1.1 Isocyanides  
 
Isocyanides, formerly known as isonitriles, have been discussed for over one and a half 
centuries due to their unusual valence structure and reactivity. They are the only class of 
stable organic molecules with a formally divalent carbon.8 Isocyanides were first synthesized 
in 1859 by Lieke,12 who did not recognize them as such, but believed them to be nitriles. 
Like many chemists today, he was struck by their pungent odour. Ivar Ugi, who described 
the four-component Ugi reaction, once stated “The development of the chemistry of 
isocyanides has probably suffered ... through the characteristic odor of volatile isonitriles, 
which has been described by Hofmann and Gautier as ‘highly specific, almost 
overpowering’, ‘horrible’, and ‘extremely distressing’. It is true that many potential workers 
in this field have been turned away by the odor.”13 Almost all commercial isocyanides carry 
this strong odour, but majority of the isocyanides with higher molecular weights are solid 
and odourless. Fortunately, despite the repulsive odour, isocyanides are only slightly toxic, 
and many natural isocyanides display a strong antibiotic, fungicidal or antineoplastic 
effect.14 
 
4.2.1.2 The Ugi Reaction 
 
Ivar Ugi et al15 described the Ugi four-component condensation (U-4CC) in 1959, which 
was the most elegant and important variant of the four-component condensations. Most of 
the condensation types known today were discovered after this publication.  
 
The U-4CC utilizes an aldehyde, an amine, and acid and an isocyanide, and converts them 


















Scheme 4.3. The Ugi four-component condensation. 
 
4.2.1.3 Solvent effects 
 
The U-4CC is mainly influenced by inductive, mesomeric and steric effects, the latter to a 
lesser extent, as established from the reactivity series of the reaction as a function of solvent 
and concentration. It has been found that the concentration of the reactants plays a more 
important role than the properties of the solvent in which the reactants are dissolved in.16 
Solvents that are suitable for solution-phase U-4CC include: (a) low molecular weight 
alcohols such as MeOH, EtOH or trifluoroethanol,17 (b) polar aprotic solvents such as DMF, 
chloroform, dichloromethane, THF and dioxane, (c) biphasic aqueous media and (d) aqueous 
media, with rate-accelerating effects on the Ugi and Passerini reactions, discovered in 2004 
by Pirrung and Sarma.18  
 
Other approaches to optimize the yield include: (a) keeping the concentration of the reactants 
between 0.5 to 2 M, (b) pre-condensation of the amine and aldehyde or ketone, and (c) 
addition of a Lewis acid. The reaction rate can be accelerated by the use of a microwave.19  
 
4.2.2 Application of multi-component reactions in drug discovery 
 
A short time after the U-4CC was discovered by Ugi, the first medicinal chemistry related 































Xylocain (Scheme 4.4).20 He also recognized that the reaction is well-suited to probe 
structure-activity relationships by synthesizing libraries of compounds.8 With the emergence 
of combinatorial chemistry and high-speed parallel synthesis today, the MCR is widely 
employed for the rapid assembly of arrays with high molecular diversity.21 The power of 
these reactions is increased even further, when coupled with post-condensation modifications, 






Scheme 4.4. Synthesis of XylocainTM using the Ugi reaction 
 
MCR synthesis is advantageous over an equivalent linear synthesis, in that the size of a 
linear derived library is a function of the number of steps and individual inputs. For example, 
a four step synthesis with 10 inputs at each step would create 104 compounds, whereas a four 
component MCR would have the same size by having 10 inputs per component, yet 
achieving this in a single chemical operation.22 
 
Combinatorial chemistry derived libraries may be split into three categories: 
 
1. General libraries. These are specifically designed to fill diversity voids in corporate 
collections, and are typically in the 103 – 104 compound range.  
2. Gene family targeted libraries. These utilize privileged chemical motifs23 or public 
























of the gene family. They are typically in the 102 – 103 compound range. 
3. Focused libraries. A library such as this is designed for a specific target and is SAR 
driven, typically in the 10 – 103 compound range. 
 
Additional advantages that the MCR methodologies bring to drug discovery,24 listed in 
chronological order from early to late stage discovery: 
 
1. Chemistry development is dramatically shortened, as more compounds can be made 
in the same amount of time taken for linear synthesis. 
2. Average library purity should be higher than linear synthesis, as impurities will not 
have the opportunity to build up as in sequential synthesis.  
3. MCRs are often compatible with a solution phase approach. This enables simpler 
reaction monitoring and reduces automation needs. 
4. The ‘hit-lead transitions’ are often dramatically shorter and relatively simple. As fast 
protocols are already in place, this is a major advantage in hit validation. 
5. MCR methodologies can produce quality drug-like hits for further optimization, by 
defining drug-likeness qualities such as log P, molecular weight, number of H-bond 
donors and acceptors, molar refractivity, rotatable bonds and polar surface area. 
6. Beyond lead optimization, the cost savings for final marketed drug production may 
be dramatic if the final compound is accessible via MCR methodology, as opposed 
to a sequential route. Multi-step chemical process development is often a bottleneck 
in drug discovery. Crixivan, a HIV protease inhibitor, requires at least 15 synthetic 
steps that render the production at the high cost end. Merck&Co has developed a 























Scheme 4.5. Ugi MCR synthesis of Crixivan. 
 
4.3 Rationale for Drug Design 
 
Based on its versatility, we have chosen the Ugi four-component condensation as the 
approach towards the synthesis of the target compounds. In principle, 1,4-naphthoquinone 
and artemisinin were chosen to be hybridized with 4-aminoquinolines to form ‘dual-drugs’ 
















































1. H2, chiral catalyst
2. NH2NH2 Crixivan (MD 639)




































The rationale for the incorporation of artemisinin and 4-aminoquinolines has already been 
discussed in the previous chapter. In this section, the rationale for the choice of 




4.3.1.1 As Antimalarial Agents 
 
Glutathione (GSH) is a major thiol responsible for the detoxification of reactive oxygen 
radicals both in man and the malaria parasite,26 to prevent oxidative damage. The level of 
GSH present depends on the efficiency of glutathione reductase (GR) in P. falciparum and in 
man, and thioredoxin reductase in P. falciparum,27 to reduce glutathione disulfide (GSSG) to 
GSH. Thus glutathione reductase is often the target when designing new antimalarials28 and 
chloroquine-resistance reversal agents.29,30 It has also been shown to be involved in the 
degradation of toxic haem released during haemoglobin digestion,26 as described in section 
2.1.1 in Chapter 2.  
 
Parasites of the Plasmodium family are exposed to higher fluxes of reactive oxygen species, 
as a result of host immune response to infection and from haemoglobin digestion, hence high 
activities of intracellular antioxidant systems are needed. Studies have shown that 
antioxidant systems are important for parasite survival, as they do not develop in 
glucose-6-phosphate dehydrogenase deficient red blood cells, or in erythrocytes depleted in 
GR activity.31 Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in the pentose 
phosphate pathway that converts glucose-6-phosphate into 6-phosphoglucono-δ-lactone. It 















adenine dinucleotide phosphate (NADPH), which in turn maintains the supply of reduced 
GSH in the cells. 1,4-Naphthaquinones are an important class of inhibitors for glutathione 
and thioredoxin reductases, with plumbagin, menadione and its hexanoic acid derivative M5 
being representatives (Scheme 4.6),29, 32  and they have been demonstrated to be 






Scheme 4.6. Structures of 1,4-naphthoquinones as glutathione and thioredoxin reductase inhibitors. 
 
The biological activity of the 1,4-naphthoquinones arises from the ability of the quinone to 
accept one and/or two electrons to form the corresponding anion or dianion radical species. 
1,4-Naphthoquinones can be reduced to semiquinone radicals, which, upon reduction of 
oxygen to superoxide anion radicals, regenerates the quinone.33 This redox cycling and 
oxygen activation leads to increased levels of hydrogen peroxide and GSSG. The 
cytotoxicity of 1,4-naphthoquinones may also be attributed to thiol and amine depletion by 
alkylation, DNA modification and oxidation of essential protein thiols by activated oxygen 
species and/or GSSG..33  
 
4.3.1.2 As Anticancer, Antifungal and Antimicrobial Agents 
 
The 1,4-naphthoquinone pharmacophore is common in numerous natural products that 
























as streptonigrin,34 actinomycins,35 mitomycins,36 alkannins,37 2-hydroxynaphthoquinone 
derivatives 38  and 1,4-furanonaphthoquinones 39  contain the 1,4-naphthoquinone or 
1,4-quinone pharmacophore. Recent studies have also found that 1,4-naphthoquinone 
derivatives were active against Walker 256 carcinoma cell lines,40 Lymphoid Leukaemia    
P 388, 41  prostate cancer 42  and many others. 43  A number of sulfur-containing 
1,4-naphthoquinone derivatives have been shown to possess antifungal activity. 44 
Additionally, significant antimicrobial activities have also been observed.45 
 
4.3.1.3 Design of 1,4-Naphthoquinones and 4-Aminoquinolines as ‘Dual-Drugs’ 
 
Double headed prodrugs based on 1,4-naphthoquinones and 4-aminoquinolines have 
previously been developed, and proved to be potent antimalarials as glutathione reductase 
inhibitors, both in vitro and in vivo.29,46 Here, we propose to hybridize them via the Ugi 
reaction, assess their biological activities, hoping to gain more insight to their possible 
mode(s) of action with respect to inhibition of endocytosis. 
 
4.3.2 Effects of Artemisinin and Chloroquine on Plasmodial Endocytosis 
 
Research conducted by H. Hoppe et al has shown that chloroquine interferes with the 
parasite endocytic pathway.47 Incubation of malaria parasites with chloroquine for 12 hours 
caused a striking increase in haemoglobin levels when compared to the control parasites, 
indicative of haemoglobin degradation inhibition. Immunofluorescence assays showed that 
haemoglobin was located prominently in the food vacuole of control parasites. By contrast, 
in chloroquine-treated parasites no haemoglobin-associated fluorescence was seen in the 















representing endocytic transport vesicles. This suggests that chloroquine causes a block in 
transport vesicle-vacuole fusion, resulting in an inability to correctly deliver the endocytosed 
haemoglobin to the food vacuole and a consequent accumulation of undigested haemoglobin 
in transport vesicles. 
 
Similar assays with artemisinin showed that artemisinin treatment also increased 
haemoglobin levels within the parasite, but to a much lesser extent than chloroquine, and that 
artemisinin does not inhibit transport vesicle-vacuole fusion. By contrast, artemisinin was 
found to more significantly inhibit the endocytosis of red blood cell haemolobin by the 
parasite. The interpretation of the combined results of the study by Hoppe et al. and others 
was that the principal effect of chloroquine is a block in vesicle-vacuole fusion, resulting in a 
marked increase in parasite haemoglobin and transport vesicle content. By contrast, 
artemisinin inhibits both the proteolytic digestion of haemoglobin in the food vacuole as well 
as haemoglobin endocytosis itself, and the combination of these effects produces a small 
increase in total parasite haemoglobin levels compared to controls.47  
 
Based on these findings, it would be informative to investigate the effects on endocytosis of 
the artemisinin-chloroquine hybrid molecules, since each of the parent compounds have been 
shown to exert different effects. The results could indicate whether these hybrid molecules 
preferentially display the effects of one of the parent molecules, a combination of the effects, 



















4.4 Synthesis of Target Compounds via the Ugi Four-Component Condensation 
 
4.4.1 Approaches for the Synthesis of Target Compounds 
 
The Ugi adducts were synthesized using 1,4-naphthoquinone-acid and artelinic acid as the 
acid component; 4-aminoquinoline amines as the amine component; paraformaldehyde as 






























































4.4.2 Synthesis of Acid Components 
4.4.2.1 Artelinic acid 
 
Artelinic acid was yielded after a two-step synthesis starting with dihydroartemisinin. 
Dihydroartemisinin was coupled with methyl 4-(hydroxymethyl)-benzoate in the presence of 
boron trifluoride etherate to form 1a, which was then hydrolyzed by KOH to give artelinic 







Scheme 4.7 Reagents and conditions: (i) methyl 4-(hydroxymethyl)-benzoate (3.4 eq), BF3·Et3O 
(1.13 eq), Et3O, N2, r.t., 24 h; (ii) 2.5% KOH/MeOH, r.t., 3 days. 
 
The β-isomer was the major product (diastereomeric ratio α:β 2:98), and can be understood 
from the reaction mechanism shown in Scheme 4.8. The Lewis acid BF3·Et3O coordinates to 
the hydroxyl group of dihydroartemisinin, and is displaced with the formation of the 
oxonium (or oxocarbenium) ion. At this point, the hydroxyl of the benzoate can attack either 
from the α or β face. Dihydroartemisinin can be seen as a pyranose ring, and the electrophilic 
carbon centre as the anomeric centre. When coupling to the oxocarbenium ion, axial attack 
from the β face is favoured, as this result in the more stable chair conformation. Even though 
the incoming benzoate is now at the higher energy axial position, this is favourable as it is 











































observed in carbohydrate chemistry, where there is orbital alignment between the oxygen 
















Figure 4.3. Axial attack at the anomeric centre and anomeric effect. 
 
The conformations of the products were also confirmed via 1H NMR spectroscopy. As 
previously mentioned, 3JHH between H-9 and H-10 is typically 3.2 Hz for β-isomer 
































































4.4.2.1.1 Spectroscopic Analyses 
 
The 1H NMR of 1b is presented below in Fig. 4.4. The AB system of the protons on the 
aromatic ring was easily distinguished in the aromatic region. Benzyl protons (H-17A and 
H-17B) were found between 4.5 and 5.0 ppm, displaying a large geminal coupling of 13.5 
Hz. H-10 was found at 4.9 ppm with the expected coupling constant of 3.0 Hz for the 
β-isomer. The singlet at 3.9 ppm corresponding to the OMe group was no longer seen in the 
spectrum, indicating a successful hydrolysis. Proton assignments were also confirmed via 2D 
NMR techniques such as COSY and HSQC; all 1H and 13C NMR data corresponded to those 







































































4.4.2.2 1,4-Naphthoquinone Acid 
 
The 1,4-naphthoquinone acid was synthesized by coupling plumbagin and succinic acid 
(HOOCCH2CH2COOH) via oxidative decarboxylation of acids, catalysed by silver nitrate in 
the presence of ammonium persulfate (Scheme 4.9).50,51 The yield was fairly modest; this 
may be due to the redox chemistry, or decomposition of the product during the reaction at 







Scheme 4.9. Reagents and conditions: (i) succinic acid (3.0 eq), silver nitrate (0.5 eq), ammonium 
persulfate (1.3 eq), 30% aq. CH3N, 65 – 70 °C, 3 h. 
 
The reaction starts with a series of redox reactions, shown in Scheme 4.10, after which the 
diacid looses one of its carboxylic acids to become a nucleophilic alkyl radical,52 at the 



















Ag(I) + S2O82- Ag(II) + SO42- +  SO4• -
Ag(I) + SO4•- Ag(II) + SO42-
Ag(II) + RCO2H Ag(I) + RCO2• + H+















The nucleophilic alkyl radical then attacks the plumbagin, forming the naphthoquinone 









Scheme 4.11. Nucleophilic attack of the alkyl radical, and subsequent radical rearrangements to form 2a. 
 



































































When compared to the 1H NMR spectrum of plumbagin, two additional triplets, each 
integrating for 2 protons (J = 7.6 Hz), were evident at 2.62 and 2.98 ppm (Fig. 4.5). 
Additionally, a singlet integrating for one proton at 12 ppm indicated the presence of the 
carboxylic acid. These signals confirmed the presence of the 1,4-naphthoquinone-acid 2a, 
and corresponded to data given in literature.50 
 







Figure 4.6. Amine components for the Ugi reaction. 
 
4-Aminoquinoline amines QN01 and QN03 (Figure 4.6) were used as the amine inputs for 
the synthesis of the Ugi adducts. As their syntheses have already been described in the 
previous chapter, they will not be discussed again here. 
 











n = 1: QN01



















For simplicity reasons, commercially available tert-butyl and cyclohexyl isocyanides were 
used as the isocyanide inputs (Figure 4.7); formaldehyde was used as the aldehyde input to 
deliberately avoid creating stereoisomers. 
 






Scheme 4.12. Reagents and conditions: Carboxylic acid (1.0 eq), amine (1.2 eq), aldehyde (1.0 eq), 
isocyanide (1.0 eq), MeOH, r.t., 3 – 5 days.  
 
All reagents were stirred in methanol at room temperature, and the reaction monitored by 
thin layer chromatography (TLC) until completion, which is typically 3-5 days. Solvent was 
removed under reduced pressure, and crude materials chromatographed to yield pure 
products. 
 
This one-step-one-pot MCR involves a sequence of steps, illustrated in Scheme 4.13 below. 
Firstly, the imine is formed by the condensation of the amine with the ketone or aldehyde. 
Upon protonation by the acid, the activated iminium ion is formed, with increased 
electrophilicity of the C=N bond, and combines with the isocyanide to form the nitrilium ion 
intermediate. The carboxylate then adds to the nitrilium ion intermediate, followed by an 
irreversible intramolecular acyl transfer that drives the reaction forward to give the classical 
Ugi skeleton. The driving force for the irreversible reaction is the oxidation of the isocyanide 










































Scheme 4.13. Reaction mechanism of the Ugi 4-CC. 
 
Yields for the artelinic acid-containing Ugi adducts were very good (80 – 90%), but not for 
the 1,4-naphthoquinone-containing ones. Their low yields may be the result of heat- 
sensitivity of the 1,4-naphthoquinone acid 2a, and its subsequent decomposition in the 
reaction vessel during the 3 day reaction period at room temperature. 
 
Compound 6c was also made into a citrate salt, to determine whether or not the salt 
derivative would enhance biological activities by virtue of being more soluble. 
 













































































Figure 4.8. Target compounds synthesized via the Ugi 4-CC. 
 
4.4.5.1 Spectroscopic Analyses 
 
Both 1H and 13C NMR spectra of 6d and 6e showed duplication of individual peaks, an 
observation attributed to the slow interconversion between the cis and trans isomers about 
the tertiary amide bond.53 When the samples were run at variable temperature between 60 
and 90 °C, peaks started to broaden and coalesce, owing to the increase in the rate of 
interconversion at elevated temperature. Here, we present the 1H NMR spectrum of 6e and 
the duplication of peaks (Fig. 4.9). 1H NMR spectra of 6a, 6b and 6e, however, did not show 
duplication of peaks, but rather peak broadening of each signal (see Fig. 4.10 for 1H NMR 
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products were formed, and running the samples in other solvents such as CD3OH or DMSO 
could not eliminate peak broadening. Hence the peak broadening may be due to a faster 
interconversion rate at room temperature for these compounds, and proton assignments were 



















Figure 4.9. 1H NMR spectrum of 6e with doubling of signals. (a) full spectrum; (b) expansion of 
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Figure 4.10. 1H NMR spectrum of 6b with peak broadening. 
 
4.5 Biological Assays and Discussion 
4.5.1 Antiplasmodial Activities 
 
Antiplasmodial activities and cytotoxicities were determined for the target compounds, and 
are tabulated in Table 4.2 below. Therapeutic indices were calculated by dividing the IC50 
obtained for HeLa cells with those obtained for the K1 parasite strain. Chloroquine was used 
as the control for both antiplasmodial and cytotoxicity assays. 
 
All three of the artemisinin-containing Ugi adducts displayed good in vitro activities 





H-30 + H18 







































































for 6a, 6b and 6c respectively, compared to 20 nM for CQ). The salt derivative of 6c, with 
its increased solubility, was expected to exhibit a significant enhancement of in vitro activity; 
however, this was not observed. As was observed for the artemisinin-containing conjugate 
addition adducts described in Chapter 3, the chloroquine-resistant K1 strain did not display 
cross-resistance to the chloroquine-artemisinin hybrids. This is shown in the resistance index 
(RI), calculated by dividing the IC50 obtained for the chloroquine-resistant strain (K1) over 
that of the chloroquine-sensitive strain (D10). A compound with low RI indicates that the 
parasite is less likely to experience cross-resistance to it, unlike chloroquine, which 
comparatively has a very high RI of 11. Although hybrid molecules that contain the 
1,4-naphthoquinone pharmacophore only exhibited moderate antiplasmodial activities, they 
also displayed low RI. 
 
The cytotoxicity assays suggest that these hybrid molecules possess a narrow therapeutic 
window, as indicated by the therapeutic indices. The IC50 for mammalian cells should ideally 
be at least two orders of magnitude higher than that for parasites, as this indicates that the 
compound acts more selectively against the parasites than mammalian cells, which would 
ultimately make dosing easier to control. Drugs with low therapeutic indices will need to be 
taken under constant monitoring to achieve therapeutic levels while minimizing toxicity. 
Hence these hybrid molecules in their current form would not be good drug candidates, 


























General structure of Ugi adducts 
Cmpd R1 R2 n 







CQ - - - 0.020 0.219 11 8.54 39 
ART - - - 0.023 0.014 0.61 ND - 
DHA - - - 0.004 0.003 0.75 ND - 
1b - - - 0.006 0.006 1 ND - 
2a - - - 38.35 20.29 0.53 ND - 
QN01 - - - 1.37 2.56 1.87 ND - 
QN03 - - - 2.15 2.74 1.27 ND - 
6a ARTc 
 
1 0.026 0.023 0.88 0.286 12 
6b ARTc 
 
3 0.035 0.021 0.60 0.169 8 
6c ARTc  1 0.027 0.019 0.70 0.496 26 
6c·citrate 
salt ART
c  1 0.024 0.018 0.75 0.356 20 
6d NQd 
 
1 0.638 0.467 0.73 5.211 11 
6e NQd  1 0.569 0.454 0.80 6.259 14 
a RI, resistance index, calculated as [IC50 (K1)] / [IC50 (D10)]; b TI, therapeutic index, calculated as [IC50 



























4.5.2 β–Haematin Inhibition Assays 
 
The hybrid compounds were tested for their ability to inhibit the polymerization of haematin 
in vitro using the colorimetric β–haematin inhibition screening assay,54 and the results are 
tabulated in Table 4.3. 
 








General structure of Ugi adducts 




CQ - - - 1.91 ± 0.3 
ART - - - 0.66 ± 0.1 
6a ART 
 
1 0.45 ± 0.04 
6b ART 
 
3 0.31 ± 0.01 
6c ART  1 0.44 ± 0.04 
6c·citrate salt ART  1 0.40 ± 0.01 
6d NQ 
 
1 Not activeb 
6e NQ  1 Not active
b 
a This study ± standard error of the mean on three determinations. 



























Chloroquine was used as the control, with an IC50 value of 1.91 equivalents. Artemisinin 
exhibited an IC50 of 0.66 equivalents. All three hybrid molecules that contain the artelinic 
acid moiety displayed enhanced β–haematin inhibitory activity when compared to CQ and 
artemisinin, with IC50 values of 0.45, 0.31 and 0.44 equivalents for 6a, 6b and 6c 
respectively. The salt derivative of 6c displayed a similar activity as the free base; this was 
also observed for chloroquine and its diphosphate salt. Compounds 6d and 6e, which contain 
the 1,4-naphthoquinone pharmacophore, displayed no inhibitory activity at 10 equivalents. 
This suggests that the 1,4-naphthoquinone moiety may interfere with the inhibitory 
mechanism of the 4-aminoquinoline ring. 
 
4.5.3 Morphological Changes in the Parasites 
 
The first 24 hours of the 48 h life cycle of the parasite is known as the ring stage. The 
nomenclature derives from the fact that the parasites morphologically resemble rings at this 
stage when stained with Giemsa and viewed by light microscopy (Fig. 4.11A). The ring 
stage is followed by the trophozoite stage, where the parasites actively endocytose and 
degrade haemoglobin, accompanied by a rapid increase in size (Fig. 4.11B). General 
morphological changes in the parasites across their life-cycle were visualized for untreated 
and drug-treated parasites. After the addition of various drugs at 0 h to ring and trophozoite 
stage cultures (at concentrations five times their respective IC50s), parasites were smeared 
onto microscope slides, fixed with methanol and stained with Giemsa before viewing under 
light microscope. Light microscope images of parasites at 0 h of drug addition are shown in 






















Figure 4.11. Light microscope images of A, ring stage and B, trophozoite stage parasites, at 0 h of 
drug addition.  
 
Microscope images for untreated and drug-treated rings are shown in Fig. 4.12. Control 
untreated ring stage parasites remained in the ring stage after 6 h, but had developed into 
prominent trophozoites by 24 and 30 h. At 48 h, parasites had progressed through a round of 
asexual reproduction to produce new rings. When parasites were treated with chloroquine, 
no morphological changes were observed after 6 h. This was expected, as chloroquine has 
been widely accepted to target parasites at the actively metabolizing trophozoite stage.55 
However, subtle morphological changes in the ring stage parasites are difficult to discern by 
light microscopy due to their small size and heterogeneity, hence the presence of parasites 
that were already under stress but could not be distinguished from normal rings cannot be 
ruled out. However, after 24 and 30 h of drug treatment, the majority of the parasites in the 
cell culture remained in the ring stage, as opposed to developing into trophozoites. This 
suggests that chloroquine action had retarded or parasite life-cycle progression. After 48 h, 
parasites had developed into trophozoites with an insubstantial ‘hollow’ appearance that 
seem not to be able to undergo nuclear division and form schizonts. 
 
Artemisinin appears to be much faster-acting than chloroquine, as dying parasites were 
















contracted, pyknotic appearance of the rings. Smears of the culture at 30 and 48 h indicated 
that the culture predominantly consisted of dead rings, marked by the tiny, dense dots. Dead 
rings in the culture suggest that artemisinin displays marked parasiticidal activity in the ring 
stage, completely preventing survival into the trophozoite stage. This is in accordance with 
the finding that artemisinins cause a rapid reduction of parasitaemia below detectable levels, 
without eliminating all parasites.56 
 
Morphological changes in parasites treated with hybrid molecules 6a, 6b, 6c and its salt all 
followed the same pattern as that of artemisinin. Cultures also mainly consisted of dead rings 
and a small percentage of dead early trophozoites after 24 h of drug treatment. 
 
Light microscope images of untreated and drug-treated trophozoites are shown in Fig. 4.13. 
After 6 h, untreated trophozoites started undergoing nuclear division (the multiple nuclei 
produce a marked punctated appearance in the parasite cytoplasm) to become schizonts. 
Each of the daughter nuclei in the schizont develops into a small, invasive merozoite, thus 
completing the asexual reproduction of the parasite. By 24h, these merozoites had invaded 
fresh red blood cells and developed into rings, staying in this stage until 48 h when 






















Figure 4.12. Phase images of parasites at various times after the addition of drugs, starting at ring stage. 






























Effects of chloroquine treatment in trophozoites were much more pronounced than in the 
ring stage. Morphological changes after 6 h demonstrated that chloroquine had already 
exerted considerable effects on these parasites, as the trophozoites were observed to be 
smaller and denser, a clear indication of stress in the parasites. After 24 h of drug treatment, 
deformed schizonts were observed, and this morphology was maintained for a further 24 h 
before the parasites eventually disappeared. Healthy schizonts typically contain between 10 
and 30 daughter nuclei, which are evenly distributed within the parasite. However, schizonts 
in the chloroquine-treated culture had very different morphologies: (i) the shape was not 
round as healthy schizonts typically appear to be, and (ii) nuclei were not evenly distributed 
within the schizonts, (iii) individual schizonts contained less nuclei on average than healthy 
control schizonts. Distortion in shape may have arisen from the smearing technique, where 
cells could have been flattened and hence distorted during smearing. However, these 
distorted schizonts were enclosed in round RBCs, indicating that the distortions were not 
from poor smearing techniques. 
 
Morphological changes in artemisinin-treated parasites were somewhat different to those 
incubated with chloroquine. After 6 h, parasites seemed to be initiating nucleation, entering 
the schizont stage. After 24 h of artemisinin treatment, parasites were still predominantly in 
this stage but had also started to deteriorate and die, and mainly dead parasites (detectable as 
small, darkly stained parasites) were observed after 30 and 48 h of drug treatment. 
 
These hybrid compounds seemed to act faster than chloroquine or artemisinin. A small 
percentage of the parasites had already taken on the contracted appearance of dead/dying 
parasites after 6 h of drug treatment, while the majority of the parasites were developing into 














































From the study of morphological changes of the drug-treated parasites, it was clear that 
chloroquine’s parasiticidal action is mainly directed against trophozoite stage parasites, 
while its effect on ring stage parasites is to slow down development into trophozoites. By 
marked contrast, artemisinin is parasiticidal against all stages of parasites and has a more 
rapid action. These findings corresponded to findings published in literature.55,57 Importantly, 
the blood smears of cultures treated with the hybrid molecules indicate that these compounds 
share the rapid parasiticidal action and wide stage-specificity of artemisinin and produce 
similar morphological changes. 
 
4.5.4 Effect on Endocytosis 
 
Various assays were conducted to determine the effects of the hybrid molecules on the 
endocytosis pathway in the D10 strain of P. falciparum. 
 
4.5.4.1 Effect of Drug Treatment on Haemoglobin Levels 
 
It has previously been shown by independent studies that chloroquine blocks haemoglobin 
degradation, 58 , 59  hence an accumulation of undigested haemoglobin is expected in 
chloroquine-treated parasites. Based on their pronounced antiplasmodial activities (Table 
4.2), compounds 6a, 6b, 6c and its salt were selected for the investigation of their effects on 
haemoglobin levels in the parasites by Western blotting. 
 
Trophozoite stage parasites were incubated with chloroquine, artesunate and the hybrid 
compounds for 5 h (at five times the IC50 of individual drugs), released from the red blood 















following the protocol by Hoppe et al.47 Artesunate was used instead of artemisinin in the 
investigation on effects on endocytosis, which is expected to penetrate the cells more 
efficiently in vitro due to its enhanced water-solubility.60  Haemoglobin levels in the 
parasites were determined by running the parasite pellets on SDS-polyacrylamide gels and 
subsequent Western blotting with anti-haemoglobin antiserum (Fig. 4.14). To ensure that the 
different intensities of the bands were not the result of uneven loading of parasite pellets, 
gels were also stained with Coomassie dye to visualize protein bands in the gels; there were 












Figure 4.14. Western blots of haemoglobin levels in parasites. Parasites were left untreated (ctrl), or 
incubated with chloroquine (CQ), artesunate (Artes), or hybrid compounds 6a, 6b, 6c and its salt at 
37 °C for 5 h. Duplicate samples are shown for each treatment. Net intensities of individual bands 
were determined with Kodak 1D image analysis software, version 3.5. Normalized values ± SD 
obtained from five independent experiments are shown. 
 
It was evident from the Western blots that both chloroquine and artesunate treatment caused 
an increase in haemoglobin level in the parasites, although the increase associated with 
artesunate was considerably less than that obtained with chloroquine. These results are in 
Ctrl      CQ     Artes      6b      6a 
Net intensity:    100    321±79   181±42   286±35  233±27 
(arbitrary units) 
Ctrl      CQ     Artes      6c     6c salt 

















agreement with published results.47 The hybrid molecules also produced an increase in 
parasite haemoglobin levels compared to controls, and the effects were intermediate between 
those of chloroquine and artesunate. 
 
To further investigate the effects of the chloroquine-artemisinin hybrid molecules on the 
endocytic pathway, the subcelluar location of haemoglobin within parasites was determined 
by immunofluorescence microscopy using anti-haemoglobin antiserum. As all four hybrid 
compounds exhibited similar patterns of haemoglobin accumulation in parasites by Western 
blotting, compound 6b was selected for the immunofluorescence assay. 
 
4.5.4 2 Localization of Transport Vesicles by Immunofluorescence Microscopy 
 
Parasite-associated haemoglobin is predominently located in the food vacuole. 
Ultrastructural studies have suggested that the increase in haemoglobin level in 
chloroquine-treated parasites may be due to the presence of endocytic vesicles (or transport 
vesicles) filled with undigested haemoglobin found either in the food vacuole, 61  or 
throughout the parasite cytoplasm.47 To investigate the effects of the drugs on endocytic 
trafficking within the parasite, subcellular localization of haemoglobin was visualized by 
immunofluorescence microscopy, with particular emphasis on the amount of haemoglobin in 
the food vacuole and the numbers and distribution of endocytic vesicles. 
 
Parasites were incubated with chloroquine, artesunate and 6b at five times their respective 
IC50 values, after which they were released from the RBCs by a brief saponin treatment to 
remove all extraparasitic haemoglobin (in order to reduce background levels and improve the 















poly-lysine-coated glass cover slips with paraformaldehyde-glutaraldehyde, permeabilzed 
with Triton and parasite-associated haemoglobin labeled by incubation with anti-Hb 
antiserum and TRITC-conjugated secondary antibodies. These cover slips were viewed by 
fluorescence microscopy to examine the localization of haemoglobin in the parasites. 
Representative images are shown in Fig. 4.15 below. 
 
In the control parasites, haemoglobin was predominantly located in the food vacuole. The 
location of the FV is readily determined by referring to the corresponding phase-contrast 
images, where the shiny haemozoin crystals, formed from haemoglobin degradation in the 
FV, are prominently visible. The food vacuoles are further indicated by large arrows in the 
fluorescence images. Punctate endocytic vesicles, filled with haemoglobin, were also visible. 
These are indicated by small arrows. For chloroquine treated parasites, there was little 
fluorescence (or in some cases, no fluorescence) in the FV, and haemoglobin was mostly 
found enclosed in endocytic vesicles. Treatment with artesunate and 6b resulted in decreased 
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Figure 4.15. Immunofluorescence microscopy localization of haemoglobin in parasites following 
incubation with various drugs. The position of the FV is indicated by large arrows, whereas those of 
the haemoglobin-containing transport vesicles are indicated by small arrows. Control, untreated 
parasites; CQ, chloroquine; Artes, artesunate; Phase, phase-contrast images, Hb, localization of 
haemoglobin; DAPI, nucleic acids were stained using DAPI in order to determine the number of 

















The average number of transport vesicles per parasite was enumerated by counting the 
amount of visible vesicles visible in 100 - 400 parasites per treatment, and it was found that 
the number of transport vesicles increased significantly in chloroquine-treated parasites, but 














Figure 4.16. Average number of transport vesicles in drug-treated and untreated parasites. 
Quantification consisted of counting the number of fluorescent foci separate from the food vacuole. 
Error bars represent standard error of the mean. Comparisons were made using the Mann-Whitney U 
test, significance α = 0.05.  
 
The results obtained for chloroquine and artesunate agreed with those reported in literature.47 
As discussed in section 4.3.2, Hoppe et al have suggested that the increase in haemoglobin 
accumulation and the number of transport vesicles in chloroquine-treated parasites may be 
the result of a block in transport vesicle-vacuole fusion, so that haemoglobin cannot be 
delivered to the FV for digestion. In addition, the decrease in endocytic vesicle counts in 
artesunate-treated parasites agrees with the reported inhibition of endocytosis by this drug – 
decreased haemoglobin endocytosis should decrease the rate of endocytic vesicle formation 















The morphology and immunofluorescence assays suggest that the mode of action of the 
hybrid molecules more closely resembles that of the artemisinin parent drug, rather than that 
of chloroquine. The hybrid molecules and artemisinin rapidly kill parasites in the ring stage, 
as opposed to the parasiticidal action of chloroquine which is more prolonged and prevalent 
in the trophozoite stage. In addition, the hybrid molecules and artemisinin reduced the 
amount of haemoglobin-filled endocytic vesicles in the parasite, likely due to an inhibition of 
endocytosis, in contrast to the vesicle-vacuole fusion block and marked increase in vesicles 
caused by chloroquine. The only result which suggests that an element of chloroquine’s 
mode of action may be maintained in the hybrid molecules is the fact that the increase in 
overall haemoglobin levels in the parasite obtained with the hybrids, as judged by Western 
blotting, is intermediate between the increase observed with artesunate and chloroquine 
respectively. As discussed earlier, the moderate increase in overall parasite haemoglobin 
levels caused by artemisinin has been interpreted as a combination of decreased 
haemoglobin uptake due to an endocytosis block on the one hand, balanced by increased 
haemoglobin content due to an inhibition of haemoglobin proteolysis in the food vacuole on 
the other.47 The β-haematin inhibition assays suggest that the hybrid compounds are even 
more effective than chloroquine at inhibiting the formation of haemozoin crystals in the food 
vacuole. Vacuole damage caused by heme accumulation may result in more extensive 
haemoglobin proteolysis inhibition by the hybrids than with the artemisinin parent drug, thus 




















4.6 Conclusion and Future Work 
 
4-Aminoquinolines were hybridized with artemisinin and 1,4-naphthoquinone derivatives 
via the Ugi 4-component condensation and their biological activities were investigated. No 
cross-resistance was observed for these hybrid compounds in chloroquine resistant parasites, 
with the artemisinin-containing compounds 6a, 6b, 6c and its salt being the most active in 
antiplasmodial assays (26, 35, 27 and 24 nM respectively). However, despite the potent in 
vitro activities, they also displayed cytotoxic properties and therapeutic indices of 
approximately 15. Hence, the challenge would be to lower the cytotoxity of these 
compounds, whilst retaining their potent antiplasmodial activity. One of the places to start 
would be the incorporation of new side chains into the molecule through the aldehyde and/or 
isocyanide inputs, or alternatively by changing the positions of the artemisinin and 
4-aminoquinoline pharmacophore by making, for example, artemisinin-amines, 
4-aminoquinoline-isocyanides, etc.  
 
Morphological changes in parasites treated with compounds 6a, 6b, 6c and its salt have 
shown that they may act by mechanism(s) similar to artemisinin, as both ring and 
trophozoite stage parasites were affected by the drug treatment. Additionally, the potent 
β-haematin inhibitory activities of these hybrids (0.45, 0.31, 0.44 and 0.40 equivalents for 6a, 
6b, 6c and 6c·salt, respectively) may have contributed to their inhibitory mechanism(s) 
against trophozoite stage parasites. 
 
The effects of the artemisinin-containing hybrids on endocytosis were also investigated, and 
were found to result in an increase in accumulation of haemoglobin within the parasites. 















6b, there was a decrease in the number of transport vesicles in the parasites. These hybrid 
molecules may act by inhibition of endocytosis, suggested by the immunofluorescence 
results, and inhibition of haemoglobin degradation, from the observed increase in 
haemoglobin levels in the parasites in Western blots, supported by the potent activities of 
these hybrids to inhibit β-haematin formation. 
 
It is also possible that these hybrid compounds do not act via the hypothesized artemisinin 
and chloroquine-related mechanisms, but on targets and/or pathways totally different to the 
two parent drugs that also impinge on the endocytic pathway. To further investigate the 
effects on endocytosis of these compounds, more extensive studies would be needed. For 
example, parasites could be incubated with the hybrid compound in the presence of protease 
inhibitors. This could eliminate haemoglobin degradation in the food vacuole, and solely 
examine the effect of the compounds on the degree of endocytosis. Alternatively, horseradish 
peroxidase could be used as a quantitative fluid-phase marker of endocytosis as it is 
indigestible by parasites. Ultimately, comparing the transcriptomic and/or proteomic profiles 
of parasites treated with artemisinin, chloroquine and the hybrid compounds should provide 
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This chapter focuses on the synthesis and characterization of a library of small molecules 
containing the β-lactam pharmacophore, using the Staudinger reaction and the Ugi 
3-component 4-centre condensation, and subsequent post-condensation modifications. Their 
antiplasmodial and cytotoxic activities are also presented. The diversities in the molecules 
would hopefully provide some insight into structure-activity relationships (SARs) for the 
β-lactams against malaria. 
 
5.2 β-Lactams Antibiotics 
 
β-Lactam antibiotics are potent, broad-spectrum agents of low toxicity to eukaryotes, and 
have served as a powerful line of defense against bacterial infection for over 60 years.1 The 
β-lactam ring is vital for their antibacterial activities, as activities were lost if the ring was 
broken. Penicillin, derived from Penicillium notatum, is one of the earliest discovered 
antibiotics, and contained the β-lactam pharmacophore. It was first discovered by Alexander 
Fleming in 1928,2 who received the Nobel Prize in 1945 for this great contribution.3 
Following the initial introduction of penicillin during the World War II, a variety of classes of 
β-lactam antibiotics were identified. These include, for example, the classical or traditional 
penicillins and cephalosporins, and the non-classical or non-traditional carbapenems and 















The term ‘monobactam’ (monocyclic β-lactam) was first used by Sykes et al to describe a 










Figure 5.1. Examples of clinically important classes of β-lactam antibiotics. 
 
5.2.1 Mode of Action 
 
The growth and division of bacterial cells necessitate production of new cell wall material. 
The cell wall is important for the preservation of cell shape and rigidity. The final step of the 
cell wall material production is the cross-linking of specific peptide chains to form a 
peptidoglycan matrix. β-Lactam antibiotics inhibit bacterial cell wall synthesis by interacting 
with enzymes responsible for the cross-linking of the these peptides, thereby causing bacteria 
death. The target proteins were identified by their ability to covalently bind isotopically 
labeled penicillin, and were termed penicillin-binding proteins (PBPs).6 PBPs are localized 
non-randomly on the outer face of the cytoplasmic membrane of the bacterium (hence 
relatively accessible by β-lactam antibiotics), and their major activities believed to be the 










































enzymes were believed to contain a serine residue at the active site. These enzymes are 
specific to bacteria, with no functional or structural counterpart in the human host, which is 
advantageous as this minimizes side-effects from antibiotic treatments. 
 
The key step in the cross-linking process is the acylation of the serine hydroxyl group. 
β-Lactam antibiotics mimic the D-alanine-D-alanine portion of the peptide substrate, 
acylating the serine hydroxyl group with the opening of the β-lactam ring. This interference 
prevents the transpeptidases from completing the peptide cross-linkages in the cell wall, 
resulting in weakening of the cell wall as the bacterium grows, leading to its death.6,7  
 
5.2.2 Bacterial Resistance Against β-Lactam Antibiotics 
5.2.2.1 β-Lactamases  
 
The heavy use of antibiotics in the past half-century has resulted in an increasing number of 
bacteria being resistant to the drugs available today.8 The most common and clinically 
relevant bacterial mechanism of resistance to β-lactam antibiotics is the production of 
β-lactamases. β-Lactamases are bacterial enzymes that inactivate β-lactam antibiotics by 
hydrolyzing the β-lactam ring. A large number of these enzymes have already been 
described,9 but new members are discovered every year.10 Other means of resistance include 
the modification or overproduction of PBPs,11 and the prevention of access of the antibiotic 
to the target by way of altered permeability or forced efflux.12 The development of β-lactam 
antibiotics has thus been a continuous battle of the design of new compounds to withstand 

















5.2.2.2 β-Lactams as β-Lactamase Inhibitors 
 
Clavulanic acid, the first β-lactam inhibitor of β-lactamase, was isolated from Streptomyces 
clavuligerus and its structure elucidated in 1976.13 After the isolation of clavulanic acid, 
many semisynthetic β-lactamase inhibitors, such as sulbactam, tazobactam and brobactam, 
have been further developed, and their comparative β-lactamase inhibitory activities studied 






Figure 5.2. Representative β-Lactam Inhibitors of β-Lactamases 
 
In combination with β-lactamase-susceptible antiobiotics, these β-lactamase inhibitors protect 
the β-lactam antibiotic from inactivation by β-lactamases, thereby extending the spectrum of 
activity of the antibiotic.  
 
5.2.2.3 Novel Targets against Resistance 
 
Due to the increasing number of bacteria being resistant to available drugs, antibacterial 
agents against novel targets in the microorganism have been developed. An example is 
inhibiting the formation of pili. Pili are a family of extracellular, supramolecular protein 
organelles that mediate attachment to host epithelial cells. Pilus assembly is performed by 





































where they are incorporated into a growing pilus.15 Colonization of host tissue cannot occur 
if the chaperone subunit complex formation is prevented.16 Almqvist and co-workers have 
designed a library of bicyclic β-lactam carboxylic acids that could potentially inhibit pili 
formation.17 
 
5.3 Other Medically Important Uses 
 
Apart from their use as potent antibacterial agents, β-lactams were also reported to display 
antimalarial,18 anticancer19 and anti-HIV20 activities. They have also been found to be able 
to inhibit cholesterol absorption 21  and target the human leukocyte elastase, 22  whose 
degradative effect on lung elastin has been implicated as the major causative factor for 
serious degenerative diseases such as chronic bronchitis, cystic fibrosis and rheumatoid 
arthritis. Activities of β-lactams against thrombin, 23  prostate specific antigen23, 24  and 
tryptase25 have also been reported. 
 
5.4 β-Lactams as Antimalarials 
 
Although there have been no studies on their mode(s) of action in the malaria parasite 
Plasmodium falciparum, β-lactams may exert their antimalarial effects by inhibiting 
important protease activities in the parasite. In humans, the human leukocyte elastase, 
thrombin, prostate specific antigen and tryptase are all serine or serine-like enzymes.26 
Bacterial enzymes such as the D-alanyl-D-alanine transpeptidases/carboxypeptidases and 
β-lactamases are also serine enzymes.27 The ability of β-lactams to react irreversibly with 
nucleophilic serine residues make them good serine protease inhibitors, and the interaction of 















Studies by Singh et al have shown that β-lactams also act as cysteine protease inhibitors.29 
Various classes of β-lactam analogs that inhibit cysteine proteases such as the cathepsins have 
been synthesized. Hence the antimalarial activities of β-lactams may be associated with their 
ability to interact with serine and/or cysteine proteases in the malaria parasite. 
 
5.5 Syntheses of β-Lactams 
 
After the landmark discovery of penicillin by Fleming,2 interest in β-lactam compounds has 
led to intensive research which generated numerous methods of synthesizing the β-lactam 
backbone. Here we present a few of the most well-known protocols. 
 
5.5.1 Staudinger Reaction 
 
The β-lactam, a four-membered cyclic amide, was first synthesized in 1907 by Hermann 
Staudinger, using the [2+2] cycloaddition of the Schiff base of aniline and benzaldehyde 
(benzalaniline) with diphenylketene (Scheme 5.1).30 This is also the most common approach 
towards β-lactam synthesis, and was chosen as one of the methods for the synthesis of the 

































5.5.1.1 Reaction Pathways and Relative Stereoselectivity 
 
The most widely accepted reaction mechanism for the Staudinger reaction is the stepwise 
ketene-imine cycloaddition reaction, which involves (a) the nucleophilic attack of the imine 
to the ketene, giving rise to a zwitterionic intermediate and (b) a conrotatory electrocyclic 
ring closure of the zwitterion to produce the final β-lactam product. 31  When a 
monosubstituted ketene reacts with an acyclic imine, two new stereocentres are produced, 
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Pathways for the formation of cis- or trans-isomers are illustrated in Scheme 5.2. The relative 
stereochemistry of the β-lactam product is decided by the competition between direct ring 
closure (exo or endo attack) and the isomerization of the imine moiety in the zwitterionic 
intermediate. Jiao et al have proposed a model that explains the relative stereoselectivity 
based on kinetic analysis of the cis/trans ratios of reaction products.32 Based on their results, 
they have proposed that the origin of the relative stereoselectivity can be described as 
follows: 
 
(i) The stereoselectivity is generated as a result of the competition between the direct 
ring closure and the isomerization of the imine moiety in the zwitterionic 
intermediate; 
(ii) The ring closure step is most likely an intramolecular nucleophilic addition of the 
enolate to the imine moiety, which would be affected by the electronic effect of the 
ketene and imine substituents; 
(iii) Electron-donating ketene substituents and electron-withdrawing imine substituents 
accelerate the direct ring closure, leading to a preference for cis-β-lactam 
formation, while electron-withdrawing ketene substituents and electron-donating 
imine substituents slow the direct ring closure, leading to a preference for 
trans-β-lactam formation, and 
(iv) The electronic effect of the substituents on the isomerization is a minor factor in 
influencing the stereoselectivity. 
 
The relationship between the relative stereoselectivity and the structural features are 
























Figure 5.3. Influence of the structural features on the relative stereoselectivity in the Staudinger 
reaction.32 
 
5.5.2 Ugi 3-Component 4-Centre Condensation (Ugi 3C-4CC) 
 
This condensation is a variant of the Ugi 4-component condensation. Here, two of the 
functional groups that take part in the reaction were tethered onto one starting material. This 
method has also been used to synthesize γ- and δ-lactams.33 For the synthesis of β-lactams, 
β-amino acids (containing the amine and carboxylic acid components) were condensed with 
aldehydes and isocyanides to yield β-lactam derivatives. 34  Bicyclic β-lactams can be 
synthesized using cyclic β-amino acids.35 This reaction was also chosen for the synthesis of 
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5.5.3 Gilman-Speeter Reaction 
 
The Gilman-Speeter was discovered by Henry Gilman and Merrill Speeter in 1943.36 This 
reaction involves the ester enolate-imine condensation between ethyl bromoacetate and 








Scheme 5.4. The Gilman-Speeter Reaction 
 
5.5.4 Kinugasa Reaction 
 
The first description of the Kinugasa reaction in 1972 involved the reaction of copper (I) 
phenylacetylide with nitrones to produce β-lactams (Scheme 5.5).37  The reaction was 
performed in anhydrous pyridine at room temperature under nitrogen atmosphere. The use of 
copper (I) phenylacetylide as the reagent was critical, as reaction of alkynes with nitrones 

















































R1 = Ph, o-MeC6H4, o-ClC6H4















5.5.5 Other Methods 
 
Other notable methods employed towards the synthesis of the β-lactam backbone include 
photo-induced rearrangements39 and radical cyclizations.40 
 
5.6 Rationale for Drug Design - Series I 
 
5.6.1 Design of Target Compounds  
 
The Staudinger reaction and the Ugi 3-component 4-centre condensation have been chosen 









Figure 5.4. Rationale for design of target molecules. 
 
The terminal acetylene moiety is present for possible post-condensation modifications, and is 
placed at different positions on the aromatic ring or directly on the β-lactam ring. This may 
be advantageous for structure-activity relationship studies. The acetylene moiety could be 


























cycloaddition (Scheme 5.6a), (b) the Mannich reaction,42 an aminomethylation reaction 
(Scheme 5.6b) or (c) the Sonogashira coupling reaction43 of aryl or vinyl halides to the 









Scheme 5.6. (a) Click chemistry, (b) the Mannich reaction and (c) Sonogashira coupling reaction. 
 
The compound with the most potent in vitro antiplasmodial activity within the exploratory 
series was chosen to be further modified to study whether modifications would enhance its 
activities. The Mannich reaction was chosen for this modification, as the inclusion of a 
tertiary amine may enhance biological activities due to, for example, vacuolar accumulation. 
 
5.6.2 The Mannich Reaction 
 
The Mannich reaction, also a multi-component condensation reaction, was first described by 
van Marle and Tollens in 1906.44 The three components for this reaction are: (i) ammonia, a 
primary or secondary amine, (ii) a non-enolizable aldehyde (usually formaldehyde) and (iii) a 
compound with an active hydrogen atom or a reactive nucleophilic site (Scheme 5.5b). When 
these components condense, water is released concomitantly to produce a new base, known 




























R' = Ar, vinyl,


















as a ‘Mannich base”. The Mannich reaction is one of the most important carbon-carbon and 
carbon-nitrogen bond-forming reactions in organic chemistry.42,45 
 
5.6.2.1 Classification of Mannich Bases 
 
The active hydrogen component employed in the Mannich reaction may be a ketone, ester, 
nitrile, nitro, α-alkylpyridine, hydrogen cyanide, phenol, thiol, tertiary aromatic amine, 
enamines, alkyne, indole, heteroaromatic or heterocyclic compounds. The amine component 
used here cannot be a tertiary amine, as it lacks the N-H proton that is needed to form the 
imine intermediate. The amine component is usually commercially available or readily 
accessible.42 The general classification of Mannich bases are presented in Table 5.1. 
 
5.7 Synthesis of Target Molecules – Series I 
 
5.7.1 Via the Staudinger Reaction 
 
Propargyloxy benzaldehydes were synthesized by reacting various hydroxy benzaldehydes 







Scheme 5.7. Reagents and conditions: (i) Propargyl bromide (1.2 eq), K2CO3 








7a: ortho, yield = 99%;
7b: meta, yield = 93%;















Table 5.1. General classification of Mannich bases. 
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The benzaldehyde was then reacted with either benzylamine or aniline to form the imine 
intermediate, followed by cycloaddition with acetoxy acetyl chloride to form the β-lactam. 
For selected compounds, the acetate group was hydrolyzed using K2CO3 to yield the free 
alcohol (Scheme 5.8). Please note that only the one enantiomer of the products is shown here, 












Scheme 5.8. Reagents and conditions: (i) amine (1.2 eq), methanol, r.t., 24 h. (ii) 
Acetoxy acetyl chloride (1.5 eq), Et3N (3.0 eq), DCM, N2, -78 °C to r.t., 14 h. (iii) 
K2CO3 (1.3 eq), methanol/H2O (5:2), r.t., 18 h. 
 
To install the propargyloxy group directly on the β-lactam ring, compound BL09 was 
synthesized in a similar way as illustrated in Scheme 5.9. After the cycloaddition of acetoxy 
acetyl chloride to the Schiff base of benzaldehyde and benzylamine, the compound was 
hydrolyzed to yield the free hydroxyl group, which was then reacted with propargyl bromide 






















































Scheme 5.9. Reagents and conditions: (i) benzylamine (1.2 eq), methanol, r.t., 24 h. (ii) 
Acetoxy acetyl chloride (1.5 eq), Et3N (3.0 eq), DCM, N2, -78 °C to r.t., 14 h. (iii) 
K2CO3 (1.3 eq), methanol/H2O (5:2), r.t., 18 h. (iv) Propargyl bromide (1.2 eq), NaH 
(1.2 eq), anhydrous DMF,  0 °C, 1 h. 
 
5.7.1.1. Mechanistic Details 
 
The imine that is formed by reacting the aldehyde and the amine undergoes a [2 + 2] 
cycloaddition with the ketene that is generated in situ from acetoxy acetyl chloride. The 
formation of the ketene from acetoxy acetyl chloride is illustrated in Scheme 5.10, which 
entails the abstraction of the acidic proton α to the carbonyl carbon, followed by the 






































Scheme 5.10. Formation of acetoxy ketene from acetoxy acetyl chloride. 
 
The final β-lactam products are exclusively of the cis-configuration (confirmed by 1H NMR 
spectroscopy), suggesting that the reaction proceeds via direct ring closure, where 
isomerization of the imine moiety of the zwitterionic intermediate was minimal (pathway a→
c in Fig. 5.2, section 5.5.1.1).  
 
The imine that is formed is assumed to be of the thermodynamically stable E (trans) 
configuration. The initial step of the Staudinger reaction may take place through the less 
hindered side of the ketene, i.e. via exo attack. Hence, the preferential exo attack during this 
step would result in lower energy conrotatory transition structures,46 giving rise exclusively 



































































It is also possible that the cis-β-lactam products may form via exo attack of the Z-imine to the 
ketene, and undergoing a fast isomerization of the imine moiety of the zwitterionic 
intermediate to form the cis-β-lactam product (pathway d→b→ c in Fig. 5.2). The 
cis-β-lactam product could be exclusively formed if the rate of isomerization was faster than 
the rate of cyclization. However, from a geometric viewpoint, intermediate D is more 
favourable than C (Fig. 5.2), hence it is unlikely, but not impossible, that this is the reaction 
pathway for the Staudinger products synthesized. 
 
5.7.1.2 Synthesized Products 
 
Compounds containing a terminal acetylene moiety, synthesized via the Staudinger reaction, 





































































5.7.1.3 Spectroscopic Analyses 
 
The syntheses of the β-lactams were confirmed by their respective 1H and 13C NMR spectra. 
Using the 1H NMR spectrum of compound BL01 as an example (Fig. 5.6), the presence of a 
sharp signal at 1.70 ppm, integrating for 3 protons, indicated the presence of the acetyl group. 















Figure 5.6. 1H NMR spectrum of BL01. 
 
Two sets of doublet of doublets (dd) were found at 4.60 and 4.66 ppm, corresponding to the 
two geminal protons H-5. They couple to each other with a coupling constant of 16.0 Hz, and 
to the alkyne proton (H-6) with a smaller coupling of 2.4 Hz. Proton signal corresponding to 





































Benzylic protons were found at 3.96 and 4.83 ppm, with a coupling constant of 14.8 Hz. The 
coupling constant between H-1 and H-2 was found to be 4.8 ppm (typically between 4 – 6 Hz 
for cis configuration and 2 – 3 ppm for trans configuration),32 confirming the configuration 
of the β-lactam products to be cis. 
 
5.7.2 Via the Ugi 4-Component 3-Centre Condensation 
 
Three compounds were synthesized via the Ugi 3-component 4-centre condensation (Ugi 


































ortho = BL10, yield = 88%;
meta = BL11, yield = 90%;
para  = BL12, yield = 83%















5.7.2.1 Reaction Mechanism 
 
The reaction mechanism for the Ugi 3C-4CC is the same as the Ugi 4-component 
condensation, the only difference is that the amine and carboxylic acid components were 













Scheme 5.13. Reaction mechanism of the Ugi 3C-4CC. 
 
A new stereocentre was created in the β-lactam (marked by an asterisk). As R1 is not a 







































































5.7.2.2 Spectroscopic Analyses 
 
The 1H NMR spectrum of BL11 is presented in Figure 5.7. The region of particular interest is 
the 2.4 – 4.0 ppm region, where the protons on the β-lactam ring were found. Two sets of 
triplet of doublets (td, J 5.6 and 3.2 Hz, 1H, H-2) appeared between 3.2 – 3.6 ppm, while two 
sets of doublet of doublet of doublets (ddd, J 14.6, 5.6 and 3.2 Hz, 1H, H-1) appeared around 
2.9 ppm. Interestingly, H-1 displayed a large geminal coupling of 14.6 Hz, while H-2 did not. 
The variation in the geminal coupling constants is striking (14.6 Hz for H-1 and 5.6 Hz for 
H-2). A J value of 14.6 Hz falls within the normal range for geminal couplings, while a J 
value of 5.6 Hz is considerably smaller than expected, and is close to values reported for 
substituted cyclopropanes. 47  This effect cannot be explained by the presence of the 
neighbouring electronegative nitrogen atom, as benzylic protons displayed a normal coupling 
constant of ~14.8 Hz (see Fig. 5.6, section 5.7.1.3). This phenomenon was also reported by 
Barrow and Spotswood,48 and they have suggested that the ring strain in the β-lactam ring 
may have been accommodated by rehybridization of C-2, and hence the observed small 
geminal coupling of H-2 that is similar to values for substituted cyclopropanes. J values of 
5.6 and 3.2 Hz for cis and trans couplings respectively were in agreement to those reported in 
literature.32  
 
The coupling constant between H-6 and H-7 was found to be 2.4 Hz, typical of long-range 
coupling. However, no geminal coupling was observed between H-6’s. The signal for H-3 
























































































5.7.3 Biological Activities of the Terminal Acetylene-Containing β-Lactams 
 
Preliminary studies on in vitro antiplasmodial activity and cytotoxity were conducted to 
determine the compound with the lowest IC50 value out of these β-lactams for further 
modifications. It was found that BL11 possessed the most potent activity against the 
chloroquine-sensitive 3D7 strain of P. falciparum, using a standard parasite viability assay 
that measures parasite luciferase activity after 60 hours of drug exposure (Table 5.2).  
 





                    BL01 – BL09             BL10 – BL11 












BL01 ortho OAc 1 100 > 50 
BL02 ortho OH 1 92 47.3 
BL03 meta OAc 1 100 > 50 
BL04 para OAc 1 55 > 50 
BL05 ortho OAc 0 27 > 50 
BL06 ortho OH 0 22 > 50 
BL09 - OCH2C≣CH 1 50 > 50 
BL10 ortho - - 24 > 50 
BL11 meta - - 3 > 50 

























The position of the O-propargyl group on the benzene ring did not seem to have an effect on 
the in vitro antiplasmodial activities against the 3D7 strain (compare BL01, BL03 and BL04; 
BL10, BL11 and BL12). For the Staudinger β-lactams, compounds bearing a free hydroxyl 
group (BL02 and BL06) displayed slightly better activities when compared to the parent 
acetate (BL01 and BL05).  
 
Compound BL05 displayed antiplasmodial activity almost 4 times higher than BL01 (27 and 
100 μM, respectively). The only difference between the two compounds is that BL05 
contains an N-aniline moiety, while BL01 contains a N-benzyl moiety. This may suggest that 
the length/size of the group attached to the β-lactam nitrogen is important, however, more 
analogues with different N-substituents will need to be synthesized to investigate this effect. 
 
5.8 Rationale for Post-Condensation Modifications – Series II 
 
As described in section 5.6, the best compound from the first series of the β-lactam (BL11) 











































The acetylene moiety of the Mannich bases adds rigidity to the molecule, and is often present 
in natural products that possess interesting biological properties such as antibacterial,49,50 
antifungal,49,51 pesticidal52,53 and antitumour53,54 activities. The molecular rigidity around 
the acetylene moiety is advantageous, as this may increase bioavailability by locking out 
access to clearance enzymes and reducing the number of rotatable bonds while retaining the 
inhibitory potency of the molecule.55,56 
 
Chemical diversity can be introduced at the amino or the alkyne site, which would be useful 
for structure-activity studies.57 The presence of a protonatable nitrogen would be beneficial 
to vacuolar accumulation, as discussed in previous chapters. Additionally, this protonatable 
nitrogen also provides a site for salt formation, which would aid in aqueous solubility. 
Commercially available amines were used in this investigation.  
 
The R group adjacent to the amide bond can be diversified by utilizing various isocyanide 
components, and commercially available isocyanides were employed. The phenoxy moiety 
could also be replaced by groups such as biaryl or alkyl groups for structure-activity 
relationship studies, but is not investigated here.  
 
5.9 Synthesis of β-Lactam Mannich Bases – Series II 
 
Mannich bases were synthesized according to the protocol described by Bieber and da 
Silva,58 using 0.02 equivalents of copper iodide as the catalyst. Copper salts were frequently 
used in the Mannich reaction, as they have been found to increase the nucleophilicity of the 
acetylene.42,59 Compared with other reported protocols for the Mannich reaction, which is 















milder and the reaction could be conducted at room temperature and without the use of dry 
solvents.  
 
5.9.1 Altering the Amine Moiety of the β-Lactam Mannich Base 
 
Compound BL11 was reacted with various commercially available amines to yield various 







Scheme 5.14. Reagents and conditions: (i) aq. formaldehyde (5.0 eq), amines (1.2 eq), 
CuI (0.02 eq), DMSO, r.t., 3 h. 
 
The mechanism of the Mannich reaction has been well investigated.59 The iminium ion that is 
formed from the secondary amine and formaldehyde undergoes attack by the 


















































5.9.2 Altering the Isocyanide Moiety of the β-Lactam Mannich Base 
 
To create a more diversified library of β-lactam Mannich bases, a Mannich base-containing 
benzaldehyde 8 was synthesized and reacted with β-alanine and various isocyanides using the 











Scheme 5.16 Synthesis of β-lactam Mannich bases utilizing various isocyanides. 
 
5.9.3 Spectroscopic Analyses 
 
Using the 1H NMR of BL17 as an example (Fig. 5.9), the deciding evidence of successful 
synthesis of the Mannich base was the signal of H-6, which changed from a doublet into a 
triplet; the signal of the acetylenic proton disappeared, and was replaced by a new signal (H-7) 
that was found at 3.33 ppm. The presence of morpholine protons (H-8 and H-9) also 





















































































































5.9.4 Products Synthesized 
 
Structure and yields of the target β-lactam Mannich bases are presented in Table 5.3. Yields 
of the Mannich bases were generally very good. 
 





General structure of β-lactam Mannich bases 
Compound R1 R2 Yield (%) 
BL13 N 72 











































































5.10 Results and Discussion 
 
5.10.1 Antimalarial Activities 
 
Antiplasmodial activities of the Mannich bases and their respective cytotoxicities are 
presented in Table 5.4.  
 
The antiplasmodial activities of the β-lactam Mannich bases were mostly in the low to mid 
micromolar range, either against the chloroquine-sensitive D10 or chloroquine–resistant Dd2 
strain. Although P. falciparum parasites are unlikely to develop resistance against these 
compounds, as IC50 values against the Dd2 strain were either similar or lower than those 
against the D10 strain (indicated by the resistance index, with values not greater than 1.4), 






















General structure of β-lactam Mannich bases 
Cmpd R1 R2 
P. falciparum IC50 




CQ - - 0.026 0.156 9.53 6.0 61 
8 - - 194.32 204.86 - 1.1 - 
BL11   12.39 11.27 > 50 0.9 >4.4 
BL13 N 15.68 13.42 44.9 0.9 3.3 
BL14 N 39.50 14.92 > 50 0.4 >3.3 
BL15 N
 
65.37 10.58 > 50 0.2 >10.7 
BL16 N 26.17 17.66 > 50 0.7 >2.83 
BL17 N
O




28.07 10.66 > 50 0.4 >4.7 
BL19 N
NH













































a Resistance index calculated as [IC50 (Dd2)] / [IC50 (D10)]; 
b Therapeutic index calculated as [IC50 (HeLa)] / [IC50 (Dd2) 
 
It is worth noting that by converting compound BL11 into various Mannich bases (BL13 to 
19), antiplasmodial activities were not enhanced. The activities of most of the Mannich bases, 
except for compound BL13, were at least two times lower than the parent compound against 
the D10 strain. However, for activities against the Dd2 strain, most compounds displayed 
activities similar to the parent BL11 (except for compound BL17, BL20 and BL22), with 
compounds BL15 and BL18 (IC50’s of 10.58 and 10.66 μM respectively) displaying the most 
potent activities. 
 
By altering the isocyanide component (R1) on the Ugi backbone of the β-lactam, 
antiplasmodial activities was enhanced (compare BL20 – BL26 with compound BL17) 
except for compounds BL20, BL21 and BL25. Compounds BL20, BL21 and BL25 
contained N-methoxyphenyl, N-1-methylbutyl and N-benzyl groups respectively, and it is 
possible that the activities of these compounds were lower as they contained a less bulky R1 
group when compared to the other Mannich bases. Compound BL26, which contained a 
benzotriazole moiety, has the best activity out of this series (15.06 and 13.74 μM against D10 
and Dd2 strains respectively). Its enhanced activities may be attributed to the presence of the 
triazole moiety, but more studies would be required to confirm this hypothesis. 
Cmpd R1 R2 
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73.31 57.70 > 50 0.8 >0.9 
BL26 N
N N  
N
O















5.10.2 Cytotoxicity Studies 
 
Cytotoxic activities of these compounds were studied on HeLa cells, using chloroquine as the 
control. These compounds did not display cytotoxicity against mammalian cells, as their IC50 
values were mostly above 50 μM, irrespective of their antiplasmodial activities. These 
β-lactam Mannich bases could become good antimalarial drug candidates if their 
antiplasmodial activities could be enhanced without compromising the low cytotoxicity (i.e. 
increase the therapeutic index for these compounds) and/or lower the selective index. 
 
5.11 Conclusion and Future Work 
 
A series of β-lactams containing terminal acetylenes were synthesized via the Staudinger and 
Ugi 4-component 3-centre reactions, and tested against the chloroquine-sensitive 3D7 strain 
of P. falciparum. The compound with the best activity (BL11) was further modified by the 
Mannich reaction, and compounds BL13 and BL26 displayed the most potent activities 
against the D10 strain (15.68 and 15.06 μM respectively), while compounds BL15 and BL18 
were the most active against the Dd2 strain (10.58 and 10.66 μM respectively). None of the 
β-lactams displayed cytotoxity against HeLa cells at 35μM. 
 
The activities of the β-lactams that contains the terminal acetylene moiety were higher than 
those containing the Mannich base, while β-lactams with a bulky N-substituent on the Ugi 
backbone also displayed enhanced activities. This may suggest that the terminal acetylene 
moiety is important for activity. More diversified analogues would need to be prepared to 
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 
4-AMINOQUINOLINE ANALOGUES 
 
This chapter describes the synthesis, characterization and biological evaluation of 
4-aminoquinoline analogues. These compounds were designed and synthesized to investigate 
whether their antiplasmodial activities could be enhanced, in comparison to chloroquine, and 
circumvent the development of cross-resistance in the malaria parasite. 
 
6.1 4-Aminoquinoline Antimalarials 
 
There has been a long history for the use of 4-aminoquinolines in the treatment of malaria. 
The most well-known antimalarials in this class are chloroquine and amodiaquine, which are 
both believed to act by inhibiting the formation of haemozoin in the food vacuole of the 
Plasmodium parasite.1 The mode of action and the mechanism of resistance of chloroquine 

































Amodiaquine is a Mannich base derivative that was introduced in the late 1950s. It was 
developed during World War II by the US Army-sponsored program to develop alternatives 
to quinine.2 It has been shown to be a superior alternative to chloroquine in areas of high 
chloroquine resistance.3,4 In the mid-1980s, reports of agranulocytosis (an acute condition 
involving a severe and dangerous leucopenia – a drop in the number of white blood cells in 
the blood) and hepatitis on the use of amodiaquine in prophylaxis caused a rapid decline in 
the use of the drug.5 However, detailed investigations have shown that when used to treat 
uncomplicated P. falciparum malaria, amodiaquine was no more toxic than chloroquine.3,6 
Results collated from 40 different clinical trials held in the late 1980s have suggested that 
adverse drug reactions to amodiaquine are likely to only occur during prophylaxis.6 To date, 
there is no evidence for serious toxicity associated with amodiaquine therapy.7  
 
6.1.1.1 Amodiaquine Resistance 
 
Very little is known about the mechanism or epidemiology of amodiaquine resistance. A 
correlation between resistance to chloroquine and amodiaquine has been found from in vitro 
studies; however, chloroquine-resistant strains appeared to have lower levels of resistance to 
amodiaquine.8  Studies have shown that amodiaquine is effective against chloroquine- 
resistant strains of malaria in vivo.9 However, it has also been observed that amodiaquine 
resistance does occur in areas where it was regularly used.10 Although some clinical 
evidence of amodiaquine sensitivity has been documented, cross-resistance between 
chloroquine and amodiaquine has been reported from laboratory analysis, which, in some 















6.1.1.2 Amodiaquine in Combination Therapy 
 
Artemisinin combination therapy (ACT), as described in section 2.2.3, has been 
recommended by the WHO as the first-line antimalarial treatment for P. falciparum 
malaria. 12  Although ACTs may have been extremely effective in Southeast Asia, 13 
Meshnick and Alker believe that they may not be appropriate for sub-Saharan Africa.14 
There are two reasons for this: (i) as artemisinins have short half-lives, when they are 
co-administered with a long half-life drug, patients may have sub-therapeutic concentrations 
of the latter drug alone in their plasma for days or weeks. This would not be a problem in 
Southeast Asia, where the risk of new infection is rare. However, people in sub-Saharan 
Africa may be subjected to infectious mosquito bites on a daily basis. This would create an 
ideal scenario for the development of resistance, when parasites could be exposed to 
sub-therapeutic concentrations of single antimalarial agents; (ii) it has been found that 
artesunate causes fetal death and malformations in pregnant rodents.15 In consideration of 
the fact that the average woman in sub-Saharan Africa gives birth 5.7 times,16 women 
between the age of 15 and 45 may be ineligible for this treatment. 
 
Zongo et al have suggested the use of amodiaquine in combination with other antimalarials 
such as sulfadoxine-pyrimethamine (SP).17 This would be advantageous over artemisinins 
as the principal active metabolite of amodiaquine has a longer half-life of 9 to 18 days.18 
Thus, if amodiaquine was to be co-administered with another long half-life drug, there 
would be little chance that the parasite would be exposed to subcurative concentrations of a 
single antimalarial agent. The combination of amodiaquine with sulfadoxine-pyrimethamine 
has been evaluated by Zongo et al in a randomized placebo-controlled clinical trial; they 















group and by others have also shown an increased efficacy for this combination.19  
 
6.1.2 Bis-, Tris- and Tetraquinolines  
 
In the P. falciparum parasites, the emergence of resistance against chloroquine has eroded 
the efficacy of chloroquine and related drugs. Mechanisms of chloroquine resistance in the 
parasite has been discussed in section 2.1.2, which include the enhanced efflux of 
chloroquine from the parasite via the P-glycoprotein homologue 1 (Pgh 1) 20  or the 
Plasmodium falciparum chloroquine resistance transporter (PfCRT)21 protein.  
 
Various efforts have been put into overcoming chloroquine-resistance, such as modifications 
to the side-chain of chloroquine or related 4-aminoquinolines,22 the use of resistance 
reversal agents such as verapamil, desipramine and chlorpromazine,20b, 23  tethering of 
4-aminoquinolines to other pharmacophores such as chimeras of trioxane-aminoquinoline 
(‘trioxaquines’)24 and tetraoxane-aminoquinolines25or the hybridization of artemisinin and 
quinine.26  
 
Bisquinolines have been designed such that owing to their bulkiness, they may potentially 
overcome drug-resistance by escaping the recognition and subsequent extrusion by the 
proteins involved in drug efflux.27 Bisquinolines have been synthesized, and found to inhibit 
the growth of both chloroquine-sensitive and chloroquine-resistant parasites with similar 
efficacy.27,28 Bis-, tris- and tetraquinolines have been designed and synthesized by Girault et 
al,29 and evaluations have shown that some of the bis- and tetraquinolines displayed potent 
























Figure 6.2. Rationale for the design of target compounds. 
 
The rationale for the target compounds is summarized in Fig 6.2 above. These compounds 
could be either amodiaquine-like, or contain an α,β-unsaturated system. Aminoquinoline 
derivatives were also tethered to form a bisquinoline compound. 
 
The general activity of the quinoline ring has been described in Chapter 3.5, and will not be 
repeated here. 
 
6.3 Synthesis of Target Compounds 
 
6.3.1 Retrosynthesis Analysis 
 
Retrosynthesis was carried out for the amodiaquine-like compounds, and the retrosynthetic 








n = 0 or 1; 































Scheme 6.1. Retrosynthesis analysis of amodiaquine-like compounds. 
 
The target compounds could be synthesized in two ways; Path A: starting from 
4,7-dichloroquinoline, and undergoing a nucleophilic substitution by the aminobenzyl 
alcohol to form the intermediate 9. The hydroxyl moiety of 9 could then be converted into a 
leaving group (intermediate 10), and displaced by the amine to form the target compound 12. 
 
Path B: after the synthesis of the benzyl alcohol intermediate 9, it could then be oxidized to 
form the aldehyde 11, which, upon reductive amination of the aldehyde moiety, would yield 
the desired amodiaquine-like target compound 12. 
 
6.3.2 Synthesis of 4-Aminoquinoline Analogues 
 
6.3.2.1 Amodiaquine-like Compounds 
 
The synthesis of the benzyl alcohols 9a and 9b were explored using two methods (Scheme 
















































N2 for 8 hours;22b the second method was simply refluxing the two starting materials in 









Scheme 6.2. Reagents and conditions: (i) aminobenzyl alcohol (1.0 eq), Et3N (8.0 eq), K2CO3 
(1.5 eq), NMP, N2, reflux, 18 h. (ii) aminobenzyl alcohol (1.0 eq), EtOH, reflux, 3 h. 
 
After exploring both methods, the ethanol method was best suited for the synthesis of 9a and 
9b, as better yields were achieved. In the case of 9a, the pure product simply precipitated out 
from the reaction mixture. Evidence of the correct products was obtained from 1H NMR, as 
the singlet at 4.5 ppm, integrating for two protons, confirmed the presence of benzylic 
protons in compounds 9a and 9b.  
 






















Method A: 9a meta  yield = 30%;
                 9b ortho  yield = 35%;
Method B: 9a meta  yield = 98%;

















Following the synthesis of the benzyl alcohols 9a and 9b, the target compound could be 




Path A entails the activation of the hydroxyl group, and its subsequent displacement by the 
amine to form the target compound. The reaction scheme is outlined in Scheme 6.4. 
Intermediate 9a was converted into the mesylate 10 using methanesulfonyl chloride in the 
presence of pyridine. Mesylation is typically conducted in DCM/Et3N,31 but for the reaction 
with compound 9a, pyridine was used as both the base and the solvent as 4-aminoquinoline 
compounds are generally poorly soluble in solvents such as DCM and THF. The mesylate 
intermediate 10 was then reacted with diethylamine, where the mesylate moiety was 
nucleophilically displaced by the amine to form compound 13a.32 The yield of this last step 







Scheme 6.4. Reagents and conditions: (i) pyridine, 0 °C, 30 min (ii) methanesulfonyl chloride  





































To prepare the aldehyde for reductive amination, oxidation of benzyl alcohol 9a was initially 
carried out using pyridinium dichromate (PDC).33 During the monitoring of the reaction 
using TLC, many spots were observed, indicating that PDC may have been too strong an 
oxidizing agent for the starting alcohol, and oxidized not only the benzyl alcohol, but also 
the quinoline nitrogen. Hence a milder oxidizing agent, sulfur trioxide/pyridine complex 
(SO3･Pyr), was chosen (Scheme 6.5).34 The disadvantage of this method was that the 








Scheme 6.5. Reagents and conditions: (A) PDC (1.2 eq), DMF/THF (1:4), r.t., 4 h. (B) SO3･Pyr 
(2.0 eq), Et3N (4.0 eq), DMSO, r.t., 2 days. 
 
After stirring for 2 days, the oxidation went to completion for 11b, but not for 11a. 1H NMR 
showed that the crude material was a mixture of the starting benzyl alcohol 9a and the 
desired aldehyde 11a, in a ratio of 42 : 58 (9a : 11a). As the product was too polar, and could 
only be dissolved in large amounts of DMSO, chromatography was not practical. Hence the 
crude material was used for subsequent reactions. On the other hand, the oxidation worked 
well for 9b; after washing the crude material with DCM, the crystals collected were pure and 







11a meta   Method A: yield = 0%;
                  Method B: yield = 58% (crude);





























Scheme 6.6. Reaction mechanism for the oxidation using sulfutrioxide/pyridine. 
 
DMSO is activated by the sulfur trioxide/pyridine complex, which, in the presence of 
triethylamine, converts primary and secondary alcohols to aldehydes and ketones at ambient 
temperature.34 The alkoxylsulfonium intermediate that is formed here is the same as that 
formed in the Swern oxidation,35 and, after oxidation, produces dimethyl sulfide as a side 
product, the causative agent in the well-known unpleasant odour that accompanies these 
oxidations. The advantage of utilizing the sulfur trioxide/pyridine complex rather than the 
more popular Swern oxidation is that the reaction could proceed at an ambient temperature, 
rather than at -60 °C for the Swern oxidation. 
 
From the spectroscopic point of view, the disappearance of the benzylic protons at 4.5 ppm 
in 1H NMR, and the appearance of a new signal at 10 ppm, corresponding to the aldehyde 















































The aldehydes 11a and 11b were then converted into various amines by reductive amination 
(Scheme 6.7), where sodium borohydride36 was used as the reducing agent for primary 










Scheme 6.7. Reagents and conditions: (i) amine (1.1 eq), NaBH4/NaCNBH3 (2.0 eq), r.t., 16 h. 
 
The aldehydes were dissolved in a mixture of DMF and MeOH, as they were sparingly 
soluble in MeOH. As with all reductive aminations, the aldehyde and the amine were reacted 
first to form an imine (or iminium ions for secondary amines), which was then reduced to the 
amine by the borohydride. The yields were generally good. 
 
Spectroscopic evidence from 1H NMR was the reappearance of the benzylic protons at 3.8 
ppm, and the disappearance of the aldehyde proton that was at 10 ppm. 
 
6.3.2.2 Wittig Products 
 
Apart from reductive amination, the aldehydes 11a and 11b were also utilized in the Wittig 















12a meta   R1 = H, R2 = i-pr; yield = 77%
12b ortho   R1 = H, R2 = i-pr; yield = 65%






















Scheme 6.8. Reagents and conditions: (i) PPh3 (1.2 eq), toluene, N2, r.t., 8 h. (ii) NaOMe (1.2 eq), 
MeOH, N2, 0 °C, 20 min. (iii) 11a/11b (0.9 eq), N2, r.t., 18 h. 
 
Ethyl bromoacetate and triphenylphosphine were stirred in toluene to form the phosphonium 
salt. The phosphorane was generated in situ using NaOMe as the base,38c followed by the 
addition of the aldehyde to afford the Wittig products 14a and 14b. The E isomer was the 
major product, as the phosphonium ylide that was generated was stabilized, and favoured the 


























14a meta yield = 76%























































Mechanistically, the abstraction of the acidic α-proton by sodium methoxide generated the 
ylide/phosphorane. The phosphorane and the aldehyde form a 4-membered cyclic 
intermediate, which, after rearrangement and elimination of the triphenylphosphine oxide, 
yielded the Wittig product 14a and 14b (Scheme 6.9). 
 
Using compound 14a as an example, the key 1H NMR signals for this Wittig product (Fig. 
6.3) were the alkene protons from the α,β-unsaturated system, appearing as two doublets 
with a coupling constant of 15.6 Hz, situated at 6.4 and 7.9 ppm. Additionally, the presence 
of signals corresponding to the ethyl protons H-15 and H-16 at 4.2 and 1.3 ppm, respectively, 















Figure 6.3. 1H NMR of the Wittig product 14a. 
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6.3.3.3 Bisquinoline Derivative 
 
Two aminoquinoline-containing compounds were tethered onto a single compound to 
investigate whether amtiplasmodial activity could be enhanced. To achieve this, reductive 











Scheme 6.10. Reagents and conditions: (i) 1,2-ethanolamine (20 eq), Et3N (0.3 eq), K2CO3   
(0.5 eq), 140 °C, 4 h. (ii) methanesulfonyl chloride (2.5 eq), pyridine, 0 °C, 5 h. (iii) 
4-hydroxybenzaldehyde (1.5 eq), K2CO3 (1.6 eq), DMF, reflux, 5 h. (iv) QN01 (1.0 eq), NaBH4 
(2.0 eq), MeOH, N2, r.t., 18 h. 
 
The aminoquinoline derivative 4a was prepared by refluxing 4,7-dichloroquinoline in 
1,2-ethanolamine in the presence of bases K2CO3 and Et3N. The hydroxyl group was 
activated by converting it into a mesylate. Spectroscopically, the product was confirmed by 
the appearance of a singlet, integrating for 3 protons, at 3.1 ppm in the 1H NMR. The 
mesylated derivative 4b was then reacted with 4-hydroxybenzaldehyde, where the hydroxyl 
of the benzaldehyde, after deprotonation by K2CO3, nucleophilically displaced the mesylate 






















































Reductive amination of aldehyde 4c by amine QN01 was carried out in a similar manner as 
described in 6.3.2.1, forming compound 4d in good yield. The product was confirmed by 1H 
NMR as two sets of quinoline protons were observed, along with two doublets from the 
phenyl ring. Additionally, the benzylic protons were observed as a distinct, sharp singlet, 
integrating for 2 protons, appearing at 5.7 ppm. 
 
6.4 Biological Results and Discussion 
 
The in vitro antiplasmodial activities of these 4-aminoquinoline compounds were determined 
against the chloroquine-sensitive D10 and chloroquine-resistant K1 strains. Cytotoxicity and 
β-haematin inhibitory activities were also assessed. Results are presented in Table 6.1. 
Chloroquine was used as the control for all three assays. 
 
The bisquinoline compound 4d displayed good antiplasmodial activities of 53 and 43 nM 
against the D10 and K1 strains respectively. However, despite its equipotent activity against 
the two strains, it also displayed cytotoxicity against HeLa cells, with a therapeutic index of 
26 with respect to the K1 strain. The cytotoxicity that is often associated with potent efficacy 
for the bisquinoline compounds has previously been observed,28b, 39  hence more 
modifications would be necessary to lower the cytotoxicity. 
 
The benzyl alcohol intermediates 9a and 9b displayed modest activities against the two 
strains of P. falciparum, and 9c was not active at the maximum concentration of 50 μM.  
When the hydroxyl moiety of 9a and 9b was converted into amino groups to form the 
amodiaquine-like compounds 12a, 12b and 13a, their antiplasmodial activities increased by 















the D10 strain for compounds 12a and 13a, this is not so for compound 12b, which 
displayed superior activity in comparison to the other two analogues against the 
chloroquine-resistant K1 strain (8 nM). Cytotoxicity against HeLa cells was weak for these 
amodiaquine-like compounds, with therapeutic indices greater than 200. 
 






General structures of target compounds 









(equiv.)c D10 K1 
CQ - - 0.017 0.219 8.54 12.8 39 1.91 ± 0.3 
4c - - 1.47 2.20 7.0 1.5 3 Not actived
4d - - 0.053 0.043 1.1 0.8 26 Not actived
9a meta CH2OH 2.16 5.52 >50 2.6 > 9 2.85 ± 0.1 
9b ortho CH2OH 1.90 2.54 23.6 1.3 9 2.32 ± 0.09
9c para COOH >50 >50 >50 - - Not actived
12a meta CH2N(Me)2 0.034 0.052 25.6 1.5 438 1.92 ± 0.09
12b ortho CH2N(Me)2 0.068 0.008 35.8 118 4366 1.92 ± 0.1 
13a meta CH2N(Et)2 0.061 0.081 18.8 1.3 229 2.4 ± 0.04 
14a ortho - 1.00 0.89 2.7 0.9 3 Not actived
14b meta - 0.936 1.50 10.3 1.6 7 Not actived
a Resistance index calculated as [IC50 (K1)] / [IC50 (D10)]; b Therapeutic index calculated as [IC50 (HeLa)] 





























Wittig products 14a and 14b did not exhibit significant antiplasmodial activities (0.89 and 
1.5 μM respectively against K1), and at the same time displayed cytotoxicity against HeLa 
cells (3 and 7μM respectively).  
 
Additionally, the positions of the side chain on the phenyl ring for these compounds did not 
seem to play an important role in terms of biological activity, as no changes have been 
observed between activities of the ortho and meta analogues. 
 
Inhibitory activities for the formation of β-haematin have also been determined for these 
aminoquinolines. It appears that there is no correlation between their ability to inhibit the 
formation of β-haematin and their antiplasmodial activities for these compounds, as the 
β-haematin inhibitory activities of the amodiaquine-like compounds 12a, 12b and 12c were 
only slightly better than the benzyl alcohol intermediates 9a and 9b, which possessed only 
modest antiplasmodial activities. Surprisingly, bisquinoline compound 4d also did not appear 
to be able to inhibit the formation of β-haematin. This may be due to the insolubility of the 
resulting complex with β-haematin. 
 
6.5 Conclusion and Future Work 
 
A series of 4-aminoquinoline analogues have been prepared, and their biological activities 
were assessed. These compounds contain either an aminomethyl moiety (amodiaquine-like), 
α,β-unsaturated system (Wittig product) or another aminoquinoline derivative (bisquinoline). 
The bisquinoline compound 4d displayed good antiplasmodial activities against both the 
D10 and K1 strains of P. falciparum, but is also associated with cytotoxicity. 















and modest cytotoxicity against HeLa cells were observed. In particular, compound 12b 
displayed potent antiplasmodial activity of 8 nM against the K1 strain. Hence compound 12b 
would be a good candidate for further studies. 
 
Wittig products 14a and 14b, on the other hand, displayed moderate antiplasmodial activities 
and cytotoxity against HeLa cells. The α,β-unsaturated system on these analogues could be 
further utilized by reacting with nucleophiles in chemical modifications in an effort to 
enhance their antiplasmodial activities and/or lower their cytotoxicity. 
 
No clear correlation between the antiplasmodial activity and the inhibition of β-haematin has 
been observed. Although these compounds may exert their activity via inhibiting the 
formation of β-haematin, more analogues would need to be synthesized and tested to 
confirm this. Interestingly, bisquinoline 4d was not active towards the inhibition of 
β-haematin formation, suggesting that alternative target(s) may be involved for this 
bisquinoline compound. Moreover, more bisquinoline compounds would also need to be 
synthesized and evaluated to confirm this. 
 
Even though the antiplasmodial activities for the ortho and meta analogues do not seem to 
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SUMMARY AND CONCLUSION  
 
Results from the various chapters are summarized below: 
 
(i) A series of artemisinin based β-aminocarbonyl compounds, some of which contain a 
4-aminoquinoline moiety, were synthesized via conjugate addition and evaluated for 
antiplasmodial and anticancer activities. Compounds MIC 08, 12 and 13A have displayed 
the most potent antiplasmodial activities against D10 and Dd2 strains of P. falciparum, with 
activities at least 4 and 20 times higher than chloroquine against the D10 and Dd2 strains 
respectively. Compound MIC 14 has been found to be the most active against HeLa cells, 






Figure 7.1. Structures of MIC 08, MIC 12, MIC 13A and MIC 14. 
 
(ii) 4-Aminoquinolines were hybridized with artemisinin or 1,4-naphthoquinone derivatives 
via the Ugi 4-component condensation. The artemisinin-quinoline hybrids 6a, 6b and 6c 
exhibited antiplasmodial activities 10 times more potent than chloroquine against the K1 
















































The influence of the artemisinin-quinoline hybrids on parasitic endocytosis was also 
investigated, by studying the effect of drug treatment on the morphology and haemoglobin 
levels in the parasites, as well as the localization of transport vesicles via 
immunofluorescence microscopy. Results have shown that the mode(s) of action of these 







Figure 7.2. Structures of 6a, 6b and 6c. 
 
(iii) A series of β-lactams containing a terminal acetylene moiety was synthesized via the 
Staudinger reaction and the Ugi 4-component 3-centre condensation. The best compound 
was further diversified and modified by employing the Mannich reaction. None of these 
compounds exhibited significant antiplasmodial activities against the D10 and Dd2 strains of 
P. falciparum, nor did they display cytotoxic activities against HeLa cells. 
 
(iv) 4-Aminoquinoline analogues containing an aminomethyl or α,β-unsaturated system were 
synthesized via reductive amination or Wittig reaction on the quinoline-aldehyde 
intermediate. A bisquinoline derivative was also synthesized. Compounds 12a, 12b and 13a 
exhibited good antiplasmodial activities, with compound 12b being the most potent, 
displaying an IC50 value of 8 nM against the K1 strain of P. falciparum, almost 30 times 

























































The bisquinoline derivative 4d displayed good antiplasmodial activities, but is also 
associated with cytotoxicity against HeLa cells, with a low therapeutic index of 26. 
Correlation between the antiplasmodial and β-haematin inhibitory activities has not been 







Figure 7.3. Structures of 12a, 12b, 13a and4d. 
 
In conclusion, novel antimalarial agents have been designed and synthesized, many of which 
are based on the ‘Designed Multiple Ligand’ strategy, with the aim of interfering with two or 
more targets at the same time. A number of compounds with potent antiplasmodial or 
anticancer activities have been identified, and further work would be needed to optimize 














12a: ortho; R1 = R2 = Me; 
12b: meta; R1 = R2 = Me;   



















8.1 Chemical Characterization 
 
Purification of solvents 
 
All solvents used for reactions, preparative and column chromatography were distilled prior 
to use. Anhydrous solvents were used in all experiments. Other reagents obtained from 




Merck Kieselgel 60: 70 – 230 mesh was used for all preparative and column chromatography. 
Reactions were monitored by thin layer chromatography using Merck F254 aluminum-backed 
precoated silica gel plates and were visualized by a combination of ultraviolet light, iodine 
vapour and staining with 5% anisaldehyde solution. Melting points were determined on a 
Reichert-Jung Thermovar hot-stage microscope. Infrared spectra were recorded on a Thermo 
Nicolete FTIR instrument in the 4000-700 cm-1 range as methylene chloride solutions. 
Microanalyses were determined using a Fisons EA 1108 CHNO-S instrument. Mass spectra 
were recorded on a VG micromass 16F spectrometer operating at 70eV with an accelerating 
voltage of 4kV and a variable temperature source. At the University of Witwatersrand, SA, 
















Physical and Spectroscopic Data 
 
1H NMR (nuclear magnetic resonance) spectra were recorded on a Varian Mercury 
spectrometer at 300 MHz or a Varian Unity Spectrometer at 400 MHz. Spectra were 
recorded in deuterated solvents: CDCl3, DMSO-d6 and CD3OD and the chemical shifts are 
reported in parts per million downfield from the internal standard tetramethylsilane; coupling 
constants are given in Hertz. 1H NMR coupling constants are rounded off to one decimal 
place, resulting in the same coupling constants for coupling partners. In cases where 
deuterated methanol was used as 1H NMR solvent, H-bonding between compounds 
containing NH2 or OH groups and the deuterated methanol solvent resulted in a reduction of 
hydrogen signals observed in 1H NMR spectra.  
 
13C NMR spectra were recorded on a Varian Mercury spectrometer at 75 Hz or Varian Unity 
Spectrometer at 100 Hz. The format used for recording 13C NMR data is that accepted by 
most international journals (including American Chemical Society journals). In this format 
























General procedure for the synthesis of QN01 – QN04. 
Et3N (0.3 eq) was added drop-wise to a stirred solution of 4,7-dichloroquinoline (1.0 eq) and 
K2CO3 (0.5 eq) in respective diamines (20.0 eq) and refluxed at 110 °C for 4 hours. Products 
that precipitated on cooling were filtered and washed with brine and H2O. For products that 
stayed in solution, NaOH was added, and the organic product was immediately basified with 
10% NaOH (w/v) and extracted with EtOAc (5 times), washed with H2O (2 times) and dried 
(Na2SO4). Recrystallisation from EtOAc afforded the amine in excellent yields. 
 
N-(7-Chloroquinolin-4-yl)-ethane-1,2-diamine, QN01 
Pure product was recrystallised from EtOAc as white powder 
(0.4861 g, 64%). m.p. 136 – 138 °C (lit. 137 – 139 °C).1     
Rf (MeOH/DCM, 0.5:9.5) 0.32. δH (400 MHz; DMSO-d6) 8.38 
(d, J 5.6, 1H, H2), 8.10 (d, J 8.4 Hz, 1H, H5), 7.76 (d, J 2.0, 1H, 
H8), 7.40 (dd, J 8.4 and 2.0, 1H, H6), 7.24 (br s, 1H, NH), 6.48 (d, J 5.6, 1H, H3), 3.25 (t, J 
5.6, 2H, H9), 2.82 (t, J 6.0, 2H, H10).  
 
N-(7-Chloroquinolin-4-yl)-propane-1,3-diamine, QN02 
Pure product was recrystallised from EtOAc as a 
light-yellow solid (1.52 g, 88%). m.p. 123 – 126 °C (lit. 
124 – 127 °C).1 Rf (NH3/MeOH, 1:49) 0.21. δH (300 MHz; 
CD3OD) 8.36 (d, J 5.7, 1H, H2), 8.08 (d, J 9.0 Hz, 1H, H5), 
7.78 (d, J 2.1, 1H, H8), 7.40 (dd, J 9.0 and 2.1, 1H, H6), 6.55 (d, J 5.7, 1H, H3), 3.44 (t, J 










































Pure product was recrystallised from EtOAc as a 
light-yellow solid (1.60 g, 87%). m.p. 43 – 46 °C (lit. 43 – 
47 °C).1 Rf (NH3/MeOH, 1:49) 0.22. δH (300 MHz; 
CD3OD) 8.48 (d, J 5.7, 1H, H2), 7.96 (d, J 9.0 Hz, 1H, 
H5), 7.69 (d, J 2.1, 1H, H8), 7.27 (dd, J 9.0 and 2.1, 1H, H6), 6.34 (d, J 5.7, 1H, H3), 3.40 (t, 
J 7.2, 2H, H9), 3.04 (t, J 7.2, 2H, H12), 1.88 (m, 2H, H10), 1.62 (m, 2H, H11).  
 
N-(7-Chloroquinolin-4-yl)-hexane-1,6-diamine, QN04 
Pure product was recrystallised from EtOAc as 
yellow needles (1.94 g, 95%). m.p. 135 – 138 °C (lit. 
136 – 138 °C).1 Rf (NH3/MeOH, 1:49) 0.22. δH (300 
MHz; CD3OD) 8.34 (d, J 5.7, 1H, H2), 8.09 (d, J 9.0 
Hz, 1H, H5), 8.77 (d, J 2.1, 1H, H8), 7.39 (dd, J 9.0 and 2.1, 1H, H6), 6.50 (d, J 5.7, 1H, H3), 




Piperazine (3.20 g, 36.73 mmol), 4,7-dichloroquinoline (1.5 g, 
7.35 mmol) and K2CO3 (0.52 g, 3.76 mmol) were refluxed in 
anhydrous NMP (10 ml) at 150 °C under N2 and cooled to r.t. 
after 4 h. The reaction mixture was diluted with DCM (50 ml), 
and washed with H2O (3 x 50 ml), brine (50 ml), dried (Na2SO4) 
and solvent reduced. The crude material was purified via column chromatography, eluting 

























































116 °C (lit. 113 – 115 °C)2. Rf (MeOH/DCM, 1:9) 0.13. δH (300 MHz; CD3OD) 8.64 (d, J 
5.4, 1H, H2), 8.07 (d, J 9.0 Hz, 1H, H5), 7.92 (d, J 2.1, 1H, H8), 7.52 (dd, J 9.0 and 2.1, 1H, 
H6), 7.01 (d, J 5.4, 1H, H3), 3.31 (pentet, J 1.8, 1H, H11), 3.24 (m, 4H, H9), 3.11 (m, 4H, 
H10). 
 







Acroylyl chloride (1.78 ml, 21.0 mmol) was added drop-wise to a chilled (0 °C) solution of 
dihydroartemisinin (3.0 g, 10.5 mmol) and Et3N (2.93 ml, 21.0 mmol) in anhydrous DCM 
(80 ml). The mixture was stirred for 3 h, whilst allowing it to slowly warm to r.t. (20 °C), 
after which the solvent was reduced, and column chromatographed to yield the pure isomers 
as white powders (2.03 g, 57%, d.e. α : β 4.7 : 5.3). 
 
A-acr-alpha 
m.p. 143 – 146 °C; Rf (EtOAc/Hex 3:7) 0.75; νmax (DCM)/cm-1 1724 (C=O), 1633 (C=C), 
1048 (C–O (ester)), 847 (O–O); δH (400 MHz; CDCl3) 6.51 (dd, J 17.6 and 1.6, 1H, H19), 
6.19 (dd, J 17.6 and 10.4, 1H, H17), 5.90 (dd, J 10.4 and 1.6, 1H, H18), 5.88 (d, J 9.2, 1H, 
H10), 5.48 (s, 1H, H12), 2.64 (m, 1H, H9), 1.45 (s, 3H, H14), 0.99 (d, J 6.0, 3H, H16), 0.88 
(d, J 7.2, 3H, H15); δc (100 MHz; CDCl3) 164.8, 132.0, 128.2, 104.5, 92.2, 91.6, 80.2, 51.7, 
45.3, 37.3, 36.3, 34.2, 32.0, 26.0, 24.6, 22.1, 20.2, 12.1; m/z 338.3997 (M+); (Found: M+, 



































































338.3997. C18H26O6 requires M, 338.4008) (Found: C, 63.87.; H, 7.77. C18H26O6 requires C, 
63.89; H, 7.74). 
 
A-acr-beta  
m.p. 134 – 137 °C; Rf (EtOAc/Hex 3:7) 0.77. νmax (DCM)/cm-1 1724 (C=O), 1635 (C=C), 
1048 (C–O (ester)), 847 (O–O); δH (400 MHz; CDCl3) 6.41 (dd, J 17.2 and 1.6, 1H, H19), 
6.34 (d, J 3.6, 1H, H10), 6.12 (dd, J 17.2 and 10.4, 1H, H17), 5.88 (dd, J 10.4 and 1.6, 1H, 
H18), 5.50 (s, 1H, H12), 2.86 (m, 1H, H9), 1.44 (s, 3H, H14), 0.99 (d, J 6.0, 3H, H16), 0.90 
(d, J 7.2, 3H, H15); δC (100 MHz; CDCl3) 164.3, 131.2, 128.5, 104.4, 95.1, 88.8, 80.5, 52.4, 
44.0, 37.6, 36.3, 34.6, 30.0, 25.9, 24.7, 24.2, 20.3, 12.5; m/z 338.3986 (M+); (Found: M+, 
338.3986. C18H26O6 requires M, 338.4008) (Found: C, 63.84.; H, 7.69. C18H26O6 requires C, 
63.89; H, 7.74). 
 
General procedure for Compounds MIC 01, 02, 05, 13 and 14 
A-acr-beta (1.0 eq), various amines (1.5 eq) and DBU (0.5 eq) were stirred in anhydrous 
DMF (2 ml) under N2 for 18 h at r.t. (20 °C). H2O (10 ml) was added to the reaction mixture, 
and extracted with EtOAc (3 x 10 ml), washed with H2O (3 x 20 ml), brine (30 ml), dried 
and solvent reduced to yield the crude products. 
 
General procedure for Compounds MIC 03, 04, 06 – 12 
A-acr-alpha (or A-acr-beta) (1.0 eq), various amines (1.5 eq) and DBU (0.5 eq) were 
stirred in anhydrous acetonitrile (2 ml) under N2 for 18 h at r.t. (20 °C). The solvent was 


















Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.5:9.5) to yield the product as a light brown 
oil (0.180 g, 73%); Rf (MeOH/DCM, 0.5:9.5) 
0.12; νmax (DCM)/cm-1 1738 (C=O), 1451 (C=C 
(Ar)), 1265 (C–N), 1048 (C–O (ester)), 847 
(O–O); δH (300 MHz; CDCl3) 8.49 (d, J 5.4, 1H, H2’), 7.94 (d, J 2.1, 1H, H8’), 7.78 (d, J 8.7, 
1H, H5’), 7.37 (dd, J 8.7 and 2.1, 1H, H6’), 6.36 (d, J 5.4, 1H, H3’), 6.29 (d, J 2.7, 1H, H10), 
5.46 (s, 1H, H12), 3.34 (t, J 6.0, 2H, H10’), 3.02 (t, J 6.0, 2H, H11’), 2.97 (t, J 6.9, 2H, H17), 
2.81 (m, 1H, H9), 2.56 (t, J 6.9, 2H, H18), 1.37 (s, 3H, H14), 0.94 (d, J 6.0, 3H, H16), 0.84 
(d, J 7.2, 3H, H15); δc (75.5 MHz; CDCl3) 171.4, 151.7, 130.9, 128.9, 128.3, 125.4, 121.7, 
104.5, 99.1, 95.0, 88.8, 80.4, 52.3, 47.2, 44.2, 43.8, 41.9, 37.5, 36.2, 34.9, 34.4, 29.7, 25.8, 




Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.5:9.5) to yield the product as a light 
brown oil (0.185 g, 71%); Rf (MeOH/DCM, 
0.5:9.5) 0.11; νmax (DCM)/cm-1 1740 (C=O), 
1447 (C=C (Ar)), 1243 (C–N), 1048 (C–O 
(ester)), 847 (O–O); δH (400 MHz; CDCl3) 






























































































2.0, 1H, H6’), 6.36 (d, J 5.6, 1H, H3’), 6.28 (d, J 3.2, 1H, H10), 5.30 (s, 1H, H12), 3.33 (t, J 
6.0, 2H, H10’), 2.96 (t, J 6.4, 2H, H17), 2.76 (t, J 6.0, 2H, H11’), 2.71 (m, 1H, H9), 2.61 (t, J 
6.4, 2H, H18), 1.27 (s, 3H, H14), 0.96 (d, J 6.0, 3H, H16), 0.87 (d, J 7.2, 3H, H15); δC (100 
MHz; CDCl3) 151.1, 127.8, 125.3, 121.8, 104.5, 98.8, 95.1, 88.8, 80.5, 52.4, 44.7, 43.9, 43.1, 
39.9, 37.6, 36.1, 34.5, 34.3, 29.8, 29.7, 27.1, 25.9, 24.6, 24.1, 22.1, 20.2, 12.5; m/z 588.2869 
(MH+); (Found: MH+, 588.2869. C31H43ClN3O6 (MH+) requires 588.2840). 
 
MIC 03 
Crude residue was purified via column chromatography, 
eluting with MeOH/DCM (0.2:9.8) to yield the product as a 
white powder (0.198 g, 72%); m.p. 102 – 105 °C. Rf 
(MeOH/DCM 1:9) 0.25; νmax (DCM)/cm-1 1743 (C=O), 
1243 (C–N), 1048 (C–O (ester)), 847 (O–O); δH (400 MHz; 
CDCl3) 6.27 (d, J 3.6, 1H, H10), 5.48 (s, 1H, H12), 2.82 (m, 1H, H9), 2.68 (m, 2H, H17), 
2.55 (m, 2H, H18), 2.42 (m, 4H, H19), 1.58 (m, 6H, H20), 1.43 (s, 3H, H14), 0.98 (d, J 6.0, 
3H, H16), 0.89 (d, J 7.2, 3H, H15); δC (100 MHz; CDCl3) 171.1, 104.4, 94.7, 88.8, 80.6, 
54.3, 54.1, 52.3, 44.0, 37.5, 36.3, 34.6, 32.7, 29.9, 25.9, 24.7, 24.3, 24.2, 20.3, 12.5; m/z 
424.2720 (MH+); (Found: MH+, 424.2720. C23H38NO6 (MH+) requires 424.2699) (Found: C, 




















































Crude residue was purified via column chromatography, 
eluting with MeOH/DCM (0.2:9.8) to yield the product as a 
light-brown oil (0.183 g, 69%); Rf (MeOH/DCM 0.5:9.5) 
0.24; νmax (DCM)/cm-1 1742 (C=O), 1240 (C–N), 1048 
(C–O (ester)), 847 (O–O); δH (400 MHz; CDCl3) 5.80 (d, J 
9.6, 1H, H10), 5.44 (s, 1H, H12), 2.81 (m, 1H, H9), 2.80 (t, J 7.2, 2H, H17), 2.63 (t, J 7.2, 
2H, H18), 2.54 (t, J 6.2, 4H, H19), 1.79 (t, J 6.2, 4H, H20), 1.44 (s, 3H, H14), 0.97 (d, J 6.0, 
3H, H16), 0.86 (d, J 7.2, 3H, H15); δC (100 MHz; CDCl3) 104.4, 91.9, 91.5, 80.1, 70.7, 66.9, 
54.0, 53.9, 51.6, 45.3, 37.3, 36.3, 34.2, 33.9, 31.9, 26.0, 24.6, 23.5, 22.0, 20.2, 12.0; m/z 
410.2543 (MH+); (Found: MH+, 410.2543. C22H36NO6 (MH+) requires 410.2558). 
 
MIC 05 
Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.2:9.8) to yield the product as a white powder 
(0.304 g, 80%); m.p. 131 – 133 °C. Rf 
(MeOH/DCM 0.5:9.5) 0.25; νmax (DCM)/cm-1 
1744 (C=O), 1451 (C=C (Ar)), 1243 (C–N), 1048 (C–O (ester)), 847 (O–O); δH (400 MHz; 
CDCl3) 8.73 (d, J 5.1, 1H, H2’), 8.05 (d, J 1.6, 1H, H8’), 7.95 (d, J 9.2, 1H, H5’), 7.43 (dd, J 
9.2 and 1.6, 1H, H6’), 6.84 (d, J 5.1, 1H, H3’), 6.32 (d, J 3.2, 1H, H10), 5.51 (s, 1H, H12), 
3.20 (t, J 4.8, 4H, H9’), 2.85 (t, J 7.2, 2H, H17), 2.80 (m, 1H, H9),2.78 (t, J 4.8, 4H, H10’), 
2.61 (t, J 7.2, 2H, H18), 1.44 (s, 3H, H14), 0.99 (d, J 6.0, 3H, H16), 0.91 (d, J 7.2, 3H, H15); 
δC (100 MHz; CDCl3) 170.8, 156.8, 151.9, 150.1, 134.8, 128.8, 126.1, 125.2, 121.9, 109.0, 




















































































24.2, 20.2, 12.5; m/z 586.2699 (MH+); (Found: MH+, 586.2699. C31H41ClN3O6 (MH+) 
requires 586.2684) (Found: C, 63.47; H, 6.69; N, 7.11. C31H40ClN3O6 requires C, 63.53; H, 
6.88; N, 7.17%). 
 
MIC 06 
Crude residue was purified via column chromatography, 
eluting with EtOAc/Hex (1:1) to yield the product as a 
colourless oil (0.207 g, 75%); Rf (EtOAc/Hex 8:2) 0.21; 
νmax (DCM)/cm-1 1740 (C=O), 1264 (C–N), 1048 (C–O 
(ester)), 848 (O–O); δH (400 MHz; CDCl3) 5.82 (d, J 9.6, 
1H, H10), 5.45 (s, 1H, H12), 3.70 (t, J 4.8, 4H, H19), 2.72 (t, J 6.8, 2H, H17), 2.60 (t, J 6.8, 
2H, H18), 2.58 (m, 1H, H9), 2.47 (t, J 4.8, 4H, H20), 1.44 (s, 3H, H14), 0.98 (d, J 6.0, 3H, 
H16), 0.87 (d, J 6.8, 3H, H15); δC (100 MHz; CDCl3) 104.5, 92.2, 92.0, 91.5, 80.1, 70.7, 
66.9, 53.7, 53.4, 51.6, 45.3, 37.3, 36.3, 34.1, 32.3, 31.9, 26.0, 24.6, 22.0, 20.2, 12.1; m/z 
426.2488 (MH+); (Found: MH+, 426.2488. C22H36NO7 (MH+) requires 426.2492). 
 
MIC 07 
Crude residue was purified via column chromatography, 
eluting with MeOH/DCM (0.2:9.8) to yield the product as a 
light-brown oil (0.145 g, 54%); Rf (MeOH/DCM 0.5:9.5) 
0.18; νmax (DCM)/cm-1 1737 (C=O), 1261 (C–N), 1049 
(C–O (ester)), 847 (O–O); δH (400 MHz; CDCl3) 5.81 (d, J 
10.0, 1H, H10), 5.45 (s, 1H, H12), 2.84 (m, 3H, H9 + H17), 
2.57 (m, 6H, H18 + H19), 1.44 (s, 3H, H14), 1.06 (t, J 7.6, 3H, H20), 1.05 (t, J 7.6, 4H, 










































































91.5, 80.1, 52.6, 51.6, 47.8, 46.7, 45.3, 37.3, 36.3, 34.1, 32.1, 31.8, 26.0, 24.6, 22.0, 20.2, 
12.7; m/z 412.2714 (MH+); (Found: MH+, 412.2714. C22H38NO6 (MH+) requires 412.2699). 
 
MIC 08 
Crude residue was purified via column chromatography, 
eluting with EtOAc/Hex (1.5:8.5) to yield the product as 
a light-yellow oil (0.186 g, 62%); Rf (EtOAc/Hex 3:7) 
0.13; νmax (DCM)/cm-1 1738 (C=O), 1510 (C=C (Ar)), 
1265 (C–N), 1048 (C–O (ester)), 849 (O–O); δH (400 
MHz; CDCl3) 7.30 (s, 5H, Ar-H), 5.82 (d, J 9.6, 1H, H10), 5.46 (s, 1H, H12), 3.53 (s, 2H, 
H20), 2.80 (m, 1H, H9), 2.79 (t, J 6.8, 2H, H17), 2.63 (t, J 6.8, 2H, H18), 1.44 (s, 3H, H14), 
0.98 (d, J 6.0, 3H, H16), 0.85 (d, J 7.2, 3H, H15); δC (100 MHz; CDCl3) 171.1, 128.2, 127.0. 
96.4, 94.7, 91.9, 91.5, 91.2, 90.0, 87.8, 80.1, 52.6, 45.3, 41.7, 37.5, 36.4, 34.1, 32.8, 31.8, 




Crude residue was purified via column chromatography, 
eluting with MeOH/DCM (0.2:9.8) to yield the product as 
a light-yellow oil (0.207 g, 80%); Rf (MeOH.DCM 0.5:9.5) 
0.25; νmax (DCM)/cm-1 1742 (C=O), 1265 (C–N), 1049 
(C–O (ester)), 847 (O–O); δH (400 MHz; CDCl3) 6.28 (d, J 
9.6, 1H, H10), 5.48 (s, 1H, H12), 2.95 (t, J 6.4, 2H, H17), 
2.91 (sept, J 6.0, 1H, H19), 2.68 (t, J 6.4, 2H, H18), 2.59 (m, 1H, H9), 1.44 (s, 3H, H14), 







































































CDCl3) 104.4, 94.6, 88.8, 80.5, 70.5, 52.6, 52.4, 51.6, 45.5, 37.5, 36.4, 34.1, 30.8, 29.8, 25.9, 




Crude residue was purified via column chromatography, 
eluting with EtOAc/Hex (6:4) to yield the product as a 
light-brown oil (0.168 g, 61%); Rf (EtOAc/Hex 1:1) 0.09; 
νmax (DCM)/cm-1 1740 (C=O), 1265 (C–N), 1051 (C–O 
(ester)), 847 (O–O); δH (400 MHz; CDCl3) 5.81 (d, J 9.6, 
1H, H10), 5.45 (s, 1H, H12), 2.92 (t, J 4.8, 4H, H19), 2.71 (t, J 7.0, 2H, H17), 2.59 (t, J 7.0, 
4H, H18), 2.50 (m, 5H, H20 + H9), 1.44 (s, 3H, H14), 0.97 (d, J 6.0, 3H, H16), 0.87 (d, J 7.2, 
3H, H15); δC (100 MHz; CDCl3) 104.5, 91.9 ,91.5, 80.1, 53.8, 53.5, 51.6, 45.8, 45.5, 37.3, 
36.3, 34.1, 34.3, 31.9, 26.0, 24.6, 22.0, 20.2, 12.0; m/z 425.2658 (MH+); (Found: MH+, 
425.2658. C22H37N2O6 (MH+) requires 425.2652). 
 
MIC 11 
Crude residue was purified via column chromatography, 
eluting with EtOAc/Hex (3:7) to yield the product as a 
light-yellow oil (0.179 g, 63%); Rf (EtOAc/Hex 1:1) 
0.37; νmax (DCM)/cm-1 1741 (C=O), 1265 (C–N), 1048 
(C–O (ester)), 849 (O–O); δH (400 MHz; CDCl3) 5.81 (d, 
J 9.6, 1H, H10), 5.44 (s, 1H, H12), 2.73 (t, J 6.8, 2H, H17), 2.59 (t, J 6.8, 2H, H18), 2.30 (s, 
3H, H21), 2.56 – 2.44 (m, 9H, H9 + H19 + H20), 1.44 (s, 3H, H14), 0.98 (d, J 6.0, 3H, H16), 











































































51.6, 45.9, 45.3, 37.3, 36.3, 34.1, 32.5, 31.9, 26.0, 24.6, 22.0, 20.2, 12.1; m/z 439.2821 
(MH+); (Found: MH+, 439.2821. C23H39N2O6 (MH+) requires 439.2808). 
 
MIC 12 
Crude residue was purified via column 
chromatography, eluting with EtOAc/Hex (4:6) to 
yield the product as a colourless oil (0.211 g, 65%); 
Rf (EtOAc/Hex 1:1) 0.28; νmax (DCM)/cm-1 1743 
(C=O), 1551 (C=C (Ar)), 1257 (C–N), 1048 (C–O 
(ester)), 847 (O–O); δH (300 MHz; CDCl3) 7.25 (dd, J 7.8 and 6.9, 2H, H22), 6.92 (d, J 7.8, 
2H, H21), 6.84 (t, J 6.9, 1H, H23), 5.82 (d, J 9.6, 1H, H10), 5.44 (s, 1H, H12), 3.18 (d, J 4.8, 
4H, H20), 2.77 (t, J 6.9, 2H, H17), 2.64 (t, J 6.9, 2H, H18), 2.63 (d, J 4.8, 4H, H19), 2.57 (m, 
1H, H9), 1.43 (s, 3H, H14), 0.97 (d, J 6.0, 3H, H16), 0.86 (d, J 6.9, 3H, H15); δc (75.5 MHz; 
CDCl3) 171.2, 151.3, 129.1, 119.6, 116.0, 104.4, 91.9, 91.5, 80.1, 53.3, 52.9, 51.6, 49.1, 45.3, 
37.3, 36.2, 34.1, 32.5, 31.9, 26.0, 24.6, 22.0, 20.2, 12.1; m/z 502.2985 (MH+); (Found: MH+, 
501.2985. C28H41N2O6 (MH+) requires 501.2965). 
 
MIC 13A 
Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.1:9.9) to yield the product as a white powder 
(0.240 g, 41%); m.p. 82 – 84 °C. Rf 
(MeOH/DCM 0.5:9.5) 0.34; νmax (DCM)/cm-1 
1741 (C=O), 1450 (C=C (Ar)), 1266 (C–N), 




























































































H8’), 7.81 (d, J 9.2, 1H, H5’), 7.38 (d, J 9.2, 1H, H6’), 6.38 (d, J 5.6, 1H, H3’), 6.28 (d, J 
3.6, 2H, H10), 5.43 (s, 2H, H12), 3.42 (t, J 5.6, 2H, H9’), 2.91 (t, J 6.8, 4H, H17), 2.81 (m, 
2H, H9), 2.64 (t, J 5.6, 2H, H11’), 2.53 (t, J 6.8, 4H, H18), 1.90 (t, J 5.6, 2H, H10’), 1.39 (s, 
6H, H14), 0.97 (d, J 6.0, 6H, H16), 0.84 (d, J 7.2, 6H, H15); δc (100 MHz; CDCl3) 151.8, 
128.3, 125.1, 121.8, 104.5, 98.1, 95.1, 88.9, 80.0, 52.4, 48.9, 45.2, 43.8, 43.5, 39.9, 37.5, 
36.2, 34.7, 34.6, 34.4, 29.8, 29.7, 27.3, 25.9, 24.7, 24.2, 20.2, 12.5; m/z 912.4432 (MH+); 
(Found: MH+, 912.4432. C48H67ClN3O12 (MH+) requires 912.4413) (Found: C, 62.99; H, 
7.18; N, 4.55. C48H66ClN3O12 requires C, 63.18; H, 7.29; N, 4.60%). 
 
MIC 13B 
Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.1:9.9) to yield the product as a white powder 
(0.137 g, 37%); m.p. 62 – 64 °C. Rf (MeOH/DCM 
0.5:9.5) 0.18; νmax (DCM)/cm-1 1741 (C=O), 1450 
(C=C (Ar)), 1266 (C–N), 1048 (C–O (ester)), 847 
(O–O); δH (400 MHz; CDCl3) 8.51 (d, J 5.6, 1H, H2’), 7.96 (d, J 2.4, 1H, H8’), 7.72 (d, J 9.2, 
1H, H5’), 7.34 (dd, J 9.2 and 2.4, 1H, H6’), 6.35 (d, J 5.6, 1H, H3’), 6.32 (d, J 3.6, 1H, H10), 
5.49 (s, 1H, H12), 3.43 (t, J 5.6, 2H, H9’), 2.99 (t, J 6.4, 2H, H17), 2.92 (t, J 5.6, 2H, H11’), 
2.85 (m, 1H, H9), 2.63 (t, J 6.4, 2H, H18), 1.94 (t, J 5.6, 2H, H10’), 1.42 (s, 3H, H14), 0.97 
(d, J 6.0, 3H, H16), 0.88 (d, J 7.2, 3H, H15); δc (100 MHz; CDCl3) 151.8, 128.4, 125.0, 
121.9, 104.5, 98.4, 95.1, 88.8, 80.5, 52.4, 48.9, 45.1, 43.9, 43.5, 40.0, 37.6, 36.2, 34.7, 34.6, 
34.4, 29.8, 29.7, 27.5, 25.9, 24.6, 24.2, 20.2, 12.5; m/z 574.2699 (MH+); (Found: MH+, 
574.2699. C30H41ClN3O6 (MH+) requires 574.2684) (Found: C, 62.66; H, 7.10; N, 7.41. 


























































Crude residue was purified via 
column chromatography, eluting with 
MeOH/DCM (0.5:9.5) to yield the 
product as a light-yellow oil (0.248 g, 
62%);. Rf (MeOH/DCM 0.5:9.5) 0.17; 
νmax (DCM)/cm-1 1740 (C=O), 1451 
(C=C (Ar)), 1266 (C–N), 1049 (C–O 
(ester)), 847 (O–O); δH (300 MHz; CDCl3) 8.52 (d, J 5.4, 1H, H2’), 7.95 (d, J 2.1, 1H, H8’), 
7.70 (d, J 9.0, 1H, H5’), 7.36 (dd, J 9.0 and 2.1, 1H, H6’), 6.40 (d, J 5.4, 1H, H3’), 6.26 (d, J 
3.6, 1H, H10), 5.46 (s, 1H, H12), 3.33 (t, J 6.9, 2H, H17), 2.90 (t, J 6.6, 2H, H10’), 2.82 (m, 
1H, H9), 2.65 (t, J 6.9, 2H, H18), 2.57 (t, J 6.6, 2H, H11’), 1.41 (s, 3H, H14), 0.97 (d, J 6.0, 
3H, H16), 0.88 (d, J 7.5, 3H, H15); δc (75.5 MHz; CDCl3) 171.2, 151.5, 128.2, 125.0, 121.4, 
104.3, 98.8, 94.7, 88.6, 80.3, 52.2, 49.4, 44.8, 43.8, 43.0, 37.4, 36.1, 34.6, 34.3, 29.7, 29.6, 
29.4, 28.5, 26.8, 25.8, 24.5, 24.0, 20.1, 12.4; m/z 616.3173 (MH+); (Found: MH+, 616.3173. 
C33H47ClN3O6 (MH+) requires 616.3153). 
 
Methyl p-[(10-dihydroartemisininoxy)methyl]benzoate, 1a 
Dihydroartemisinin (1.00 g, 
3.500 mmol, 1.0 eq) and 
4-(hydroxylmethyl)-benzoa
te (2.036 g, 12.006 mmol, 
3.43 eq) were stirred in 
anhydrous Et2O under N2, 




















































































































stirred under N2 at room temperature for 23 hours, washed with 5% NaHCO3 (until pH 8), 
H2O (2 x 100 ml), dried (Na2SO4) and solvent evaporated. The crude product was purified 
via column chromatography (EtOAc/Hex, 1:9) to yield the pure product as colourless oil 
(1.460 g, 97% (both isomers)). Rf (EtOAc/Hex 1:9) 0.21. δH (400 MHz; CDCl3) 8.01 (d, J 
8.4, 2H, H19), 7.37 (d, J 8.4, 2H, H18), 5.44 (s, 1H, H12), 4.95 (d, J 13.2, 1H, H17), 4.91 (d, 
J 3.2, 1H, H10), 4.57 (d, J 13.2, 1H, H17), 3.91 (s, 3H, OCH3), 2.69 (m, 1H, H9), 2.36 (ddd, 
J 14.0, 13.2 and 4.0, 1H, not knowna), 2.20 – 1.50 (m, 4H, not knowna), 1.45 (s, 3H, H14), 
0.96 (d, J 7.6, 3H, H15), 0.94 (d, J 6.4, 3H, H16). α-Isomer: δH (400 MHz; CDCl3) 8.00 (d, J 
8.4, 2H, H19), 7.43 (d, J 8.8, 2H, H18), 5.34 (s, 1H, H12), 5.02 (d, J 14.2, 1H, H17), 4.68 (d, 
J 13.2, 1H, H17), 4.52 (d, J 9.2, 1H, H10), 3.91 (s, 3H, OCH3), 2.53 (m, 1H, H9), 2.39 (ddd, 
J 14.4, 13.2 and 4.0, 1H, not knowna), 2.20 – 1.50 (m, 4H, not knowna), 1.45 (s, 3H, H14), 
0.93 (d, J 5.6, 3H, H16), 0.93 (d, J 7.2, 3H, H15). 
a Protons could not be assigned due to complexity. 
 
p-[(10-Dihydroartemisininoxy)methyl]benzoic acid (Artelinic Acid), 1b 
The methyl ether 1a (1.272 g, 
2.932 mmol) was stirred in 
2.5% KOH/MeOH (25 ml) at 
room temperature for 3 days, 
and the solvent reduced under 
pressure. The residue was 
dissolved in H2O (25 ml), and the pH adjusted to 8 via addition of acetic acid. The solution 
was extracted with Et2O (3 x 50 ml), dried (Na2SO4) and solvent evaporated. The resulting 
oil was seeded and the pure compound crystallized out to yield white crystals (1.091 g, 89%). 











































































CDCl3) 8.01 (d, J 8.4, 2H, H19), 7.40 (d, J 8.4, 2H, H18), 5.45 (s, 1H, H12), 4.98 (d, J 13.5, 
1H, H17), 4.93 (d, J 3.0, 1H, H10), 4.60 (d, J 13.5, 1H, H17), 2.70 (m, 1H, H9), 2.38 (ddd, J 
14.0, 13.2 and 4.0, 1H, not knownb), 2.20 – 1.50 (m, 4H, not knownb), 1.45 (s, 3H, H14), 
0.98 (d, J 7.2, 3H, H15), 0.95 (d, J 6.0, 3H, H16). α-isomer: δH (300 MHz; CDCl3) 8.06 (d, J 
8.4, 2H, H19), 7.46 (d, J 8.4, 2H, H18), 5.35 (s, 1H, H12), 5.05 (d, J 13.5, 1H, H17), 4.70 (d, 
J 13.2, 1H, H17), 4.53 (d, J 9.0, 1H, H10), 2.55 (m, 1H, H9), 2.39 (ddd, J 14.4, 13.2 and 4.2, 
1H, not knownb), 2.20 – 1.50 (m, 4H, not knownb), 1.46 (s, 3H, H14), 0.95 (d, J 6.0, 3H, 
H16), 0.94 (d, J 7.2, 3H, H15).  
a Protons could not be assigned due to complexity. 
 
3-Carboxyethyl-5-hydroxy-2-methyl-1,4-naphthoquinone, 2a 
Plumbagin (1.00 g, 5.314 mmol, 1.0 eq) and succinic acid 
(1.902 g, 15.942 mmol, 3.0 eq) were stirred in 30% aqueous 
acetonitrile (40 ml) at 65 °C, followed by the addition of 
silver nitrate (0.456g, 2.657 mmol, 0.5 eq). A solution of 
ammonium persulfate (1.609 g, 6.908 mmol, 1.3 eq) in 30% aqueous acetonitrile (20 ml) 
was added drop-wise over 2 hours, and the resulting solution stirred at 65 – 70 °C for 3 hours. 
On cooling, the mixture was extracted with EtOAc (4 x 60 ml), and the organic layer washed 
with H2O (3 x 20 ml), dried (Na2SO4) and solvent evaporated. The crude material was 
purified via column chromatography (DCM/MeOH 9.5:0.5) to yield the pure product as an 
orange powder (0.581 g, 58%). m.p. 155–159 °C.4 Rf (DCM/MeOH, 9.5:0.5) 0.49. δH (400 
MHz; CDCl3) 7.62 (d, J 6.8, 1H, H8), 7.57 (t, J 7.6, 1H, H7), 7.23 (d, J 7.6, H6), 2.98 (t, J 





























Ugi Adduct, 6a 
Purified via column chromatography, first with 
EtOAC and then with EtOAC/MeOH 9.5:0.5 to 
yield the pure product as a white powder (0.5115 g, 
89%). (m.p. 121 – 124 °C. Rf (MeOH/EtOAC, 1:9) 
0.18; νmax (CHCl3)/cm-1 3223 (N-H), 2920 (Ar-H), 
1580 (C=O), 1216 (C-N), 781 (C-Cl); δH (400 MHz; 
CDCl3) 8.45 (br s, 1H, H24), 8.28 (br s, 1H, H26), 7.96 (br s, 2H, H19), 7.41 (d, J 8.8, 2H, 
H18), 7.39 (br s, 1H, H27), 7.03 (br s, 1H, H27), 6.35 (br s, 1H, H25), 5.42 (s, 1H, H12), 
4.88 (br s, 2H, H17 + H10), 4.51 (br s, 1H, H17), 4.09 (m, 2H, H22), 3.61 (br s, 2H, H23), 
2.68 (m, 1H, H9), 2.38 (ddd, J 14.4 and 13.2, 4.2 Hz, 1H, not known), 1.45 – 1.93 (m, 15H), 
1.44 (s, 3H, H14), 0.95 (d, J 6.0, 6H, H16 + H15); δc (75.5 MHz; DMSO-d6) 171.6, 171.0, 
170.2, 167.5, 151.9, 151.5, 150.1, 149.5, 149.1, 139.9, 139.2, 135.2, 134.9, 133.4, 127.5, 
126.6, 126.3, 124.1, 123.7, 123.5, 117.5, 103.3, 100.6, 98.6, 87.0, 80.4, 52.0, 47.7, 36., 34.0, 
32.1, 30.5, 25.6, 25.1, 24.4, 24.2, 20.0, 12.7; m/z 761.3596 (M+); (Found: M+, 761.3596. 
C42H53ClN4O7 requires M, 761.3584) (Found: C, 66.00, H, 7.26, N, 7.67 %; Requires C, 
66.26, H, 7.02 N, 7.36 %). 
 
Ugi Adduct 6b 
Purified via column chromatography, first with 
EtOAC and then with EtOAC/MeOH 9.5:0.5 to yield 
the pure product as a white powder (0.5009 g, 84%). 
(m.p. 121 – 123 °C. Rf (MeOH/EtOAC, 1:9) 0.48; 









































































































(alkyls), 1666 (C=O), 1580 (Ar-C), 1010 (C-N), 753 (C-Cl); δH (400 MHz; CDCl3) 8.45 (d, J 
5.2, 1H, H24), 8.23 (br s, 1H, H29), 7.99 (s, 2H, H31), 7.36 (br s, 5H, H30+H18+H19), 7.13 
(br s, 1H, NH), 6.31 (br s, 1H, H28), 6.10 (br s, 1H, NH), 5.44 (s, 1H, H12), 4.91 (d, J 12.4, 
1H, H17), 4.90 (d, J 4.0, 1H, H10), 4.56 (d, J 12.4, 1H, H17), 4.11 (m, 2H, CH2, H22), 3.81 
(br s, 2H, CH2, H25), 3.52 (br s, 2H, CH2, H23), 3.48 (s, 2H, H20), 3.26 (br s, 2H, CH2, 
H24), 2.52 (m, 1H, H9), 2.00 – 1.45 (m, 20H), 1.45 (s, 3H, H14), 0.96 (d, J 7.2, 3H, H15), 
0.95 (d, J 5.6, 3H, H16); δc (100 MHz; DMSO-d6) 170.9, 167.1, 151.8, 150.0, 149.0, 139.5, 
135.7, 132.3, 127.4, 126.8, 126.6, 126.5, 124.4, 124.0, 123.9, 117.4, 103.3, 100.6, 98.6, 87.0, 
80.4, 68.7, 52.0, 47.6, 45.8, 43.7, 42.3, 36.6, 36.0, 34., 32.4, 32.1, 30.5, 25.6, 24.7, 24.4, 20.0, 
12.7; m/z 789.4125 (M+); (Found: M+, 789.4125. C44H57ClN4O7 requires M, 789.4122) 
(Found: C, 66.80, H, 6.91, N, 6.92 %; Requires C, 66.95, H, 7.28 N, 7.10 %). 
 
Ugi Adduct 6c 
Purified via column chromatography, first with 
EtOAC and then with EtOAC/MeOH 9.5:0.5 to yield 
the pure product as a white powder (0.453 g, 82%). 
(m.p. 127 – 129 °C. Rf (MeOH/EtOAC, 1:9) 0.18; νmax 
(CHCl3)/cm-1 3385 (N-H), 3017 (Ar-H), 1520 (C=O), 
1215 (C-N), 756 (C-Cl); δH (400 MHz; CDCl3) 8.47 
(br s, 1H, H24), 8.24 (br s, 1H, H26), 8.12 (d, J 8.6, 
2H, H19), 8.00 (s, 1H, H28), 7.40 (d, J 8.6, 2H, H18), 7.39 (br s, 1H, H27), 7.04 (br s, 1H, 
NH), 6.35 (br s, 1H, H25), 5.42 (s, 1H, H12), 4.87 (br s, 2H, H17 + H10), 4.51 (br s, 1H, 
H17), 3.93 (br s, 2H, H22), 3.64 (br s, 2H, H23), 2.68 (m, 1H, H9), 2.38 (ddd, J 14.4, 13.2 
and 4.2, 1H, not known), 2.10 – 1.57 (m, 4H), 1.44 (s, 3H, H14), 1.35 (s, 9H, t-butyl), 0.95 


























































101.6, 101.6, 98.2, 88.1, 81.1, 70.7, 69.5, 69.1, 52.7, 52.6, 52.1, 44.5, 44.4, 37.5, 36.4, 34.6, 
31.0, 30.9, 29.1, 28.7, 26.2, 24.7, 24.6, 20.3, 13.1; m/z 735.3211 (M+); (Found: M+, 735.3211. 
C40H51ClN4O7 requires M, 735.3205) (Found: C, 65.68, H, 7.28, N, 7.56 %; Requires C, 




Purified via column chromatography, first with 
EtOAC and then with EtOAC/MeOH 9.5:0.5 to yield 
the pure product as an orange powder (0.1138 g, 25%). 
(m.p. 135 – 138 °C. Rf (MeOH/EtOAc, 1:9) 0.11; νmax 
(CHCl3)/cm-1 3273 (N-H), 3020 (Ar-H), 2926 (alkyls), 
1606 (C=O), 1430 (Ar-C), 1216 (C-N), 770 (C-Cl); δH 
(300 MHz; CDCl3) 8.48 (d, J 5.7, 1H, H10), 8.44 (d, J 5.4, 1H, H10), 7.96 (d, J 1.8, 1H, 
H14), 7.88 (d, J 1.8, 1H, H14), 7.88 (d, J 9.0, 1H, H12), 7.74 (d, J 9.0, 1H, H12), 7.55 (m, 
4H, (H2+H3)x2), 7.35 (dd, J 9.0 and 1.8, 1H, H13), 7.31 (dd, J 9.0 and 1.8, 1H, H13), 7.13 
(d, J 7.5, 1H, H1), 7.13 (d, J 7.5, 1H, H1), 6.97 (br s, 1H, NH), 6.34 (d, J 5.4, 1H, H11), 6.33 
(d, J 5.7, 1H, H11), 4.09 (s, 2H, H7),4.00 (s, 2H, H7), 3.88 (m, 2H, H8), 3.70 (br s, 4H, H8 + 
H9), 3.50 (m, 2H, H9), 2.97 (t, J 7.8, 2H, H6), 2.72 (t, J 8.1, 2H, H5), 2.57 (t, J 7.8, 2H, H6), 
2.28 (t, J 8.1, 2H, H5), 2.24 (s, 3H, H4), 1.92 (s, 3H, H4), 1.75 (m, 11H, cyclohexyl-H), 1.22 
(m, 11H, cyclohexyl-H); δc (100 MHz; CDCl3) 174.9, 161.2, 151.6, 151.0, 137.3, 136.8, 
136.2, 136.1, 132.0, 125.9, 125.8, 125.7, 123.9, 122.2, 122.0, 119.2, 119.1, 98.6, 98.0, 53.1, 
43.0, 41.0, 32.9, 32.2, 31.5, 25.5, 25.2, 24.8, 24.7, 22.7, 22.4, 12.9; m/z 603.1182 (M+); 
(Found: M+, 603.1182. C33H35ClN4O5 requires M, 603.1177) (Found: C, 66.67, H, 7.07, N, 







































Purified via column chromatography, first with EtOAC 
and then with EtOAC/MeOH 9.5:0.5 to yield the pure 
product as an orange powder (0.123 g, 28%). m.p. 
205 – 207 °C; Rf (EtOAc) 0.11; νmax (CHCl3)/cm-1 3320 
(N-H), 3026 (Ar-H), 1736 (C=O), 1430 (Ar-C), 1216 
(C-N); 753 (C-Cl); δH (400 MHz; CDCl3) 8.35 (d, J 5.2, 
1H, H10), 8.34 (d, J 5.2, 1H, H10), 7.90 (d, J 9.2, 1H, H12), 7.85 (d, J 2.0, 1H, H14), 7.84 (d, 
J 9.2, 1H, H12), 7.79 (d, J 2.0, 1H, H14), 7.51 (m, 4H, (H2+H3)x2), 7.29 (dd, J 9.2 and 2.0, 
1H, H13), 7.28 (dd, J 9.2 and 2.0, 1H, H13), 7.15 (d, J 7.2, 1H, H1), 7.14 (d, J 7.2, 1H, H1), 
6.36 (d, J 5.6, 1H, H11), 6.35 (d, J 5.6, 1H, H11), 3.99 (s, 2H, H7), 3.79 (s, 2H, H7), 3.77 (d, 
J 5.6, 2H, H8), 3.66 (d, J 5.6, 2H, H9), 3.63 (d, J 5.6, 2H, H8), 3.49 (d, J 5.6, 2H, H9), 2.91 
(t, J 8.0, 2H, H6), 2.72 (t, J 8.0, 2H, H6), 2.51 (t, J 8.0, 2H, H5), 2.30 (t, J 8.0, 2H, H5, 2.19 
(s, 3H, H4), 1.93 (s, 3H, H4), 1.37 (s, 9H, t-butyl), 1.27 (s, 9H, t-butyl); δc (100 MHz; 
CDCl3) 151.6, 150.3, 145.6, 136.1, 127.2, 126.4, 125.6, 123.7, 123.6, 122.5, 122.4, 119.0, 
98.9, 98.2, 52.7, 52.0, 49.4, 14.2, 49.0, 48.7, 48.5, 47.7, 42.1, 40.8, 32.0, 31.4, 28.4, 22.5, 
22.3, 12.6; m/z 577.0805 (M+); (Found: M+, 577.0805. C31H33ClN4O5 requires M, 577.0798) 












































Citric acid (0.131 g, 0.680 mmol, 2.5 eq) in acetone 
(5 ml) was added to a solution of 6c (0.200 g, 0.272 
mmol, 1.0 eq) in acetone (5 ml). The product 
precipitated out over 2 days at 4°C to yield white 
solid (0.247 g, 98%). νmax (CHCl3)/cm-1 3419 (OH 
(alcohol)), 3317 (N-H), 3017 (Ar-H), 2962 (OH 
(acid)), 1707 (C=O), 1612 (Ar-H), 1215 (C-N), 1007 
(C-O), 752 (C-Cl); δH (300 MHz; CD3OD) 8.51 (br s, 1H, H24), 8.43 (br s, 1H, H26), 7.91 
(br s, 1H, H28), 7.61 (br s, 1H, H27), 7.39 (br s, 2H, H19), 6.99 (br s, 2H, H18), 6.42 (br s, 
1H, H25), 5.44 (s, 1H, H12), 4.04 (br s, 2H, H22), 3.95 (br s, 2H, H23), 2.58 (m, 1H, H9), 
2.33 (td, J 14.4 and 13.0, 4.2 Hz, 1H, not known), 2.20 – 1.50 (m, 4H, not known), 1.44 (br s, 
4H, H29+H30), 1.37 (s, 3H, H14), 1.32 (s, 9H, t-butyl), 0.94 (d, J 6.0, 6H, H16 + H15); m/z 
927.4471 (M+); (Found: M+, 927.4471. C40H51N4ClO7 requires M, 927.4459) (Found: C, 
59.76, H, 6.63, N, 5.74 %; Requires C, 59.57, H, 6.41, N, 6.04 %). 
 
General procedure for the synthesis of propargyl-benzaldehydes 7a, 7b and 7c: 
Propargyl bromide (3.2 ml, 80%w/w solution in toluene, 28.9 mmol) was added drop-wise to 
a mixture of the hydroxyl benzaldehyde (3.0 g, 24.1 mmol) and K2CO3 (4.99 g, 36.1 mmol) 
in anhydrous DMF (30 ml) at r.t., and stirred for 18 h. The reaction mixture was then diluted 
with H2O (100 ml), and extracted with EtOAc (4 x 50 ml), washed with H2O (4 x 200 ml) 




































































The crude product was purified via column chromatography, eluting 
with EtOAc/Hex (1:9) to yield the pure product as white solid (3.80 
g, 99 %), m.p. 70 – 73 °C (lit. 69 – 72 °C).5 Rf (EtOAc/Hex, 1:9) 
0.20. δH (400 MHz; CDCl3) 10.4 (s, 1H, H1), 7.81 (m, 1H, H2), 
7.1 – 6.9 (m, 3H, H3, H4 and H5), 4.79 (d, J 2.4, 2H, H6), 2.56 (t, J 
2.4, 1H, H7). 
 
3-(Prop-2-ynyloxy)benzaldehyde, 7b 
The crude product was purified via column chromatography, eluting 
with EtOAc/Hex (1:9) to yield the pure product as a yellow oil (3.54 
g, 93 %).6 Rf (EtOAc/Hex, 2:8) 0.48. δH (400 MHz; CDCl3) 9.97 (s, 
1H, H1), 7.49 (m, 3H, Ar-H), 7.25 (m, 1H, Ar-H), 4.75 (d, J 2.4, 2H, 
H2), 2.54 (t, J 2.4, 1H, H3). 
 
4-(Prop-2-ynyloxy)benzaldehyde, 7c 
The crude product was purified via column chromatography, eluting 
with EtOAc/Hex (2:8) to yield the pure product as a white powder 
(3.75 g, quantitative), m.p. 77 – 80 °C  (lit. 77 – 79 °C).7 Rf 
(EtOAc/Hex, 3:7) 0.53. δH (400 MHz; CDCl3) 9.87 (s, 1H, H1), 7.83 
(d, J 8.4, 2H, H2), 7.07 (d, J 8.4, 2H, H3), 4.76 (d, J 2.4, 2H, H4), 















































General procedures for Staudinger products 
The aldehyde (1.0 eq) and amine (1.2 eq) were stirred in anhydrous MeOH (15 ml) at r.t., 
and stirred further for 18 h. The solvent was removed and the crude imine was dried on 
high-vacuum pump for 1 h. The dried imine was then stirred with Et3N (3.0 eq) in anhydrous 
DCM (10 ml) at -78 °C and under N2, followed by the drop-wise addition of acetoxy acetyl 
chloride (1.5 eq) in anhydrous DCM (6 ml). The mixture was allowed to slowly warm to r.t., 
and stirred further overnight. When the reaction has completed, the reaction mixture was 
washed with saturated NaHCO3 (20 ml) and brine (20 ml), dried (Na2SO4) and solvent 
removed to yield the crude products. 
 
1-Benzyl-2-oxo-4-[2-(prop-2-ynyloxy)phenyl]azetidin-3-yl acetate, BL01 
The crude product was purified via column chromatography, 
eluting with Hex/DCM (2:8) to yield the pure product as a white 
powder, (0.42 g, 81%); m.p. 89 – 91 °C; Rf (Hex/DCM, 2:8) 0.24; 
νmax (DCM)/cm-1 3275 (C≣C–H), 2116 (C≣C), 1758 (C=O), 
1223 (C–O–C (ester)) and 1028 (C–O (ether)); δH (400 MHz; 
CDCl3) 7.38 – 7.00 (m, 9H, Ar–H), 5.84 (d, J 4.8, 1H, H2), 5.21 
(d, J 4.8, 1H, H1), 4.83 (d, J 14.8, 1H, H3), 4.66 (dd, J 16.0 and 2.4, 1H, H5), 4.60 (dd, J 
16.0 and 2.4, 1H, H5), 3.96 (d, J 14.8, 1H, H3), 2.43 (t, J 2.4, 1H, H6), 1.70 (s, 3H, H4); δc 
(100 MHz; CDCl3) 169.1, 164.6, 157.4, 134.5, 129.4, 128.4, 128.4, 128.0, 121.6, 115.2, 
114.6, 78.0, 77.4, 75.7, 60.6, 56.1, 44.7 and 19.8; m/z 349.3872 (M+); (Found: M+, 349.3872. 
C21H19NO4 requires M, 349.3862) (Found: C, 71.98; H, 5.61; N, 3.88 requires C, 72.19; H, 




























General procedure for the free alcohol products BL 02, BL 06 and BL 08. 
The acetates (1.0 eq) were stirred in a solution of K2CO3 (1.3 eq) in MeOH/H2O (5:2 ml) at 
r.t. for 18 h. H2O (5 ml) was added to the reaction mixture, and neutralized with 1 M HCl. 
The mixture was extracted with EtOAc (3 x 10 ml), washed with H2O (15 ml) and brine  
(15 ml), dried (Na2SO4) and solvent removed in vacuo to yield the crude products. 
 
1-Benzyl-3-hydroxy-4-[2-(prop-2-ynyloxy)phenyl]azetidin-2-one, BL02 
The crude product was purified via column chromatography, 
using EtOAc/Hex (1:1) as the eluent to yield the product as a 
white powder, (0.210 g, 80%); m.p. 105 – 108 °C; Rf 
(EtOAc/Hex, 1:1) 0.18; νmax (DCM)/cm-1 3470 (O–H), 3283 
(C≣C–H), 2116 (C≣C), 1736 (C=O), 1223 (C–O–C (ester)) 
and 1021 (C–O (ether)); δH (400 MHz; CDCl3) 7.4 – 7.0 (m, 9H, Ar–H), 5.07 (d, J 4.8, 1H, 
H2), 4.92 (d, J 4.8, 1H, H1), 4.80 (d, J 14.8, 1H, H3), 4.71 (dd, J 16.0 and 2.4, 1H, H4), 4.64 
(dd, J 16.0 and 2.4, 1H, H4), 3.95 (d, J 14.8, 1H, H3), 2.51 (t, J 2.4, 1H, H5); δc (100 MHz; 
CDCl3) 169.0, 155.8, 135.2, 129.7, 129.6, 128.7, 128.6, 127.8, 122.9, 122.1, 112.9, 78.7, 
78.0, 76.2, 59.3, 56.2 and 44.6; m/z 307.3497 (M+); (Found: M+, 307.3497. C19H17NO3 































1-Benzyl-2-oxo-4-[3-(prop-2-ynyloxy)phenyl]azetidin-3-yl acetate, BL03 
The crude product was purified via column 
chromatography, eluting with (EtOAc/Hex, 3:7) to 
yield the pure product as a light yellow oil (1.1 g, 
84%); Rf (EtOAc/Hex, 3:7) 0.31; νmax (DCM)/cm-1 
3275 (C≣C–H), 2116 (C≣C), 1762 (C=O), 1223 
(C–O–C (ester)) and 1035 (C–O (ether)); δH (400 MHz; CDCl3) 7.38 – 6.80 (m, 9H, Ar–H), 
5.78 (d, J 4.4, 1H, H2), 5.29 (d, J 14.8, 1H, H3), 4.72 (d, J 4.4, 1H, H1), 4.65 (d, J 2.4, 2H, 
H5), 3.95 (d, J 14.8, 1H, H3), 2.61 (t, J 2.4, 1H, H6), 1.70 (s, 3H, H4); δc (100 MHz; CDCl3) 
169.0, 164.6, 157.5, 134.5, 134.3, 129.5, 128.4, 128.5, 128.0, 121.6, 115.4, 114.6, 78.3, 77.3, 
75.7, 60.8, 55.9, 44.7 and 19.9; m/z 349.3871 (M+); (Found: M+, 349.3871. C21H19NO4 
requires M, 349.3862). 
 
1-Benzyl-2-oxo-4-[4-(prop-2-ynyloxy)phenyl]azetidin-3-yl acetate, BL04 
The crude product was purified via column 
chromatography, eluting with (EtOAc/Hex, 3:7) to 
yield the pure product as a light yellow oil (0.63 g, 
96%); Rf (EtOAc/Hex, 3:7) 0.26; νmax (DCM)/cm-1 
3275 (C≣C–H), 2116 (C≣C), 1765 (C=O), 1223 
(C–O–C (ester)) and 1028 (C–O (ether)); δH (400 MHz; CDCl3) 7.29 (m, 3H, Ar–H), 7.14 
(m, 4H, Ar–H), 6.95 (m, 2H, Ar–H), 5.73 (d, J 4.8, 1H, H2), 4.84 (d, J 14.8, 1H, H3), 4.71 (d, 
J 4.8, 1H, H1), 4.70 (d, J 2.4, 2H, H5), 3.89 (d, J 14.4, 1H, H3), 2.52 (t, J 2.4, 1H, H6), 1.70 
(s, 3H, H4); δc (100 MHz; CDCl3) 169.1, 164.7, 157.9, 134.5, 129.7, 128.9, 128.0, 125.3, 
114.9, 78.3, 77.5, 75.7, 60.5, 55.9, 44.5 and 19.9; m/z 349.3868 (M+); (Found: M+, 349.3868. 




































2-Oxo-1-phenyl-4-[2-(prop-2-ynyloxy)phenyl]azetidin-3-yl acetate, BL05 
The crude product was purified via column chromatography, 
using EtOAc/Hex (2:8) as the eluent to yield the product as a 
cream-coloured powder, (0.49 g, 75%); m.p. 109 – 112 °C; Rf 
(EtOAc/Hex, 2:8) 0.25; νmax (DCM)/cm-1 3275 (C≣C–H), 2123 
(C≣C), 1758 (C=O), 1223 (C–O–C (ester)) and 1020 (C–O 
(ether)); δH (400 MHz; CDCl3) 7.40 – 6.93 (m, 9H, Ar–H), 6.11 (d, J 5.2, 1H, H2), 5.78 (d, J 
5.2, 1H, H1), 4.79 (dd, J 16.0 and 2.4, 1H, H4), 4.73 (dd, J 16.0 and 2.4, 1H, H4), 2.54 (t, J 
2.4, 1H, H5), 1.75 (s, 3H, H3); δc (100 MHz; CDCl3) 168.7, 162.5, 155.7, 137.0, 129.6, 
129.2, 128.4, 124.6, 121.4, 117.5, 112.3, 78.4, 75.8, 75.5, 58.9, 56.3, 56.1 and 20.0; m/z 
335.3598 (M+); (Found: M+, 335.3598 C20H17NO4 requires M, 335.3593) (Found: C, 71.89; 
H, 5.12; N, 4.55. requires C, 71.63; H, 5.11; N, 4.18%). 
 
3-Hydroxy-1-phenyl-4-[2-(prop-2-ynyloxy)phenyl]azetidin-2-one, BL06 
The crude product was purified via column chromatography, using 
EtOAc/Hex (2.5:7.5) as the eluent to yield the product as a 
yellow-brown powder, (0.23 g, 85%); m.p. 120 – 122 °C; Rf 
(EtOAc/Hex, 4:6) 0.42; νmax (DCM)/cm-1 3471 (O–H), 3275 
(C≣C–H), 2122 (C≣C), 1736 (C=O) and 1023 (C–O (ether)); δH 
(300 MHz; CDCl3) 7.3 – 6.5 (m, 9H, Ar–H), 5.39 (br s, 1H, H2), 4.84 (dd, J 16.0 and 2.4, 
2H, H3), 4.65 (d, J 5.2, 1H, H1), 2.54 (t, J 2.4, 1H, H4), 1.59 (br s, 1H, OH); δc (100 MHz; 
CDCl3) 174.0, 155.1, 146.2, 129.1, 128.5, 128.3, 127.9, 124.4, 119.9, 117.8, 113.9, 112.1, 
78.5, 76.0, 72.4, 56.3, 53.0 and 52.9; m/z 293.3231 (M+); (Found: M+, 293.3231. C18H15NO3 


































1-Benzyl-2-oxo-4-phenylazetidin-3-yl acetate, BL07 
The crude product was purified via column chromatography, 
eluting with EtOAc/Hex (3:7) to yield the pure product as a 
colourless oil, (0.77 g, 78%); Rf (EtOAc/Hex, 3:7) 0.41; νmax 
(DCM)/cm-1 1751 (C=O), 1223 (C–O–C (ester)) and 1021 (C–O 
(ether)); δH (400 MHz; CDCl3) 7.34 (m, 3H, Ar–H), 7.29 (m, 3H, 
Ar–H), 7.20 (m, 2H, Ar–H), 7.15 (m, 2H, Ar-H), 5.77 (d, J 4.4, 1H, H2), 4.87 (d, J 14.8, 1H, 
H3), 4.75 (d, J 4.4, 1H, H1), 4.91 (d, J 14.8, 1H, H3), 1.66 (s, 3H, H4); δc (100 MHz; CDCl3) 
169.1, 164.7, 134.5, 132.5, 128.9, 128.7, 128.5, 128.4, 128.1, 77.4, 60.9, 44.6 and 19.8; m/z 
295.3381 (M+); (Found: M+, 295. 3381. C18H17NO3 requires M, 295.3379). 
 
1-Benzyl-3-hydroxy-4-phenylazetidin-2-one. BL08 
The crude product was purified via column chromatography, using 
EtOAc/Hex (1:1) as the eluent to yield the product as a white powder, 
(0.55 g, 84%); m.p. 119 – 121 °C; Rf (EtOAc/Hex, 1:1) 0.35; νmax 
(DCM)/cm-1 3333 (O–H) 1733 (C=O); δH (400 MHz; CDCl3) 7.39 
(m, 3H, Ar–H), 7.27 (m, 5H, Ar-H), 7.13 (m, 2H, Ar–H), 5.03 (d, J 
4.8, 1H, H2), 4.85 (d, J 14.8, 1H, H3), 4.66 (d, J 4.8, 1H, H1), 3.89 (d, J 14.8, 1H, H3), 1.63 
(br s, 1H, OH); δc (100 MHz; CDCl3) 168.9, 134.8, 133.5, 128.9, 128.8, 128.5, 127.9, 78.1, 
61.9, 44.2; m/z 253.3014 (M+); (Found: M+, 253.3014 C16H15NO2 requires M, 253.3006) 































Propargyl bromide (0.13 ml, 80% w/w solution in toluene, 
1.42 mmol) was added drop-wise to a stirred solution of 
NaH (60% suspension in oil, 0.057 g, 1.42 mmol) and BL08 
(0.30 g, 1.18 mmol) in anhydrous DMF (5 ml) at 0 °C , and 
stirred for 1 h. H2O (20 ml) was added to the reaction 
mixture, and extracted with EtOAc (3 x 30 ml), washed with H2O (4 x 30 ml) and brine (40 
ml), dried (Na2SO4) and solvent removed in vacuo. The crude product was purified via 
column chromatography, using EtOAc/Hex (3:7) as the eluent to yield the product as a light 
yellow oil, (0.30 g, 92%); Rf (EtOAc/Hex, 3:7) 0.51; νmax (DCM)/cm-1 3289 (C≣C–H), 
2115 (C≣C), 1751 (C=O) and 1021 (C–O (ether)); δH (400 MHz; CDCl3) 7.36 (m, 3H, 
Ar–H), 7.28 (m, 5H, Ar–H), 7.12 (m, 2H, Ar–H), 5.07 (d, J 4.4, 1H, H2), 4.83 (d, J 14.8, 1H, 
H3), 4.59 (d, J 4.4, 1H, H1), 4.05 (dd, J 16.0 and 2.4, 1H, H4), 3.82 (d, J 14.8, 1H, H3), 3.78 
(dd, J 16.0 and 2.4, 1H, H4), 2.35 (d, J 2.4, 1H, H5); δc (100 MHz; CDCl3) 134.9, 133.3, 
128.8, 128.7, 128.6, 128.5, 128.4, 127.9, 82.4, 78.2, 75.7, 75.4, 61.0, 57.4 and 44.0; m/z 
291.3499 (M+); (Found: M+, 291.3499. C19H17NO2 requires M, 291.3495). 
 
General procedures for the Ugi adducts 
Propargyloxy-benzaldehyde (1.5 eq), β-alanine (1.0 eq) and isocyanide (1.0 eq) were stirred 



























N-Cyclohexyl-2-(2-oxoazetidin-1-yl)-2-[2-(prop-2-ynyloxy)phenyl]acetamide, BL10  
The crude product was purified via column chromatography, 
using EtOAc/Hex (6:4) as the eluent to yield the product as a 
white powder, (0.37 g, 88%); m.p. 152 – 154 °C; Rf 
(EtOAc/Hex, 1:1) 0.34; νmax (DCM)/cm-1 3289 (C≣C–H), 
2116 (C≣C), 1740 (C=O), 1660 (C=O) and 1220 (C–N); δH 
(400 MHz; CDCl3) 7.34 (m, 2H, Ar–H), 7.06 (m, 2H, Ar–H), 5.82 (d, 7.6, 1H, H4), 5.65 (s, 
1H, H3), 4.76 (d, J 2.8, 2H, H6), 3.79 (m, 1H, H5), 3.67 (td, J 5.6 and 2.8, 1H, H1), 3.21 (td, 
J 5.6 and 2.8, 1H, H1), 3.00 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 2.88 (ddd, J 14.8, 5.6 and 2.8, 
1H, H2), 2.54 (t, J 2.4, 1H, H7), 1.9 – 1.0 (m, 10H, cyclohexyl–H); δc (100 MHz; CDCl3) 
168.1, 167.7, 154.9, 129.9, 124.1, 121.9, 112.5, 78.2, 76.0, 64.5, 56.1, 54.8, 48.5, 39.6, 36.3, 
32.8, 32.7, 25.5, 24.7 and 24.6; m/z 340.4230 (M+); (Found: M+, 340.4230. C20H24N2O3 




The crude product was purified via column 
chromatography, using EtOAc/Hex (6:4) as the eluent to 
yield the product as a white powder, (0.38 g, 90%); m.p. 
134 – 156 °C; Rf (EtOAc/Hex, 1.1) 0.24; νmax 
(DCM)/cm-1 3283 (C≣C–H), 2116 (C≣C), 1736 
(C=O), 1653 (C=O) and 1248 (C–N); δH (300 MHz; CDCl3) 7.30 (s, 1H, Ar–H), 6.96 (m, 3H, 
Ar–H), 6.02 (d, 8.0, 1H, H4), 5.28 (s, 1H, H3), 4.68 (d, J 2.4, 2H, H6), 3.78 (m, 1H, H5), 
3.61 (td, J 5.6 and 3.2, 1H, H1), 3.19 (td, J 5.6 and 3.2, 1H, H1), 2.90 (ddd, J 14.6, 5.6 and 







































10H, cyclohexyl–H); δc (100 MHz; CDCl3) 167.9, 167.3, 158.0, 136.4, 130.2, 121.3, 115.1, 
114.8, 78.3, 75.7, 61.2, 60.2, 55.9, 48.7, 39.0, 36.3, 32.8, 25.4 and 24.7; m/z 340.4228 (M+); 
(Found: M+, 340.4228. C20H24N2O3 requires M, 340.4222) (Found: C, 70.65; H, 7.07; N, 
8.19. requires C, 70.57; H, 7.11; N, 8.23%). 
 
N-Cyclohexyl-2-(2-oxoazetidin-1-yl)-2-[4-(prop-2-ynyloxy)phenyl]acetamide, BL12 
The crude product was purified via column chromatography, 
using EtOAc/Hex (7:3) as the eluent to yield the product as a 
light-yellow oil, (0.35 g, 83%); Rf (EtOAc/Hex, 1:1) 0.21; 
νmax (DCM)/cm-1 3290 (C≣C–H), 2116 (C≣C), 1730 (C=O), 
1660 (C=O) and 1223 (C–N); δH (400 MHz; CDCl3) 7.28 (d, J 
8.8, 2H, H6), 6.97 (d, 2H, H7), 5.99 (d, 6.8, 1H, H4), 5.27 (s, 1H, H3), 4.69 (d, J 2.4, 2H, 
H8), 3.76 (m, 1H, H5), 3.58 (td, J 5.6 and 2.8, 1H, H1), 3.13 (td, J 5.6 and 2.8, 1H, H1), 2.98 
(ddd, J 14.4, 5.6 and 2.8, 1H, H2), 2.84 (ddd, J 14.4, 5.6 and 2.8, 1H, H2), 2.52 (t, J 2.4, 1H, 
H9), 1.87 (m, 2H, cyclohexyl–H), 1.68 (m, 3H, cyclohexyl–H), 1.34 (m, 2H, cyclohexyl–H), 
1.12 (m, 3H, cyclohexyl–H); δc (100 MHz; CDCl3) 167.8, 167.7, 157.7, 129.5, 127.9, 115.4, 
78.3, 75.8, 59.5, 55.9, 48.7, 38.8, 36.2, 32.8, 25.5, 24.7 and 24.6; m/z 340.4231 (M+); (Found: 
M+, 340.4231. C20H24N2O3 requires M, 340.4222). 
 
General procedure for Mannich Reactions 
The terminal acetylene (1.0 eq), aqueous formaldehyde (5.0 eq), amine (1.2 eq) and copper 
(I) iodide (0.02 eq) were stirred in commercial DMSO at 25 °C for 2 h. H2O was added to 
the reaction mixture, and basified to pH 8. The mixture was extracted with EtOAc, washed 


































Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.5:9.5) to yield the product as a white powder, 
(75.1 mg g, 72%); m.p. 88 – 91 °C; Rf 
(MeOH/DCM, 0.5:9.5) 0.33; νmax (DCM)/cm-1 
2312 (C≣C), 1742 (C=O), 1672 (C=O), 1249 (C–N) and 1025 (C–O (ether)); δH (300 MHz; 
CDCl3) 7.26 (m, 6H, Ar–H), 6.98 (m, 3H, Ar–H), 5.90 (d, 7.5, 1H, H4), 5.24 (s, 1H, H3), 
4.76 (t, J 1.8, 2H, H6), 3.73 (m, 1H, H5), 3.56 (td, J 5.7 and 2.7, 1H, H1), 3.50 (s, 2H, H9), 
3.31 (t, J 1.8, 2H, H7), 3.11 (td, J 5.7 and 2.7, 1H, H1), 2.95 (ddd, J 14.7, 5.7 and 2.7, 1H, 
H2), 2.79 (ddd, J 14.7, 5.7 and 2.7, 1H, H2), 2.29 (s, 3H, H8), 2.0 – 0.8 (m, 10H, 
cyclohexyl–H); δc (75.5 MHz; CDCl3) 167.9, 167.4, 158.1, 138.1, 136.4, 130.0, 129.1, 128.3, 
127.1, 121.0, 115.1, 114.9, 82.8, 80.0, 60.1, 59.9, 56.2, 48.6, 45.1, 41.9, 39.0, 36.2, 32.7, 
29.6, 25.4, 24.7 and 24.6 m/z 473.6162 (M+); (Found: M+, 473.6162. C29H35N3O3 requires M, 




Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc (0.1:9.9 
to 1:9) to yield the product as a white powder, (83.0 
mg, 89%); m.p. 102 – 105 °C; Rf (EtOAc) 0.12; νmax 
(DCM)/cm-1 2305 (C≣C), 1741 (C=O), 1672 (C=O) 












































3H, Ar–H), 5.94 (d, 7.8, 1H, H4), 5.25 (s, 1H, H3), 4.71 (t, J 2.1, 2H, H6), 3.76 (m, 1H, H5), 
3.60 (td, J 6.0 and 2.4, 1H, H1), 3.44 (t, J 2.1, 2H, H7), 3.17 (td, J 6.0 and 2.4, 1H, H1), 2.99 
(ddd, J 14.7, 6.0 and 2.4, 1H, H2), 2.86 (ddd, J 14.7, 6.0 and 2.4, 1H, H2), 2.51 (q, J 7.5, 4H, 
H8), 2.0 – 1.1 (m, 10H, cyclohexyl–H), 1.03 (t, J 7.5, 6H, H9); δc (100 MHz; CDCl3) 167.9, 
167.4, 158.2, 136.3, 130.0, 120.9, 115.1, 114.8, 82.9, 79.2, 60.1, 56.3, 48.7, 47.2, 41.0, 39.0, 
36.3, 32.8, 25.4, 24.7, 24.6 and 12.5; m/z 425.5715 (M+); (Found: M+, 425.5715. 
C25H35N3O3 requires M, 425.5712) (Found: C, 70.41; H, 7.98; N, 9.85. requires C, 70.56; H, 




Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc (0.3:9.7 
to 1:9) to yield the product as a white powder, (74.2 
mg, 80%); m.p. 89 – 91 °C; Rf (MeOH/EtOAc, 
0.3:9.7) 0.11; νmax (DCM)/cm-1 2305 (C≣C), 1742 
(C=O), 1672 (C=O) and 1245 (C–N) and 1022 (C–O (ether)); δH (300 MHz; CDCl3) 7.26 (m, 
1H, Ar–H), 6.97 (m, 3H, Ar–H), 6.00 (d, 7.8, 1H, H4), 5.26 (s, 1H, H3), 4.71 (t, J 2.1, 2H, 
H6), 3.76 (m, 1H, H5), 3.61 (td, J 6.0 and 2.4, 1H, H1), 3.44 (t, J 2.1, 2H, H7) , 3.17 (td, J 
6.0 and 2.4, 1H, H1), 2.99 (ddd, J 14.7, 6.0 and 2.4, 1H, H2), 2.86 (ddd, J 14.7, 6.0 and 2.4, 
1H, H2), 2.59 (m, 4H, H8), 1.78 (m, 4H, H9), 2.1 – 1.0 (m, 10H, cyclohexyl–H); δc (100 
MHz; CDCl3) 167.9, 167.4, 158.2, 136.4, 130.0, 121.0, 120.9, 115.1, 114.9, 83.7, 78.8, 60.0, 
56.3, 52.6, 48.7, 43.3, 39.0, 36.3, 32.7, 32.6, 25.4, 24.7, 24.6 and 23.8; m/z 423.5558 (M+); 
(Found: M+, 423.5558. C25H33N3O3 requires M, 423.5553) (Found: C, 70.67; H, 7.81; N, 
































Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc (0.3:9.7) 
to yield the product as a white powder, (70.8 mg, 
73%); m.p. 107 – 109 °C; Rf (MeOH/EtOAc, 0.3:9.7) 
0.24; νmax (DCM)/cm-1 2305 (C≣C), 1741 (C=O), 
1672 (C=O) and 1262 (C–N) and 1015 (C–O (ether)); δH (300 MHz; CDCl3) 7.29 (m, 1H, 
Ar–H), 6.96 (m, 3H, Ar–H), 5.92 (d, 7.8, 1H, H4), 5.25 (s, 1H, H3), 4.71 (t, J 1.8, 2H, H6), 
3.78 (m, 1H, H5), 3.60 (td, J 5.7 and 2.4, 1H, H1), 3.28 (t, J 1.8, 2H, H7), 3.17 (td, J 5.7 and 
2.4, 1H, H1), 3.01 (ddd, J 14.7, 5.7 and 2.4, 1H, H2), 2.87 (ddd, J 14.7, 5.7 and 2.4, 1H, H2), 
2.45 (m, 4H, CH2’s), 1.9 – 1.0 (m, 16H, CH2’s); δc (100 MHz; CDCl3) 167.9, 167.4, 136.3, 
130.1, 121.0, 115.1, 114.9, 83.5, 79.3, 60.1, 56.4, 53.4, 48.7, 47.9, 39.0, 36.3, 32.8, 25.9, 
25.4, 24.7, 24.6 and 23.8; m/z 437.5827 (M+); (Found: M+, 437.5827. C26H35N3O3 requires 
M, 437.5822) (Found: C, 71.61; H, 8.14; N, 9.61. requires C, 71.37; H, 8.06; N, 9.60%). 
 
N-Cyclohexyl-2-{3-[(4-morpholin-4-ylbut-2-ynyl)oxy]phenyl}-2-(2-oxoazetidin-1-yl)aceta
mide, BL17  
Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc 
(0.1:9.9 to 1:9) to yield the product as a white 
powder, (74.2 mg, 77%); m.p. 102 – 105 °C; Rf 
(EtOAc) 0.17; νmax (DCM)/cm-1 2305 (C≣C), 1740 
(C=O), 1682 (C=O) and 1263 (C–N) and 1031 (C–O (ether)) δH (300 MHz; CDCl3) 7.29 (m, 












































H6), 3.71 (m, 4H, H9 + H5), 3.61 (td, J 5.4 and 2.4, 1H, H1), 3.33 (t, J 1.8, 2H, H7) , 3.15 
(td, J 5.4 and 2.4, 1H, H1), 2.99 (ddd, J 14.7, 5.4 and 2.4, 1H, H2), 2.85 (ddd, J 14.7, 5.4 and 
2.4, 1H, H2), 4.50 (m, 4H, H8), 1.9 – 1.0 (m, 10H, cyclohexyl–H); δc (100 MHz; CDCl3) 
167.8, 167.4, 158.1, 136.4, 130.0, 120.9, 115.4, 114.9, 82.5, 80.2, 66.8, 59.7, 56.2, 52.1, 48.7, 
47.4, 38.9, 36.3, 32.8, 25.5, 24.8 and 24.7; m/z 439.5552 (M+); (Found: M+, 439.5552. 
C25H33N3O4 requires M, 439.5547) (Found: C, 68.45; H, 7.67; N, 9.40. requires C, 68.31; H, 
7.57; N, 9.56%) 
 
N-Cyclohexyl-2-(2-oxoazetidin-1-yl)-2-(3-{[4-(4-isopropylpiperazin-1-yl)but-2-ynyl]oxy} 
phenyl)acetamide, BL18  
Crude residue was purified via column 
chromatography, eluting with MeOH/DCM 
(0.5:9.5) to yield the product as a light yellow 
oil, (91.0 mg, 86%); Rf (MeOH/DCM, 0.5:9.5) 
0.26; νmax (DCM)/cm-1 2305 (C≣C), 1740 
(C=O), 1675 (C=O) and 1265 (C–N) and 1022 (C–O (ether)); δH (400 MHz; CDCl3) 7.26 (m, 
1H, Ar–H), 6.93 (m, 3H, Ar–H), 6.06 (br s, 1H, H4), 5.25 (s, 1H, H3), 4.67 (t, J 2.0, 2H, H6), 
3.73 (m, 1H, H5), 3.59 (td, J 5.6 and 2.8, 1H, H1), 3.29 (t, J 2.0, 2H, H7) , 3.16 (td, J 5.6 and 
2.8, 1H, H1), 2.96 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 2.83 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 
2.65 (septet, J 6.4, 1H, H10), 2.56 (br s, 8H, H8 + H9), 2.0 – 1.1 (m, 10H, cyclohexyl–H), 
1.02 (d, J 6.4, 6H, H11); δc (100 MHz; CDCl3) 167.9, 167.8, 167.4, 158.2, 136.4, 130.1, 
120.9, 115.1, 115.0, 114.9, 83.0, 79.7, 59.9, 56.3, 52.3, 48.7, 48.4, 47.1, 39.0, 36.3, 32.8, 





































acetamide, BL19  
Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc 
(0.5:9.5) to yield the product as a white powder, 
(67.4 mg, 65%); m.p. 115 – 117 °C; Rf 
(MeOH/EtOAc, 0.3:9.7) 0.14; νmax (DCM)/cm-1 
2305 (C≣C), 1741 (C=O), 1672 (C=O) and 1265 (C–N) and 1025 (C–O (ether)); δH (400 
MHz; CDCl3) 7.25 (m, 1H, Ar–H), 6.92 (m, 3H, Ar–H), 6.18 (d, J 8.0, 1H, H4), 5.29 (s, 1H, 
H3), 4.67 (t, J 1.6, 2H, H6), 3.73 (m, 1H, H5), 3.59 (td, J 5.6 and 2.8, 1H, H1), 3.31 (t, J 1.6, 
2H, H7), 3.17 (td, J 5.6 and 2.8, 1H, H1), 2.95 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 2.83 (ddd, 
J 14.8, 5.6 and 2.8, 1H, H2), 2.56 (br s, 4H, H8), 2.17 (br s, 2H, cyclohexyl–H), 1.84 (br s, 
4H, H9), 1.7 – 1.1 (m, 8H, cyclohexyl–H); δc (100 MHz; CDCl3) 167.9, 167.4, 158.1, 136.4, 
130.1, 120.9, 115.0, 114.9, 114.8, 82.7, 80.0, 59.8, 59.7, 56.3, 51.7, 48.7, 47.0, 39.1, 36.3, 
32.8, 25.5, 24.8, 24.7; m/z 438.5704 (M+); (Found: M+, 438.5704. C25H34N4O3 requires M, 
438.5700) (Found: C, 68.20; H, 7.53; N, 12.59. requires C, 68.47; H, 7.81; N, 12.77%). 
 
3-[(4-Morpholin-4-ylbut-2-ynyl)oxy]benzaldehyde, 8  
Crude residue was purified via column chromatography, 
eluting with MeOH/EtOAc (0.3:9.7) to yield the product as a 
light-yellow oil, (1.57 g, 88%); Rf (Hex/EtOAc, 2:8) 0.26; νmax 
(DCM)/cm-1 3058 (C–H (aromatic)), 2862 and 2812 (C–H 
(aldehyde)), 2312 (C≣C), 1700 (C=O), 1586 (C=C (aromatic)), 1478 (C–C (aromatic)) 
and1266 (C–N); δH (300 MHz; CDCl3) 9.97 (s, 1H, H1), 7.48 (m, 3H, Ar–H), 7.23 (m, 1H, 










































δc (100 MHz; CDCl3) 191.8, 158.2, 137.8, 130.1, 124.1, 122.3, 113.5, 83.1, 79.6, 66.8, 56.3, 




1-yl)acetamide, BL20  
Crude residue was purified via column 
chromatography, eluting with EtOAc to yield the 
product as a light-brown oil, (0.172 g, 97%); Rf 
(EtOAc) 0.22; νmax (DCM)/cm-1 2304 (C≣C), 1743 
(C=O), 1282 (C=O), 1262 (C–N) and 1031 (C–O 
(ether)); δH (400 MHz; CDCl3) 7.39 (d, J 8.8, 2H, H5), 7.27 (m, 1H, Ar–H), 7.04 (m, 2H, 
Ar–H), 6.93 (m, 1H, Ar–H), 6.80 (d, J 8.8, 2H, H6), 5.51 (s, 1H, H4), 5.26 (s, 1H, H3), 4.70 
(s, 2H, H8), 3.74 (s, 3H, H7), 3.67 (m, 5H, H11 + H1), 3.28 (s, 2H, H9), 3.19 (td, J 5.6 and 
2.8, 1H, H1), 2.99 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 2.85 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 
2.45 (ddd, J 11.2, 6.0 and 3.2, 4H, H10); δc (100 MHz; CDCl3) 168.1, 166.5, 158.1, 156.6, 
135.9, 130.8, 130.2, 121.7, 120.9, 115.9, 114.8, 114.1, 82.6, 80.3, 66.8, 60.2, 65.8, 56.2, 55.5, 
51.9, 47.3, 39.2, 36.3 and 15.2; m/z 463.5340 (M+); (Found: M+, 463.5340. C26H29N3O5 











































din-1-yl)acetamide, BL21  
Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc 
(0.1:9.9) to yield the product as a white powder, 
(0.110 g, 62%); m.p. 86 – 89 °C; Rf (EtOAc) 0.38; 
νmax (DCM)/cm-1 2305 (C≣C), 1737 (C=O), 1694 
(C=O) and 1266 (C–N) and 1035 (C–O (ether)); δH (400 MHz; CDCl3) 7.27 (m, 1H, Ar–H), 
6.93 (m, 3H, Ar–H), 5.93 (s, 1H, H4), 5.19 (s, 1H, H3), 4.69 (s, 2H, H8), 3.69 (m, 4H, H11), 
3.59 (td, J 5.6 and 6.0, 1H, H1), 3.30 (s, 2H, H9), 3.14 (td, J 6.0 and 2.8, 1H, H1), 2.95 (ddd, 
J 14.8, 6.0 and 2.8, 1H, H2), 2.84 (ddd, J 14.8, 6.0 and 2.8, 1H, H2), 2.49 (m, 4H, H10), 1.74 
(d, J 14.8, 1H, H6), 1.56 (d, J 14.8, 1H, H6), 1.38 (s, 3H, H5), 1.34 (s, 3H, H5), 0.89 (s, 9H, 
H7); δc (100 MHz; CDCl3) 168.1, 167.2, 155.6, 130.1, 121.1, 115.2, 115.0, 82.5, 80.1, 66.8, 
65.8, 60.4, 56.2, 55.8, 52.1, 52.0, 47.4, 39.0, 36.3, 31.7, 31.6, 31.5, 31.4, 29.0 and 28.7; m/z 
469.6256 (M+); (Found: M+, 469.6256. C27H39N3O4 requires M, 469.6244) (Found: C, 69.13; 




Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc 
(0.1:9.9) to yield the product as a colourless oil, 
(0.148 g, 91%); Rf (EtOAc) 0.33; νmax (DCM)/cm-1 
2305 (C≣C), 1735 (C=O), 1695 (C=O), 1266 (C–N) 




















































6.10 (m, 1H, H4), 5.29 (s, 1H, H3), 4.69 (s, 2H, H6), 3.95 (m, 1H, H5), 3.68 (m, 4H, H9), 
3.60 (td, J 5.6 and 3.2, 1H, H1), 3.30 (s, 2H, H7), 3.12 (td, J 5.6 and 3.2, 1H, H1), 2.94 (ddd, 
J 14.8, 5.6 and 3.2, 1H, H2), 2.85 (ddd, J 14.8, 5.6 and 3.2, 1H, H2), 2.48 (m, 4H, H8), 1.4 – 
0.7(m, 10H, alkyl–H); δc (100 MHz; CDCl3) 167.8, 167.6, 158.1, 136.4, 130.1, 120.9, 115.4, 
114.9, 82.5, 80.2, 66.8, 65.8, 59.7, 59.6, 56.2, 52.0, 47.4, 45.5, 45.4, 38.9, 38.8, 36.3, 27.3 
and 27.2; m/z 427.5444 (M+); (Found: M+, 427.5444. C24H33N3O4 requires M, 427.5437). 
 
N-2-Naphthyl-2-{3-[(4-morpholin-4-ylbut-2-ynyl)oxy]phenyl}-2-(2-oxoazetidin-1-yl)aceta
mide, BL23  
Crude residue was purified via column 
chromatography, eluting with Hex/EtOAc (3:7) to 
EtOAc, to yield the product as a light-brown oil, 
(0.152 g, 82%); Rf (EtOAc) 0.26; νmax (DCM)/cm-1 
2305 (C≣C), 1737 (C=O), 1694 (C=O), 1266 
(C–N) and 1021 (C–O (ether)); δH (400 MHz; CDCl3) 7.73 (m, 3H, Ar–H), 7.4 – 7.2 (m, 5H, 
Ar–H), 7.08 (m, 2H, Ar–H), 6.95 (m, 1H, Ar–H), 5.60 (s, 1H, H4), 5.26 (s, 1H, H3), 4.71 (s, 
2H, H5), 3.71 (m, 5H, H8 + H1), 3.25 (m, 3H, H6 + H1), 3.03 (ddd, J 14.8, 5.6 and 2.8, 1H, 
H2), 2.92 (ddd, J 14.8, 5.6 and 2.8, 1H, H2), 2.45 (m, 4H, H7); δc (100 MHz; CDCl3) 168.3, 
167.0, 158.1, 135.7, 135.2, 133.8, 130.8, 130.2, 128.7, 127.7, 127.5, 126.5, 125.1, 120.9, 
119.8, 116.9, 116.0, 114.8, 82.6, 80.2, 66.8, 65.8, 60.6, 56.2, 51.9, 47.3, 39.3 and 36.3; m/z 




































(2-oxoazetidin-1-yl)acetamide, BL24  
Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc 
(0.1:9.9 to 0.3:9.7 ), to yield the product as a 
light-brown oil, (0.143 g, 69%); Rf (EtOAc) 0.16; 
νmax (DCM)/cm-1 2305 (C≣C), 1745 (C=O), 1700 
(C=O), 1324 (O=S=O), 1266 (C–N), 1145 (O=S=O) and 1031 (C–O (ether)); δH (400 MHz; 
CDCl3) 7.64 (m, 3H, Ar–H), 7.25 (m, 2H, Ar–H), 6.94 (m, 1H, Ar–H), 6.89 (m, 1H, Ar–H), 
6.77 (m, 1H, Ar–H), 5.36 (s, 1H, H3), 4.74 (dd, J 14.0 and 6.8, 1H, H5), 4.72 (s, 2H, H7), 
4.51 (dd, J 14.0 and 6.8, 1H, H5), 3.70 (m, 4H, H10), 3.41 (td, J 5.6 and 2.8, 1H, H1), 3.34 
(s, 2H, H8), 3.02 (td, J 5.6 and 2.8, 1H, H1), 2.90 (ddd, J 14.4, 5.6 and 2.8, 1H, H2), 2.81 
(ddd, J 14.4, 5.6 and 2.8, 1H, H2), 2.51 (m, 4H, H9), 2.41 (s, 3H, -OCH3); δc (100 MHz; 
CDCl3) 168.3, 167.7, 158.0, 145.3, 134.9, 134.0, 130.1, 130.0, 128.8, 121.0, 116.1, 114.9, 
82.3, 80.5, 66.7, 66.6, 65.8, 60.2, 59.0, 56.1, 52.3, 51.9, 47.3, 38.8, 36.3, 21.7 and 15.3; m/z 




Crude residue was purified via column 
chromatography, eluting with MeOH/EtOAc 
(0.3:9.7 ), to yield the product as a light-brown oil, 
(0.168 g, 99%); Rf (MeOH/EtOAc, 0.3:9.7) 0.26; 
νmax (DCM)/cm-1 2306 (C≣C), 1745 (C=O), 1683 




















































7.12 (m, 3H, Ar–H), 6.95 (m, 3H, Ar–H), 6.76 (br s, 1H, H4), 5.37 (s, 1H, H3), 4.67 (m, 2H, 
H6), 4.43 (dd, J 14.8 and 6.0, 1H, H5), 4.38 (dd, J 14.8 and 6.0, 1H, H5), 3.60 (m, 5H, H9 + 
H1), 3.28 (s, 2H, H7), 3.12 (td, J 5.6 and 2.8, 1H, H1), 2.93 (ddd, J 14.8, 5.6 and 2.4, 1H, 
H2), 2.82 (ddd, J 14.8, 5.6 and 2.4, 1H, H2), 2.45 (m, 4H, H8); δc (100 MHz; CDCl3) 168.4, 
167.9, 158.1, 137.8, 136.0,130.1, 128.7, 127.7, 127.5, 121.0, 115.6, 115.0, 82.5, 80.2, 66.7, 
59.6, 56.2, 52.0, 47.3, 43.7, 39.0, 36.3 and 29.7; m/z 447.5351 (M+); (Found: M+, 437.5351. 
C26H29N3O4 requires M, 447.5340). 
 
N-(1H-1,2,3-Benzotriazol-1-ylmethyl)-2-{3-[(4-morpholin-4-ylbut-2-ynyl)oxy]phenyl}-2- 
(2-oxoazetidin-1-yl)acetamide, BL26  
Crude residue was purified via column 
chromatography, eluting with EtOAc to yield the 
product as a brown powder, (0.113 g, 60%); m.p. 
131 – 134 °C; Rf (MeOH/DCM, 0.5:9.5) 0.21; νmax 
(DCM)/cm-1 2304 (C≡C), 2163 (N=N/N–N), 1743 
(C=O), 1705 (C=O), 1265 (C–N) and 1035 (C–O (ether)); δH (400 MHz; CDCl3) 8.15 (t, J 
6.4, 1H, H4) 7.98 (dt, J 8.4 and 2.0, 1H, H11), 7.87 (dt, J 8.4 and 2.0, 1H, H13), 7.48 (td, J 
7.6 and 1.6, 1H, H7/H8), 7.35 (td, J 7.6 and 1.6, 1H, H7/H8), 7.11 (t, J 8.4, 1H, H12), 6.84 
(dd, J 7.6 and 1.6, 1H, H6/H9), 6.80 (t, J 2.0, 1H, H10), 6.70 (dd, J 7.6 and 1.6, 1H, H6/H9), 
6.11 (dd, J 14.0 and 6.4, 1H, H5), 5.99 (dd, J 14.0 and 6.4, 1H, H5), 5.38 (s, 1H, H3), 4.55 (t, 
J 1.6, 2H, H14), 3.66 (m, 4H, H17), 3.51 (td, J 5.6 and 2.8, 1H, H1), 3.28 (t, J 1.6, 2H, H15), 
3.04 (td, J 5.6 and 2.8, 1H, H1), 2.91 (ddd, J 14.4, 5.6 and 2.8, 1H, H2), 2.80 (ddd, J 14.4, 
5.6 and 2.8, 1H, H2), 2.43 (m, 4H, H16); δc (100 MHz; CDCl3) 169.5, 169.4, 167.9, 158.0, 
146.0, 135.0, 130.1, 128.0, 124.0, 120.8, 119.7, 116.1, 114.9, 110.7, 82.5, 80.2, 66.8, 59.2, 










































C26H28N6O4 requires M, 488.5461) (Found: C, 64.28.; H, 6.05; N, 17.29. requires C, 63.92; 
H, 5.78; N, 17.20%) 
 
2-(7-Chloroquinolin-4-ylamino)-ethanol, 4a 
Triethylamine (0.2 ml, 1.52 mmol, 0.3 eq) was added drop-wise 
to a solution of 4,7-dichloroquinoline (1.00 g, 5.04 mmol, 1.0 
eq) and K2CO3 (0.34 g, 2.52 mmol, 0.5 eq) in ethanolamine (6.4 
ml, 20.0 eq), and refluxed at 140 °C for 4 hours. The product 4a 
precipitated on cooling, and was filtered and washed with brine and H2O. Pure product was 
recrystallised from MeOH as white powder (1.071 g, 95%). m.p. 213 – 215 °C (lit. 214 °C)8. 
Rf (MeOH/DCM, 1:9) 0.17. δH (400 MHz; DMSO-d6) 8.36 (d, J 5.6, 1H, H2), 8.23 (d, J 8.8, 
1H, H5), 7.76 (d, J 2.0, 1H, H8), 7.41 (dd, J 8.8 and 2.4, 1H, H6), 7.21 (t, J 5.6, 1H, NH), 
6.48 (d, J 5.2, 1H, H3), 4.80 (t, J 5.2, 1H, OH), 3.64 (t, J 5.6, 2H, H9), 3.35 (q, J 5.6, 2H, 
H10).  
 
Methanesulfonic acid 2-(7-chloroquinolin-4-ylamino)-ethyl ester, 4b 
A solution of 4a (0.90 g, 4.041 mmol, 1.0 eq) in pyridine 
(3.7 ml) was stirred at 0 °C for 30 min, after which a 
solution of methanesulfonyl chloride (0.78 ml, 2.5 eq) was 
added drop-wise. After stirring further for 5 hours at 0 °C, 
the mixture was diluted with 25% aqueous ammonium hydroxide solution until pH 8, 
extracted with EtOAc (3 x 20 ml), dried (Na2SO4) and solvent evaporated. The residue was 
recrystallised from MeOH/H2O to yield white needle-like crystals (1.095 g, 90 %). m.p. 
138 – 140 °C (lit. 138 – 140 °C)9. Rf (MeOH/DCM, 1:9) 0.41. δH (400 MHz; DMSO-d6) 










































2.4, 1H, H6), 7.45 (t, J 5.6, 1H, NH), 6.57 (d, J 5.6, 1H, H3), 4.41 (t, J 5.6, 2H, H10), 3.65 (q, 
J 5.6, 2H, H9), 3.14 (s, 3H, H11).  
 
4-[2-(7-Chloroquinolin-4-ylamino)-ethoxy]-benzaldehyde, 4c 
4-Hydroxybenzaldehyde (2.284 g, 18.70 mmol, 1.5 
eq), 4b (3.750 g, 12.47 mmol, 1.0 eq) and K2CO3 
(2.757 g, 19.95 mmol, 1.6 eq) were stirred in DMF 
(100 ml) and refluxed between 140 – 150 °C for 5 
hours. Upon cooling, the mixture was diluted with H2O (100 ml), extracted with EtOAc (3 x 
200 ml), washed with brine (200 ml), dried (Na2SO4) and solvent evaporated to yield the 
crude product as brown powder. As the product is slightly soluble in EtOAc, the crude 
product was washed with EtOAc (10 ml) to remove excess benzaldehyde, filtered and 
recrystallised from MeOH/H2O to yield cream-coloured powder (3.10 g, 76%). m.p. 179 – 
181 °C (lit. 175 – 176 °C)9. Rf (MeOH/DCM, 0.5:9.5) 0.18. δH (300 MHz; DMSO-d6) 9.86 
(s, 1H, H13), 8.42 (d, J 5.1, 1H, H2), 8.26 (d, J 9.0, 1H, H5), 7.84 (d, J 8.4, 2H, H12), 7.79 
(d, J 2.1, 1H, H8), 7.47 (t, J 5.1, 1H, NH), 7.43 (dd, J 8.7 and 1.8, 1H, H6), 7.13 (d, J 8.7, 




The amine 4d (0.5 g, 2.255 mmol, 
1.0 eq) and aldehyde QN01 (0.737 
g, 2.255 mmol, 1.0 eq) were stirred 



































































N2 at room temperature for 5 hours Sodium borohydride (0.171 g, 2.510 mmol, 2.0 eq) was 
added, and the reaction mixture was stirred further overnight. The sodium borohydride was 
destroyed by the slow addition of H2O (50 ml), extracted with DCM (3 x 100 ml), dried 
(Na2SO4) and solvent evaporated to yield 4e as light brown crystals (1.115 g, 92.8 %). m.p. 
79 – 81 °C. Rf (MeOH/DCM/NH4OH, 0.5:9.5:0.1) 0.44. νmax (CHCl3)/cm-1 3290 (N-H), 
3017 (Ar-H), 2942 (CH2’s), 1582 (Ar-C), 1215 (C-N) 753 (C-Cl); δH (400 MHz; DMSO-d6) 
8.40 (d, J 5.2, 1H, H20/H2), 8.35 (d, J 5.6, 1H, H2/H20), 8.26 (d, J 9.2, 1H, H23/H5), 8.20 
(d, J 9.2, 1H, H5/H23), 7.78 (d, J 2.4, 1H, H26/H8), 7.76 (d, J 2.4, 1H, H8/H26), 7.45 (s, 1H, 
NH), 7.42 (dd, J 9.2 and 2.4, 1H, H24/H6), 7.40 (dd, J 9.2 and 2.0, 1H, H6/H24), 7.21 (d, J 
8.4, 2H, H15), 7.17 (s, 1H, NH), 6.85 (d, J 8.4, 2H, H14), 6.56 (d, J 5.2, 1H, H21/H3), 6.44 
(d, J 5.2, 1H, H3/H21), 5.73 (s, 2H, H13), 4.20 (d, J 5.6, 2H, H16), 3.66 (m, 4H, H11 + H17), 
2.76 (t, J 6.4, 2H, H10); δc (100 MHz; DMSO-d6) 157.1, 151,9, 151.8, 150.1, 150.0, 149.1, 
149.0, 133.4, 133.3, 133.0, 129.0, 127.8, 127.5, 127.4, 124.1, 124.0, 123.9, 117.4, 114.1, 
114.0, 103.2, 98.8, 98.7, 65.5, 65.5, 52.0, 46.5, 42.5, 41.9; m/z 532.48 (M+); (Found: M+, 
532.48. C29H27Cl2N5O requires M, 532.48) (Found: C, 65.69, H, 5.01, N, 13.37 %; Requires 
C, 65.42, H, 5.11, N, 13.15 %). 
 
General procedure for the synthesis of 6a – 6e 
The amine (0.902 mmol, 1.2 eq) and the aldehyde (0.752 mmol, 1.0 eq) were stirred in 
MeOH (12 ml) at 25 °C for 30 min, followed by the addition of the carboxylic acid (0.752 
mmol, 1.0 eq) and the isocyanide (0.752 mmol, 1.0 eq) drop-wise. After stirring for 3 – 5 


















General procedure for the benzyl alcohols 9a and 9b and benzoic acid 9c. 
4,7-Dichloroquinoline (1.0 eq) and the amine (1.0 eq) were refluxed in EtOH at 80 – 85 °C 
for 3 h. The volume was reduced in vacuo, followed by drop-wise addition of ice-cold 
ammonium hydroxide solution (5%) until pH 8, and the resulting precipitate collected. In the 
case of 10b, sticky oil was formed instead of precipitation. The oil was extracted into DCM, 
washed with H2O, dried over Na2SO4, filtered and solvent reduced.  
 
{3-[(7-Chloroquinolin-4-yl)amino]phenyl}methanol, 9a  
Pure product (0.68 g, 98%) was yielded as cream-coloured 
powder, m.p. 247 – 250 °C; Rf (MeOH/DCM, 0.5:9.5) 0.23; 
νmax (DCM)/cm-1 3260 (O–H), 2880 (C–O) and 1358 (O–H 
bend); δH (400 MHz; DMSO-d6) 9.07 (s, 1H, NH), 8.44 (d, 
J 5.3, 1H, H2), 8.42 (d, J 8.8, 1H, H5), 7.87 (d, J 2.2, 1H, 
H8), 7.54 (dd, J 8.8 and 2.2, 1H, H6), 7.35 (t, J 7.9, 1H, H10), 7.33 (s, 1H, H12), 7.21 (d, J 
7.9, 1H, H9), 7.09 (d, J 7.9, 1H, H11), 6.91 (d, J 5.3, 1H, H3), 5.22 (s, 1H, OH) and 4.52 (s, 
2H, H13); δc (75.5 MHz; DMSO-d6) 151.8, 149.5, 148.0, 144.0, 139.9, 133.8, 129.0, 127.5, 
124.8, 124.4, 122.0, 120.8, 120.5, 118.2, 101.7 and 62.6; m/z 284.7441 (M+); (Found: M+, 
284.7441. C16H13ClN2O requires M, 284.7450) (Found: C, 67.66; H, 4.41; N, 9.50. requires 
C, 67.69; H, 4.60; N, 9.84%). 
 
{2-[(7-Chloroquinolin-4-yl)amino]phenyl}methanol, 9b 
The crude residue was washed with DCM (30ml) to yield pure 
9b (3.0 g, 45%) as white needles, m.p. 194 – 197 °C; Rf 












































2881 (C–O) and 1358 (O–H bend); δH (300 MHz; DMSO-d6) 8.80 (br s, 1H, NH), 8.38 (d, J 
8.7, 1H, H5), 8.36 (d, J 5.4, 1H, H2), 7.89 (d, J 2.4, 1H, H8), 7.61 (d, J 7.2, 1H, H9 or 12), 
7.56 (dd, J 8.7 and 2.4, 1H, H6), 7.33 (m, 3H, Ar-H), 6.29 (d, J 5.4, 1H, H3) and 4.50 (s, 2H, 
H13); δc (75.5 MHz; DMSO-d6) 151.8, 149.3, 149.0, 138.1, 136.6, 133.7, 128.0, 127.8, 
127.6, 126.0, 125.9, 123.9, 117.6, 101.0 and 59.4; m/z 284.7445 (M+); (Found: M+, 284.7445. 
C16H13ClN2O requires M, 284.7450) (Found: C, 67.89; H, 4.26; N, 9.96. C16H13ClN2O 
requires C, 67.69; H, 4.60; N, 9.84%). 
 
4-[(7-Chloroquinolin-4-yl)amino]benzoic acid, 9c  
Pure product (0.68 g, 98%) was collected as light yellow 
powder, m.p. >326 °C; Rf (MeOH/DCM, 0.8:9.2) 0.24; νmax 
(DCM)/cm-1 3038 (O–H), 1569 (C=O) and 1384 (C–O); δH 
(400 MHz; DMSO-d6) 8.492 (d, J 5.6, 1H, H2), 8.429 (d, J 
8.8, 1H, H5), 7.910 (d, J 8.0, 1H, H10), 7.893 (d, J 2.4, 1H, 
H8), 7.544 (dd, J 8.8 and 2.4, 1H, H6), 7.317 (d, J 8.0, 2H, H9) and 7.054 (d, J 5.6, 1H, H3); 
δc (100 MHz; DMSO-d6) 168.2, 152.1, 149.8, 147.5, 142.3, 134.0, 131.8, 130.4 (x2), 127.8, 
125.2, 124.4 (x2), 120.3, 118.5 and 103.1; m/z 298.7298 (M+); (Found: M+, 298.7298. 
C16H11ClN2O2 requires M, 298.7285) (Found: C, 64.07; H, 4.17; N, 9.55. requires C, 64.33; 
H, 3.71; N, 9.38%). 
 
General procedure for aldehydes 11a and 11b 
SO3·Pyr (2.0 eq) was added to a solution of the benzyl alcohol 10a (10b) (1.0 eq) and Et3N 
(4.0 eq) in DMSO and stirred for 2 days at 26 °C. The reaction mixture was diluted with 
EtOAc, washed with H2O (2 times) and brine, dried over Na2SO4, filtered and solvent 































Crude product isolated as cream-coloured powder (1.44 g, 
58%). 1H NMR shows that the crude material contained 
only 58% of the desired product. Attempts of purification 
were unsuccessful, as product was too polar and could only 
be dissolved in DMSO, which was difficult to be 
chromatographed. Hence the crude product was used for the subsequent reactions.  
 
2-[(7-Chloroquinolin-4-yl)amino]benzaldehyde, 11b  
The crude residue was washed with DCM (10 ml) and the 
aldehyde 11b (0.97 g, 94%) was collected as light yellow 
powder, m.p. 164 – 166 °C; Rf (EtOAc/Hex, 7:3) 0.74; νmax 
(DCM)/cm-1 2829, 2749 (aldehydic C–H stretch), 1668 (C=O) 
and 1378 (aldehydic C–H bend); δH (300 MHz; DMSO-d6) 
10.25 (s, 1H, NH), 10.07 (s, 1H, H13), 8.61 (d, J 5.1, 1H, H2), 8.27 (d, J 9.0, 1H, H5), 7.98 
(d, J 1.8, 1H, H8), 7.93 (dd, J 7.5 and 1.8, 1H, H12), 7.68 (m, 2H, H9 and H10), 7.28 (t, J 
7.5, 1H, H11), 7.62 (d, J 8.4, 1H, H6) and 7.20 (d, J 5.4, 1H, H3); δc (75.5 MHz; DMSO-d6) 
193.9, 152.1, 149.4, 145.8, 142.9, 135.7, 134.2, 133.8, 128.0, 126.2, 125.2, 123.5, 122.8, 
120.0 and 105.4; m/z 282.7298 (M+); (Found: M+, 282.7298. C16H11ClN2O requires M, 
282.7291) (Found: C, 68.23; H, 3.67; N, 10.04. Requires C, 67.97; H, 3.92; N, 9.91%). 
 
General method for the amines 12a, 12b and 13a 
The aldehyde 11a (11b) (1.0 eq) was dissolved in MeOH/DMF (5:2), followed by the 
drop-wise addition of the amine (1.0 eq) and stirred at 26 °C for 5 h. NaBH4 (2.0 eq) was 















































NaCNBH3 was used as the reducing agent). The borohydride was destroyed by the slow 
addition of H2O, and the mixture extracted with DCM. The combined organic layer was 
washed with H2O (3 times), dried over Na2SO4, filtered and solvent removed in vacuo. The 
residue was purified by column chromatography slowly increasing the polarity from 0.2 : 9.8 
to 1 : 9 : 0.1 MeOH/DCM/Et3N to yield the pure product. 
 
7-Chloro-N-{3-[(isopropylamino)methyl]phenyl}quinolin-4-amine, 12a 
The product was yielded as beige-coloured powder (0.07 g, 
77%), m.p. 124 – 127 °C; Rf (MeOH/DCM, 0.5:9.5) 0.14; 
νmax (DCM)/cm-1 3458 (N-H), 2963 (CH3) and 1164 (C–N); 
δH (400 MHz; CDCl3) 8.54 (d, J 5.3, 1H, H2), 8.01 (d, J 
2.0, 1H, H8), 7.88 (d, J 9.0, 1H, H5), 7.43 (dd, J 9.0 and 
2.0, 1H, H6), 7.35 (t, J 7.7, 1H, H10), 7.29 (br s, 1H, H12), 7.19 (br d, J 7.7, 1H, H9), 7.15 
(br d, J 7.9, 1H, H11), 6.96 (d, J 5.3, 1H, H3), 3.81 (s, 1H, H13), 2.90 (septet, J 6.2, 1H, H14) 
and 1.13 (d, J 6.2, 6H, 2 x CH3); δc (100 MHz; DMSO-d6) 151.9, 149.5, 148.0, 142.1, 140.0, 
133.8, 129.0, 127.6, 124.8, 124.4, 123.8, 122.2, 120.9, 118.3, 91.4, 50.0, 47.4 and 22.4; m/z 
325.8415 (M+); (Found: M+, 325.8415. C19H20ClN4 requires M, 325.8409) (Found: C, 69.28; 
H, 6.14; N, 12.97. requires C, 70.04; H, 6.19; N, 12.90%). 
 
7-Chloro-N-{2-[(isopropylamino)methyl]phenyl}quinolin-4-amine, 12b 
Product yielded as beige-coloured powder (0.22 g, 65%), 
m.p. 118 – 121 °C; Rf (MeOH/DCM, 0.5:9.5) 0.26; νmax 
(DCM)/cm-1 3458 (N–H), 2960 (CH3) and 1162 (C–N); 















































J 9.0, 1H, H5), 8.006 (d, J 2.1, 1H, H8), 7.562 (dd, J 8.4 and 0.9, 1H, H9), 7.423 (dd, J 9.0 
and 2.1, 1H, H6), 7.332 (m, 2H, H10 and H11), 7.079 (dd, J 8.7 and 0.9, 1H, H12), 7.042 (d, 
J 5.4, 1H, H3), 3.881 (s, 2H, H13), 2.945 (septet, J 6.3, 1H, H14) and 1.210 (d, J 6.3, 6H, 2 x 
CH3); δc (75.5 MHz; CDCl3) 155.6, 151.9, 149.8, 140.7, 135.2, 130.8, 129.7, 128.6, 125.7 
(x2), 123.4, 122.7, 118.85, 107.0, 101.6, 49.0, 45.7, 22.5 and 9.1; m/z 325.8417 (M+); 
(Found: M+, 325.8417. C19H20ClN4 requires M, 325.8409) (Found: C, 69.29; H, 6.12; N, 
12.60. requires C, 70.04; H, 6.19; N, 12.90%). 
 
7-Chloro-N-{3-[(diethylamino)methyl]phenyl}quinolin-4-amine, 13a 
Product yielded as beige-coloured powder (0.16 g, 68%), 
m.p. 142 – 145 °C; Rf (MeOH/DCM, 0.5:9.5) 0.14; νmax 
(DCM)/cm-1 2968 (CH3) and 1158 (C–N); δH (400 MHz; 
CDCl3) 8.600 (d, J 5.2, 1H, H2), 8.05 (d, J 2.4, 1H, H8), 
7.93 (d, J 8.8, 1H, H5), 7.79 (s, 1H, H12), 7.47 (dd, J 
8.8 and 2.4, 1H, H6), 7.34 (t, J 7.6, 1H, H10), 7.23 (d, J 7.6, 1H, H9), 7.15 (d, J 7.6, 1H, 
H11), 7.01 (d, J 5.2, 1H, H3), 3.67 (s, 2H, H13), 2.64 (q, J 7.2, 4H, 2 x H14) and 1.11 (t, J 
7.2, 6H, 2 x CH3); δc (100 MHz; DMSO-d6) 151.8, 149.5, 148.0, 140.0, 133.8, 129.0, 127.6, 
124.8, 124.4, 124.2, 122.6, 122.0, 120.9, 120.5, 101.7, 62.6, 56.6, 46.2 and 11.5 (x2); m/z 
339.8681 (M+); (Found: M+, 339.8681. C20H22ClN3 requires M, 339.8676) (Found: C, 70.88; 
H, 6.22; N, 12.42. requires C, 70.68; H, 6.57; N, 12.36%). 
 
General procedure for the Wittig products 14a and 14b 
Ethyl bromoacetate (1.0 eq) was added drop-wise to a solution of triphenylphosphine (1.2 eq) 
in tolune under N2, and stirred for 8 h. The mixture was left standing overnight at rt for 































phosphonium salt. The salt was dissolved in anhydrous MeOH under N2, followed by the 
drop-wise addition of NaOMe (1.2 eq, dissolved in MeOH) at 0 °C and stirred for 20 min. 
The aldehyde 11a (11b) (0.9 eq) was then added to the mixture, and stirred further at 26 °C 
under N2. Equal amounts of H2O and aqueous NaHCO3 were added to the reaction mixture, 
and the resulting mixture extracted with EtOAC (3 times), washed with brine, dried over 
Na2SO4, filtered and solvent removed in vacuo. 
 
Ethyl (2E)-3-{3-[(7-chloroquinolin-4-yl)amino]phenyl}acrylate, 14a 
Crude residue was purified via column 
chromatography, eluting with Hex/EtOAc (3:7) to 
yield the product 14a (0.09 g, 76%) as 
beige-coloured powder, m.p. 75 – 78 °C; Rf 
(EtOAc/Hex, 7:3) 0.49; νmax (DCM)/cm-1 2925 
(alkyl), 1710 (C=O), 1638 (C=C (alkene)), 1179 (C–C–O) and 1036 (O–C–C); δH (400 MHz; 
DMSO-d6) 9.11 (s, 1H, H12), 8.48 (d, J 5.2, 1H, H2), 8.41 (d, J 9.2, 1H, H5), 7.89 (d, J 2.0, 
1H, H8), 7.65 (d, J 15.6, 1H, H14), 7.56 (dd, J 9.2 and 2.0, 1H, H6), 7.50 (d, J 7.6, 1H, H9), 
7.45 (t, J 7.6, 1H, H10), 7.38 (d, J 7.6, 1H, H11), 6.95 (d, J 5.2, 1H, H3), 6.60 (d, J 15.6, 1H, 
H13), 4.18 (q, J 7.2, 2H, CH2) and 1.24 (t, J 7.2, 3H, CH3); δc (100 MHz; DMSO-d6) 166.0, 
152.0, 149.5, 147.6, 144.0, 140.8, 135.3, 133.9, 130.0, 127.7, 125.0, 124.3, 123.6, 122.0, 
118.7, 118.4, 102.2, 60.0 and 14.1; m/z 352.8209 (M+); (Found: M+, 352.8209. 
C20H17ClN2O2 requires M, 352.8202) (Found: C, 67.92; H, 4.77; N, 7.90. requires C, 68.09; 


































Ethyl (2E)-3-{2-[(7-chloroquinolin-4-yl)amino]phenyl}acrylate, 14b 
Crude residue was purified via column chromatography, 
eluting with MeOH/DCM (0.01:0.99) to yield the product 
14b (0.1 g, 79%) as cream-coloured powder, m.p. 182 – 185 
°C; Rf (DCM) 0.14; νmax (DCM)/cm-1 2919 (alkyl), 1714 
(C=O), 1634 (C=C (alkene)), 1178 (C–C–O) and 1038 
(O–C–C); δH (400 MHz; CDCl3) 8.52 (d, J 5.2, 1H, H2), 8.03 (d, J 2.0, 1H, H8), 7.89 (d, J 
9.0, 1H, H5), 7.80 (d, J 15.6, 1H, H14), 7.45 (dd, J 9.0 and 2.0, 1H, H6), 7.40 (m, 2H, Ar-H), 
7.26 (m, 2H, Ar-H), 6.93 (d, J 5.2, 1H, H3), 6.44 (d, J 15.6, 1H, H13), 3.60 (q, J 7.2, 2H, 
CH2) and 1.28 (t, J 7.2, 3H, CH3); δc (100 MHz; DMSO-d6) 166.1, 151.9, 151.8, 150.5, 
139.7, 139.6, 134.0, 131.7, 127.8, 126.8, 125.0, 124.9, 124.3, 124.2, 119.1, 119.0, 101.8, 
60.0 and 14.0; m/z 352.8210 (M+); (Found: M+, 352.8210. C20H17ClN2O2 requires M, 
352.8202) (Found: C, 67.84; H, 4.72; N, 7.71. requires C, 68.09; H, 4.86; N, 7.94%). 
 
8.2 Biological Testing Protocols 
 
Preparation of stock solution of test compounds 
All compounds were dissolved in DMSO or methanol to the concentration of 4 mg/ml, and 
stored at -20 °C until use. All samples were further diluted in complete medium to their 
desired concentrations on the day of the experiment, whilst ensuring the maximum 
concentration of DMSO or methanol to be under 0.5 % after dilution. Chloroquine was used 
as the positive control in all experiments. The 50 % inhibitory concentration (IC50) values 

































in vitro Activities of compounds against D10, K1 and Dd2 strains of P. falciparum  
All samples were tested in duplicate on at least three occasions against the various strains of 
Plasmodium falciparum. Continuous in vitro cultures of asexual erythrocyte stages of P. 
falciparum were maintained using a modified method of Trager and Jensen.10 Quantitative 
assessment of antiplasmodial activity in vitro was determined via the parasite lactate 
dehydrogenase (pLDH) assay using a modified method described by Makler.11 The pLDH 
assay compares well with other available assays.12 The 50% inhibitory concentration values 
of the compounds were determined at ten different concentrations. 
 
in vitro Activities of compounds against 3D7 strain of P. falciparum using the Luciferase 
assay 
Parasites expressing cytoplasmic luciferase were synchronized at ring stage using 5 % 
sorbitol solution (Sigma) for at least two cycles prior to the assay. Compounds were added to 
ring stage parasites and allowed to grow for 60 hours. To assay the plates, Bright-Glo® 
Luciferase Substrate (Promega) was dispensed. Immediately following, luminescence read 
by an EnVision multilable reader 2102 (Perkin Elmer). Growth in the presence of each 
compound is compared to DMSO controls. 
 
Drug treatments of parasites for Western blotting and Immunofluorescence assays 
Various drugs were added to 1 ml early trophozoite-stage parasite cultures at 1 % 
haematocrit, approximately 10 % parasitaemia, at final concentrations of approximately 5 
times the IC50 values of respective drug. Experiments were performed in 24-well plates in 
triplication, and each plate was incubated at 37 °C for 5 h for Western blotting and 8 h for 
















Incubations were terminated before the parasites enter the schizont stage. This was assessed 
by Giemsa-staining or fluorescence microscopy of 4’,6’-diamidino-2-phenylindole (DAPI) 
stained parasites to ensure there were no more than two nuclei per parasite. 
 
Parasite isolation by saponin lysis 
Incubated parasite samples were collected in microcentrifuge tubes and centrifuged at 750 G 
for 3 min. The supernatant was removed and the infected RBC pellet resuspended in 0.5 ml 
PBS containing 0.1 % (w/v) saponin (Sigma-Aldrich, Steinheim, Germany) to lyse the RBCs. 
Parasites were pelleted at 1500 G for 3 min and washed extensively (5 times) by 
centrifugation in cold PBS to remove RBC membranes and excess haemoglobin. 
 
SDS-PAGE and Western blotting 
SDS-PAGE was performed according to the procedure described by Laemmli.13 Parasite 
pellets of pre-incubated cultures were resuspended in 3 volumes of dH2O and 1 volume of 4 
x reducing SDS-PAGE sample buffer and boiled for 5 min to ensure protein denaturation. 
Samples (20 μl) were electrophoresed on a 10 % sodium dodecyl sulfate polyacrylamide 
(SDS-PAGE) gel at a constant current of 20 mA until properly resolved. Resolved proteins 
were transblotted onto Hybond-ECL nitrocellulose membranes (GE Healthcare) at 100 V for 
approximately 1 h. Membranes were subsequently incubated in blocking solution (2 % (w/v) 
fat-free milk powder, 0.1 % (v/v) Tween in PBS) for 45 min before being incubated in 
blocking solution containing rabbit anti-haemoglobin antiserum (1:1000) (Sigma-Aldrich, 
Steinheim, Germany) for 1 h. The membranes were washed in blocking solution and further 
incubated in blocking solution containing peroxidase-conjugated goat anti-rabbit IgG 
(1:5000) (Sigma-Aldrich, Steinheim, Germany) for another hour. Membranes were washed 















chemilluminescence western blotting detection reagent) (KPL, Gaithersburg, MD). 
Membranes were exposed to Kodak Biomax Light autoradiography film for between 10 and 
30 seconds and the film developed to visualize bound secondary antibodies. Photos of the 
developed films were taken with a Kodak DC290 digital camera with Kodak EDAS 290 gel 
documentation system. The net intensities of the individual haemoglobin bands were 
determined using Kodak 1D image analysis software version 3.5. 
 
Immunofluorescence assay 
Immunofluorescence assays were performed on untreated (control) and drug-pressured 
parasites to assess the effects of drugs on endocytic vesicle trafficking, and to visualize the 
location of haemoglobin inside the parasites. 
 
Glass coverslips were treated with 1 mg/ml poly L-lysine in PBS for 15 min, placed into 
24-well plates and washed 4 times with PBS. Parasite pellets of drug-treated and untreated 
cultures were resuspended in 30 μl PBS and added to wells containing coverslips in 300 μl 
PBS. The plates were centrifuged at 100 G for 2 min to pellet the parasites onto glass 
coverslips. Glass coverslips were washed with PBS (4 times) to remove unbound parasites. 
Bound parasites were fixed onto coverslips with PBS containing 4 % PFA, 0.25 % GLA (w/v) 
for 15 min, and coverslips washed for a further 4 times. Unreacted aldehydes were quenched 
by immersing coverslips in 0.15 M glycine for 20 min, and washed (4 times) in PBS. 
Coverslips were incubated in blocking solution (PBS containing 2 % (w/v) BSA, 50 % (v/v) 
fetal calf serum (FCS), 1 mM MgCl2, 1 mM CaCl2 and 0.1 % (v/v) Tween 20) for 30 min, 
followed by 1 h incubation with rabbit anti-haemoglobin antiserum (Sigma-Aldrich, 
Steinheim, Germany) diluted 1:200 in blocking solution. The coverslips were then washed in 















blocking solution containing the secondary antibody (tetramethylrhodamine 
(TRITC)-conjugated goat anti-rabbit antiserum, 1:250)(Invitrogen, Carlsbar, CA) for 1 h in 
the dark. Coverslips were washed 4 times, and incubated in PBS containing 30 μg/ml 
4’,6’-diamidino-2-phenylindole (DAPI) for 1 min to stain the parasite nuclei. The coverslips 
were rinsed by dipping into water (3 times), dried by gently dabbing on soft tissue and 
mounted onto glass microscope slides in Permafluor polyvinyl alcohol mounting medium 
(Immunotech) and allowed to dry overnight in a dry dark container. Slides were examined by 
fluorescence microscopy (Nikon Eclipse E600 fluorescence microscope) under a 100 times 
oil immersion objective lens. Images of the parasites were capture by media Cybernetics 
CoolSNAP-Pro monochrome cooled charge-couple device camera. Only parasites at mid to 
late trophozoite stage were included (≦ 2 DAPI-stained nuclei) in subsequent transport 
vesicle enumeration.  
 
Cytotoxicity Assays 
HeLa (Human cervical carcinoma) (ATCC no CCL 2) 
HeLa cells are adherent epithelial cells, maintained in Eagles minimum essential medium 
(EMEM) supplemented with 2 mM L-glutamine, 0.1mM non-essential amino acids, 1.0 mM 
sodium pyruvate and 10 % bovine fetal calf serum (FCS). 
 
Preparation of cells for proliferation experiments 
Cell cultures were prepared in the prescribed ATCC tissue culture medium (specified for 
each cell line) supplemented with 10% FCS in 75 cm3 culture flasks and sub-cultured three 
times a week.  Tissue culture medium was discarded from the tissue culture flask 
containing the cells that were to be used and ± 5 ml trypsin/versene was added. Care was 















of trypsin/versene (2-5 ml) was added, enough to cover the adherent cells on the bottom of 
the flask. The culture flask with trypsin/versene cell mixture was incubated at 37 ºC for a 
few minutes until the cells detached from the flask. The trypsin/versene cell mixture was 
transferred to a 15 ml centrifuge tube. Tissue culture media supplemented with 10% bovine 
FCS was used to rinse the culture flask and this was added to the mixture in the centrifuge 
tube, thus neutralizing the action of the trypsin/versene. Cell cultures which grow in 
suspension were decanted directly into 15 ml centrifuge tubes. The cell suspension was 
centrifuged for 6 minutes at 200 G.  The supernatant was discarded and the cell pellet was 
re-suspended in 1 ml of the tissue culture medium specified for that specific cell line, 
supplemented with 10% bovine FCS. The cell suspension was mixed repeatedly by 
pippetting repeatedly with an automatic pipette to make sure that the cells were separated 
from each other and that a uniform suspension was formed. 
 
Counting of cells 
50 µl of the cell suspension which was prepared as described above was added to 450 µl of 
white cell counting fluid and mixed well. A small volume of this suspension was put onto a 
Haemocytometer and the cells were counted using a Reichert Jung Micro Star microscope.  
Dilutions were then made with the tissue culture medium specified for the specific cell line 
used, supplemented with 10% bovine FCS to achieve the required cell concentration for the 
cell proliferation assay.   
 
Cell proliferation assay 
Tissue culture plates were divided into different sections for controls (untreated cells) and 
experimental compounds (treated cells). 80 µl of the tissue culture medium (specified for the 















lymphocytes earmarked to be stimulated) was dispensed into each well of a 96 well tissue 
culture plate. 100 µl cell suspension was added to each well. Cultures were incubated at   
37 ºC in an atmosphere of 5 % CO2 for an hour. 20 µl of dilutions of the drugs to be tested 
(different concentrations) was added to the wells.  Untreated control wells received 20 µl of 
culture medium. A control with DMSO was also done to make sure that there was no DMSO 
effect. Lymphocytes earmarked to be stimulated received 20 µl PHA 5 minutes after the 
addition of the drug. Cultures were incubated at 37 ºC in an atmosphere of 5 % CO2 for 
seven days with the exception of the lymphocytes, which were incubated for three days 
before the MTT was added. All the cell cultures were incubated before the MTT was added. 
 
MTT assay 
After the incubation period (five days) of the tissue culture plates, 20 µl MTT (5 mg/ml) was 
added to each well. Cultures were incubated for 4 h at 37 ºC in an atmosphere of 5 % CO2 
and then centrifuged for 10 minutes at 800 G. Supernatant was removed from each well 
without disturbing the pellet with a Pasteur pipette and cells were washed by addition of  
150 µl PBS and centrifuged 10 minutes at 800 G. Supernatant was removed from each well 
without disturbing the pellet with a Pasteur pipette and plates were left an hour to dry off at 
37 ºC. 100 µl DMSO was added to each well to solubilize the formazan crystals. Culture 
plates containing the DMSO/formazan solution were put on a shaker for about 1-2 hours and 
absorbance was measured on a Universal Microplate Reader (ELx800 UV, Bio-tek 
Instruments) using a wavelength of 570 nm and a reference wavelength of 630 nm.   
 
Percentage of control of cell growth in drug treated wells was calculated by dividing the 
mean absorbance of the treated cells by the mean absorbance of the untreated controls x 100 















β-Haematin inhibition assays 
Serial dilutions of the drug solutions were carried out in triplicate in a 96-well plate. 
Concentrations of drug solution corresponded to 0 – 10 equivalents relative to haematin in 
the final mixture. Each well contained 10.12 μl of drug solution. 101.2 μl of haematin stock 
solution (1.68 mM in 0.1 M NaOH) was added to each well. After mixing the solutions,  
58.7 μl of acetate solution (12.9 M, pH 5.0) pre-incubated at 60 ºC was added and the plate 
was incubated for 60 min at 60 ºC. Thereafter, 80 μl of 30 % (v/v) pyridine solution in    
20 mM Hepes, pH 7.5, was added at room temperature. Solids were resuspended and 
allowed to settle for 15 min at ambient temperature. 38 μl of supernatant was transferred to 
another plate and diluted to 250 μl with 30 % (v/v) pyridine solution (pH 7.5, 20 mM Hepes). 




This was carried out using 1 and 5 equivalents of drugs or related compounds relative to 
haematin. Haematin stock solution (20.2 µl) was mixed with 2.02 µl of each drug dissolved 
in 1.0 M HCl in methanol. Acetate solution (11.74 µl, 12.9 M, pH 5.0) pre-warmed at 60 ºC 
was added. After 60 minutes of incubation, 250 µl of 12 % (v/v) pyridine solution (pH 7.5, 
20 mM Hepes, ambient temperature) was added. Supernatants were carefully transferred to a 
flat-bottomed 96-well plate. Detection of β-haematin inhibition was by visual inspection and 
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